STOCK TITAN

MBody AI proposes conditional 175M-share authorization

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

MBody AI Ltd. (MBAI) will hold its annual general meeting on December 22, 2026, in two virtual sessions at 10:00 a.m. and 2:00 p.m. Eastern Time. Shareholders will vote on 10 proposals comprising 16 separate votes: the first session covers director elections, the auditor appointment and share-structure matters; the second covers the equity plan and compensation proposals.

The company proposes to increase authorized share capital from 18,000,000 to 175,000,000 ordinary shares, conditional on approval of redesignating the shares as no par value. The proposed 2026 Equity Incentive Plan would reserve 1,841,517 shares. The notice reports 15,345,971 ordinary shares outstanding as of November 13, 2026. The authorization would not itself approve a particular financing or acquisition.

Other proposals include electing two external directors, approving a three-year compensation policy and CEO and director compensation, and appointing Simon & Edward LLP as independent auditor for fiscal 2026. The 2025 audited financial statements will be discussed, with no vote required. The company completed its business combination with MBody AI Corp. on August 26, 2026; MBody AI Corp. became a wholly owned subsidiary, and the company changed its name from Check-Cap Ltd.

Filing Explained

If approved, the share authorization would create additional unissued, unreserved capacity, not an immediate issuance.

At the December 22, 2026 shareholder meeting, MBody AI is asking for approval to increase authorized ordinary shares from 18 million to 175 million, conditional on approval of the no-par-value proposal; if approved, the additional capacity would be authorized but unissued—not issued shares.

Any later issuance from that capacity would dilute existing holders’ ownership and voting interests; the company says it has no current agreement or arrangement to issue these additional shares.

The separate no-par-value proposal would not change existing holders’ share counts, rights or proportionate ownership, and would confirm that the company will not seek unpaid nominal value on shares issued below NIS 48.00 before the amendment takes effect.

The compensation proposals will be voted on in the second session only if both proposed external directors are elected in the first session; in the interval, the reconstituted committee and then the board are to consider them and, if they see fit, approve and recommend them.

The current Compensation Policy expires on December 18, 2026, four days before the meeting; if the second-session votes proceed, proposals 9(b) and 9(d) require special-majority approval whether or not Proposal 8 passes.

Ordinary shares outstanding 15,345,971 shares As of November 13, 2026.
Current authorized share capital 18,000,000 ordinary shares Current amount before the proposed increase.
Proposed authorized share capital 175,000,000 ordinary shares Shareholder proposal, conditional on the no-par-value proposal becoming effective.
2026 Equity Incentive Plan reserve 1,841,517 shares Proposed reserve under the plan to be considered at the meeting.
Regan McGee beneficial ownership 6,860,097 ordinary shares As of November 13, 2026; the proxy table reports 44.7% of the class.
Regan McGee ownership percentage 44.7% Of ordinary shares as of November 13, 2026.
Proposed annual director cash compensation US$40,000 per year Proposed for non-employee directors other than the external directors and any controlling shareholder; the external directors are proposed to receive the same amount.
Proposed annual director equity compensation US$60,000 per year Proposed for non-employee directors other than the external directors and any controlling shareholder; the equity component is conditional on approval of the 2026 Equity Incentive Plan.
external directors regulatory
"the Company is required to elect two external directors"
Members of a company’s board of directors who are not current employees or executives of the company and who typically have no significant business ties to it. They act like outside referees, bringing independent judgment to oversight of management, strategy, and risks; their presence matters to investors because they can influence corporate decisions, monitor conflicts of interest, and help ensure transparent governance.
Special Majority regulatory
"require an Ordinary Majority, and in addition require"
no par value financial
"re-designate the Ordinary Shares as no par value shares"
Shares described as "no par value" are equity securities issued without a fixed face amount written into the corporate charter; their legal capital is not tied to a specific per-share number and the company may record proceeds differently than for par-value shares. This matters to investors because it affects how a company records equity, sets minimum legal capital, and handles bookkeeping for issuances, dividends and splits—similar to buying slices of a pie where the slice has no printed sticker price and market forces determine worth.
authorized share capital financial
"increase in authorized share capital to 175,000,000 Ordinary Shares"
The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.
broker non-vote regulatory
"A broker non-vote occurs when a broker holding shares in street name"
A broker non-vote happens when a brokerage firm holds shares in street name for a client but does not cast a ballot on a particular shareholder item because the broker lacks discretionary authority to vote that matter. Think of it like a person who owns a ticket but the ticket-holder refuses to vote on some issues; the share counts for ownership but not for that vote, which can affect whether proposals reach the required number of votes or a quorum.
beneficial ownership regulatory
"information regarding the beneficial ownership of our Ordinary Shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is MBAI's annual meeting, and how will it be held?

The meeting is scheduled for December 22, 2026, as a virtual meeting. It has two sessions, at 10:00 a.m. and 2:00 p.m. Eastern Time, with the first session adjourned to the second. Shareholders can attend, ask questions and vote online.

What share-capital increase is MBAI proposing?

Shareholders are being asked to approve an increase from 18,000,000 to 175,000,000 authorized ordinary shares, conditional on Proposal 1 becoming effective. Proposal 1 would redesignate the shares as no par value. The company says issuing additional shares could dilute existing ownership and voting interests, earnings per share and book value per share.

Why is MBAI holding its annual meeting in two sessions?

The compensation committee must include the external directors before the relevant compensation matters are considered for shareholder approval. The external directors are to be elected at the first session; during the adjournment, the reconstituted committee and board will consider the plan and compensation proposals. The compensation proposals go to a second-session vote only if both external directors are elected.

What compensation is MBAI proposing for non-employee directors?

The proposals set annual compensation at US$40,000 in cash and US$60,000 in equity for non-employee directors other than the external directors and any controlling shareholder; the external directors are proposed to receive the same amounts. The equity components depend on approval of the 2026 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026.

 

Commission File Number 001-36848

 

MBody AI Ltd.

(Translation of registrant’s name into English)

 

7111 Syntex Drive, 3rd Floor,
Mississauga, Ontario,
Canada
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

 

 

 

 

This Form 6-K is being incorporated by reference into the Registration Statements of MBody AI Ltd. (formerly known as Check-Cap Ltd.) (the “Company”) on Form F-3 (File No. 333-299083) and Form S-8 (File No. 333-203384, 333-203384, 333-226490 and 333-259666) filed with the Securities and Exchange Commission (the “SEC”), to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Annual General Meeting of Shareholders

 

The Company will hold an Annual General Meeting of Shareholders (the “Annual General Meeting”) on December 22, 2026 in two sessions: the first at 10:00 a.m. Eastern Time, and the second, to which the first session will be adjourned, at 2:00 p.m. Eastern Time on the same day, in each case as a virtual meeting held exclusively by live audio webcast at https://edge.media-server.com/mmc/p/im8ebjko (password: mbodyai2026). There will be no physical meeting location. Copies of the Notice of Annual General Meeting of Shareholders, the Proxy Statement and the Proxy Card are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference.

 

Change in Independent Registered Public Accounting Firm

 

As previously reported, on December 19, 2025, the Audit Committee of the Board of Directors of the Company approved the appointment of BCRG LLP (“BCRG”) as the Company’s independent registered public accounting firm. BCRG audited the Company’s consolidated financial statements for the year ended December 31, 2025 included in the Company’s Annual Report on Form 20-F filed with the SEC on April 27, 2026.

 

On June 15, 2026, BCRG merged with Simon & Edward, LLP (“Simon & Edward”), and Simon & Edward is the successor firm. As a result of the merger, BCRG effectively ceased to serve as the Company’s independent registered public accounting firm and Simon & Edward became the Company’s independent registered public accounting firm. At the Annual General Meeting, shareholders will be asked to approve the appointment of Simon & Edward as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 and until the next annual general meeting of shareholders, and to authorize the Board of Directors of the Company, upon the recommendation of the Audit Committee, to fix its compensation.

 

Exhibit

 

Exhibit No.   Description
99.1   Notice of the Annual General Meeting of Shareholders.
99.2   Proxy Statement for the Annual General Meeting of Shareholders.
99.3   Proxy Card for the Annual General Meeting of Shareholders.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MBODY AI LTD.
   
  By: /s/ John Fowler
  Name: John Fowler
  Title: Chief Executive Officer

 

Date: November 18, 2026

 

2

 

Exhibit 99.1

 

MBODY AI LTD.

 

7111 Syntex Drive, 3rd floor
Mississauga, Ontario
Canada

 

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

 

To be held on December 22, 2026 in two sessions, at 10:00 a.m. Eastern Time and, by adjournment, at 2:00 p.m. Eastern Time

 

Dear Shareholder:

 

We cordially invite you to attend the Annual General Meeting of Shareholders (the “Meeting”) of MBody AI Ltd. (formerly Check-Cap Ltd.) (“MBody AI,” the “Company,” “we,” “us” or “our”) to be held on December 22, 2026 in two sessions: the first at 10:00 a.m. Eastern Time, and the second, to which the first session will be adjourned, at 2:00 p.m. Eastern Time on the same day, in each case as a virtual meeting held exclusively by live audio webcast at https://edge.media-server.com/mmc/p/im8ebjko (password: mbodyai2026). There will be no physical meeting location. Shareholders of record and holders of a legal proxy may attend, ask questions and vote at the Meeting online.

 

At the Meeting, you will be asked to consider and vote on the following proposals. The proposal numbers are the item numbers on the enclosed proxy card.

 

At the first session (10:00 a.m. Eastern Time):

 

4. to appoint SIMON & EDWARD, LLP, the successor by merger to BCRG LLP, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 and until the next annual general meeting of shareholders, and to authorize the Board of Directors, upon the recommendation of the Audit Committee, to fix its compensation (the “Auditor Proposal” or “Proposal 4”);

 

3. to elect each of Regan McGee, John Fowler and David Lontini as a director of the Company, each to serve until the next annual general meeting of shareholders, unless his office is vacated earlier in accordance with the Articles of Association or the Israeli Companies Law, 5759-1999 (the “Companies Law”) (the “Director Election Proposal” or “Proposal 3”);

 

3A. to elect each of Fiona George and Daniel Kokiw as an external director of the Company, within the meaning of the Companies Law, each for a three-year term commencing on the date of the Meeting (the election of Daniel Kokiw being conditional upon the election of Fiona George) (the “External Director Proposal” or “Proposal 3A”);

 

6. to approve the adoption of a new Article 42A of the Articles of Association, in the form set out in Part D of Appendix D, confirming that the powers of the Board and of the continuing directors under Article 42 to appoint directors do not include the power to appoint external directors, who may be elected only by the general meeting, and that if the office of an external director becomes vacant the Board will convene a general meeting to elect an external director in accordance with the Companies Law (the “External Director Vacancies Proposal” or “Proposal 6”);

 

7. to authorize the Board of Directors, in its discretion and at any time within 24 months after the date of the Meeting, to change the name of the Company from “MBody AI Ltd.” to “MBody SI Ltd.”, or to such similar name as the Registrar of Companies may approve, and to approve the corresponding amendment of the Articles of Association of the Company, in the form set out in Part A of Appendix D, effective upon the determination of the Board of Directors and the approval of the Registrar of Companies (the “Name Change Authority Proposal” or “Proposal 7”);

 

1

 

 

1.

to approve an amendment to the Company’s Articles of Association, in the form set out in Part B of Appendix D, so that all of the Company’s authorized and issued Ordinary Shares, currently of nominal value NIS 48.00 each, are re-designated as Ordinary Shares of no par value, together with conforming amendments to Articles 2, 6, 7, 9, 12, 14, 53, 55 and 69 of the Articles of Association, including concerning the consolidation and division of shares and fractional shares, and to confirm that the Company shall not seek payment of any unpaid nominal value from any holder of Ordinary Shares issued before the effective time of the amendment (the “No Par Value Proposal” or “Proposal 1”); and

 

2. subject to and conditional upon Proposal 1 becoming effective, to approve an increase in the Company’s authorized share capital from 18,000,000 Ordinary Shares to 175,000,000 Ordinary Shares of no par value, and the corresponding amendment of the Articles of Association in the form set out in Part C of Appendix D (the “Authorized Share Capital Proposal” or “Proposal 2”).

 

At the second session (2:00 p.m. Eastern Time the same day), to which the first session will be adjourned:

 

5.to approve the MBody AI Ltd. 2026 Equity Incentive Plan, including its Israeli, United States and Canadian appendices, in the form attached as Appendix B, with a reserve of 1,841,517 Ordinary Shares, and to acknowledge that the Check-Cap Ltd. 2015 Equity Incentive Plan expired by its terms on June 23, 2025, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to it, including the Interval Approvals (the “Equity Plan Proposal” or “Proposal 5”);

 

8.to approve the Company’s amended and restated compensation policy (the “Compensation Policy”) for Executive Officers and Directors, including amendments to its compensation caps and ratios, in the form attached as Appendix A, for a period of three years from the date of the Meeting (the “Compensation Policy Proposal” or “Proposal 8”);

 

9(a).to approve the terms of office and engagement of John Fowler as Chief Executive Officer of the Company, as described in the Proxy Statement, including the guarantee by the Company of the obligations of MBody AI Corp. to Mr. Fowler under his employment agreement, the indemnification and exculpation undertaking in the form attached as Appendix C and the amended and restated indemnification agreement between MBody AI Corp. and Mr. Fowler (the “CEO Compensation Proposal” or “Proposal 9(a)”);

 

9(b).to approve the compensation of the non-employee directors of the Company, other than the external directors and any director who is a controlling shareholder of the Company (the “Director Compensation Proposal” or “Proposal 9(b)”);

 

9(c).to approve, in accordance with Regulation 5(f) of the Israeli Companies Regulations (Reliefs for Companies with Securities Listed on an Exchange Outside of Israel), 5760-2000, and Regulations 8A and 8B of the Companies Regulations (Rules Regarding Compensation and Expenses of External Directors), 5760-2000 (the “External Director Regulations”), the compensation of the external directors in excess of the amounts otherwise prescribed by those regulations (the “External Director Compensation Proposal” or “Proposal 9(c)”); and

 

9(d).to approve the grant of indemnification and exculpation undertakings to the directors of the Company, other than the Chief Executive Officer and any director who is a controlling shareholder of the Company, in the form attached as Appendix C (the “Indemnification Proposal” or “Proposal 9(d)”).

 

2

 

 

Proposals 4, 3, 3A, 6, 7, 1 and 2 will be voted on at the first session of the Meeting, at 10:00 a.m. Eastern Time. Proposals 5, 8, 9(a), 9(b), 9(c) and 9(d) will be voted on at the second session, at 2:00 p.m. Eastern Time on the same day. The Meeting will be adjourned at the close of the first session and will reconvene for the second session. The reason for the two sessions is explained under “Background of the Meeting” and “Why the Meeting is held in two sessions on the same day” below. A single proxy card covers both sessions.

 

In addition, at the first session of the Meeting, representatives of management will present and discuss with shareholders the Company’s audited consolidated financial statements for the year ended December 31, 2025. The financial statements are included in the Company’s Annual Report on Form 20-F for that year, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 27, 2026, under the Company’s former name, Check-Cap Ltd. (the “2025 Annual Report”). The 2025 Annual Report is available on the SEC’s website at www.sec.gov and on the Company’s website at ir.mbody.ai. It is not part of the proxy solicitation material. No vote is required on this item.

 

We are not aware of any other matters that will come before the Meeting. If any other matters properly come before the Meeting, the persons designated as proxies intend to vote on such matters in accordance with the judgment and recommendation of the Board of Directors.

 

Background of the Meeting

 

On August 26, 2026, the Company completed its business combination with MBody AI Corp., a Nevada corporation (the “Business Combination”), following which MBody AI Corp. became a wholly-owned subsidiary of the Company and the Company changed its name from Check-Cap Ltd. to MBody AI Ltd. Our Ordinary Shares continue to trade on the Nasdaq Capital Market under the symbol “MBAI.” The Company remains incorporated in the State of Israel and is governed by the Companies Law.

 

The Business Combination changed the Company’s business, its board of directors and its shareholder base. This Meeting is the first annual general meeting since the Business Combination. Several of the proposals address matters that follow directly from it: the re-designation of our shares as no par value shares, which we undertook to bring to this Meeting in our prospectus dated August 27, 2026; the election of directors; the election of two external directors, as required under the Companies Law now that the Company has a controlling shareholder; the approval and updating of our Compensation Policy; and the adoption of a new equity incentive plan for the combined company.

 

The Company’s current Compensation Policy was approved by shareholders on December 18, 2023. Under Section 267A of the Companies Law, a compensation policy must be approved by shareholders at least once every three years. The current Compensation Policy will therefore cease to be in effect on December 18, 2026, four days before the Meeting. Under the Companies Law, a new compensation policy must first be recommended by a compensation committee that includes the external directors, who are to be elected at the first session of the Meeting. Proposal 8 asks shareholders to approve an amended and restated Compensation Policy for a period of three years from the date of the Meeting. See “Proposal 8” for the consequences if Proposal 8 is not approved.

 

Following the Business Combination, Regan McGee, the Chairman of the Board, is a controlling shareholder of the Company under the Companies Law. As a result, the exemption from the requirement to appoint external directors on which the Company previously relied ceased to apply at the closing, and the Company is required to elect two external directors. The Company is doing so at this Meeting, which is the earliest practicable general meeting following the closing. Until the external directors are elected, the Company’s Compensation Committee does not meet the composition requirements of the Companies Law for the approval of office holder compensation. See “Why the Meeting is held in two sessions on the same day.”

 

3

 

 

Why the Meeting is held in two sessions on the same day

 

Under the Companies Law, the compensation policy and the terms of office and engagement of the Company’s office holders must be approved by a compensation committee that includes the external directors, then by the Board, and then by shareholders. The Company’s current compensation committee (the “Current Compensation Committee”), none of whose members is an external director, does not meet that requirement. Because the external directors are elected at this Meeting, the Board has structured the Meeting in two sessions on the same day. At the first session, at 10:00 a.m. Eastern Time, shareholders will vote on the proposals that do not depend on the composition of the Compensation Committee, including the election of the external directors. The first session will then be adjourned. In the interval, the external directors take office, the Board will reconstitute the Compensation Committee to include the external directors as required by the Companies Law (as reconstituted, the “Reconstituted Compensation Committee”), and the Reconstituted Compensation Committee and then the Board will meet to consider and, if they see fit, approve and recommend the 2026 Equity Incentive Plan described in Proposal 5 and the compensation matters described in Proposals 8 and 9 (the “Interval Approvals”). References in this Notice and the Proxy Statement to the “Compensation Committee” without qualification are to the compensation committee of the Board as constituted from time to time. The Meeting will reconvene at 2:00 p.m. Eastern Time for the second session, at which shareholders will vote on those proposals. The terms of the compensation proposals, as approved by the Board for submission to the shareholders, are described in the Proxy Statement; if the Reconstituted Compensation Committee or the Board makes any change as part of the Interval Approvals, the chairman of the Meeting will announce the change at the second session before the vote, and the Company will furnish a report on Form 6-K that describes the change as soon as practicable.

 

Who Can Vote

 

You are entitled to notice of, and to vote in person or by proxy at, the Meeting if you are a holder of record of Ordinary Shares as of the close of business on November 20, 2026 (the “Record Date”). As of November 13, 2026, the latest practicable date before the date of this Notice and the Proxy Statement (the “Reference Date”), there were 15,345,971 Ordinary Shares outstanding. You are also entitled to notice of the Meeting and to vote at the Meeting if you held Ordinary Shares through a bank, broker or other nominee that is one of the Company’s shareholders of record at the close of business on the Record Date, or which appeared in the participant listing of a securities depository on that date. The Record Date applies to both sessions of the Meeting.

 

How You Can Vote

 

●Voting at the virtual Meeting. If you are a shareholder of record, that is, your shares are registered directly in your name with the Company’s transfer agent, Equiniti Trust Company, LLC, you may attend and vote at the virtual Meeting by logging on to https://edge.media-server.com/mmc/p/im8ebjko, entering the password mbodyai2026 and entering your control number. If you are a beneficial owner of shares registered in the name of your broker, bank, trustee or nominee (that is, your shares are held in “street name”), you are also invited to attend the Meeting; however, to vote at the virtual Meeting as a beneficial owner, you must first obtain a “legal proxy” from your broker, bank, trustee or nominee giving you the right to vote the shares at the Meeting.

 

●Voting by mail. If you are a shareholder of record, you may submit your proxy by completing, signing and mailing the enclosed proxy card in the enclosed postage-paid envelope. If your Ordinary Shares are held in street name, please follow the voting instructions provided by your broker, trustee or nominee. Proxies must be received by the Company’s transfer agent, Equiniti Trust Company, LLC, Attn: Proxy Department, 1110 Centre Pointe Curve, Suite 101, Mendota Heights, MN 55120-4100, no later than December 20, 2026 at 10:00 a.m. Eastern Time. Proxies received by the transfer agent after that time and before the first session will be presented to the chairman of the Meeting and, at his discretion, may be voted as marked if received before the vote on the relevant matter. A proxy received by that deadline is valid for both sessions and carries to the second session.

 

●Voting by Internet. If you are a shareholder of record, you can submit a proxy over the Internet by logging on to the website listed on the enclosed proxy card, entering your control number and following the on-screen prompts. If you hold shares in street name, you may vote by the methods described in the instructions provided by your broker, bank, trustee or nominee. Submitting an Internet proxy will not affect your right to vote at the Meeting should you decide to attend.

 

The persons named as proxies on the enclosed proxy card are Sean Donahue and Carl Sherer, neither of whom is an office holder of the Company or has a personal interest in any proposal.

 

4

 

 

Change or Revocation of Proxy

 

If you are a shareholder of record, you may change or revoke your proxy in one of the following ways: (i) deliver a written notice of revocation to the Company’s Chief Financial Officer, Tim Hayden, at the address above; (ii) grant a new proxy that bears a later date; (iii) vote again via the Internet; or (iv) attend the virtual Meeting and vote online. A notice of revocation or a new proxy under (i), (ii) or (iii) is effective only if the Company or its transfer agent receives it by the proxy deadline stated above. Attendance at the Meeting will not by itself revoke a previously granted proxy. A proxy given for the first session carries to the second session, and the proxy deadline applies to both sessions.1 If your shares are held in street name, you may change your vote by submitting new voting instructions to your broker, bank, trustee or nominee or, if you have obtained a legal proxy, by attending the virtual Meeting and voting online.

 

Quorum

 

The presence, in person or by proxy, of two or more shareholders holding or representing, in the aggregate, at least twenty-five percent (25%) of the Company’s voting rights will constitute a quorum at the Meeting. A shareholder attending the virtual Meeting online is treated as present in person. No business will be considered or determined at the Meeting unless the requisite quorum is present within half an hour from the time designated for the Meeting. If a quorum is not present within that time, the Meeting will stand adjourned to Tuesday, December 29, 2026, at the same times, in the same virtual format. At the adjourned meeting, any two (2) shareholders present in person or by proxy will constitute a quorum. The same 25% quorum requirement applies at the second session of the Meeting on the same day.

 

Abstentions and broker non-votes will be counted towards the quorum. A broker non-vote occurs when a broker holding shares in street name submits a proxy for those shares (in which case the shares are considered present for the purposes of determining presence of a quorum at the Meeting) but does not have the discretionary authority to vote on a particular proposal. This occurs when brokers have not received voting instructions from their customers, in which case the brokers, as the holders of record, are permitted to vote on “routine” matters, but not on non-routine matters. The proposals described in this Notice are non-routine matters except for the Auditor Proposal (Proposal 4) and, we expect, the No Par Value Proposal (Proposal 1) and the Authorized Share Capital Proposal (Proposal 2); therefore, it is important that you vote your shares, either by proxy or at the virtual Meeting.

 

Unsigned or unreturned proxies, including those not returned by banks, brokers or other record holders, will not be counted for quorum or voting purposes.

 

 

 
1 The two sessions of the Meeting are held on the same day, and the proxies for both sessions are tabulated on the basis of proxies received by the proxy deadline. For that reason, a proxy, notice of revocation or new proxy received after the proxy deadline will not change a vote at the second session, except that a shareholder of record may attend the virtual Meeting and vote online. The Company does not expect any change between the sessions to the matters to be voted on at the second session. If a material change is made, the Company will announce it at the second session before the vote and furnish a report on Form 6-K describing the change as soon as practicable.

 

5

 

 

Vote Required for Approval of the Proposals

 

Your vote is very important, regardless of the number of Ordinary Shares that you own. Each Ordinary Share entitles the holder to one vote.

 

Ordinary majority. Proposals 1, 2, 3 (each nominee voted on separately), 4, 5, 6 and 7 each require the affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter (an “Ordinary Majority”). Abstentions and broker non-votes are not considered votes cast and have no effect on the result.

 

Special majority. Proposals 3A(a), 3A(b), 8, 9(a), 9(b), 9(c) and 9(d) each require an Ordinary Majority, and in addition require that either: (i) the majority of the votes cast in favor of the proposal includes at least a majority of the votes cast by shareholders who are not controlling shareholders of the Company and who do not have a personal interest in the approval of the proposal (in the case of Proposals 3A(a), 3A(b) and 9(c), only a personal interest arising from a relationship with the controlling shareholder), excluding abstentions; or (ii) the total number of votes cast against the proposal by the shareholders described in clause (i) does not exceed two percent (2%) of the total voting rights in the Company (a “Special Majority”). Because the current Compensation Policy will cease to be in effect on December 18, 2026, before the Meeting, the Company is submitting Proposals 9(b) and 9(d) for approval by a Special Majority, whether or not Proposal 8 is approved. The terms “controlling shareholder” and “personal interest” are explained under “Controlling Shareholders and Personal Interests” below.

 

Board override. If shareholders do not approve Proposal 8 by the required Special Majority, the Compensation Committee and the Board may nonetheless approve the Compensation Policy under Section 267A(c) of the Companies Law, following further discussion and on the basis of detailed reasons, if they determine that approval is in the best interests of the Company. If shareholders do not approve Proposal 9(a), the Compensation Committee and the Board may approve the Chief Executive Officer’s terms under Section 272(c1)(2) of the Companies Law on the same basis, to the extent that the Companies Law permits for an office holder who is also a director. No such override is available for Proposals 3A(a), 3A(b) or 9(c).

 

Conditional proposals. Proposal 2 is conditional upon Proposal 1 becoming effective. The election of Daniel Kokiw under Proposal 3A(b) is conditional upon the election of Fiona George under Proposal 3A(a). Proposals 8, 9(a), 9(b), 9(c) and 9(d) will be voted on at the second session only if both external directors are elected under Proposal 3A at the first session. Proposal 5 will be voted on at the second session whether or not the external directors are elected, because Israeli law does not require a compensation committee that includes the external directors to approve an equity incentive plan; if the Compensation Committee cannot be reconstituted, the Board will consider the Interval Approvals for Proposal 5. The equity components of Proposal 9(b) and 9(c) are conditional upon the approval of Proposal 5, and Proposal 9(c) is conditional upon the approval of Proposal 9(b). Proposal 7 is not conditional on any other proposal; the Part A regularization in Appendix D is drafted so that the Articles carry the current name if the Board does not use the authority. Otherwise, each proposal stands on its own and the approval of one proposal is not conditioned on the approval of any other.

 

Controlling Shareholders and Personal Interests

 

Under the Companies Law, in counting the Special Majority the votes of a “controlling shareholder” and of any shareholder having a “personal interest” in the approval of the proposal are excluded from the second count described in clause (i) above and are not counted toward the two percent threshold in clause (ii). In this Notice and the Proxy Statement, the “second count” means that separate count of the votes of shareholders who are not controlling shareholders and do not have a personal interest; it does not refer to the second session of the Meeting.

 

6

 

 

A “controlling shareholder” is a shareholder who has the ability to direct the activities of the Company, other than by virtue of being a director or other office holder. A person is presumed to be a controlling shareholder if he or she holds fifty percent (50%) or more of the voting rights in the Company or the right to appoint a majority of its directors or its chief executive officer. For the purposes of approving the terms of office and engagement of office holders and transactions with interested parties, a controlling shareholder also includes any shareholder who holds twenty-five percent (25%) or more of the voting rights in the Company if no other shareholder holds more than fifty percent (50%) of the voting rights, and two or more shareholders who each have a personal interest in the approval of the same transaction are treated as joint holders for this purpose. Regan McGee, the Chairman of our Board of Directors, beneficially owns approximately 45% of our outstanding Ordinary Shares and is a controlling shareholder of the Company for the purposes of the Companies Law.

 

A “personal interest” of a shareholder in an action or transaction of the Company includes a personal interest of any member of the shareholder’s immediate family (including a spouse, sibling, parent, grandparent, descendant, or spouse’s descendant, sibling or parent, or the spouse of any of these) or of any entity in which the shareholder or any such family member serves as a director or chief executive officer, owns at least five percent (5%) of the outstanding shares or voting rights, or has the right to appoint a director or the chief executive officer. A personal interest also includes the interest of a person voting under a proxy given by another person, whether or not the person granting the proxy has a personal interest. A vote cast by a proxy holder on behalf of a shareholder who has a personal interest is also treated as a vote of a person with a personal interest. A personal interest does not include an interest arising solely from the ownership of Ordinary Shares. A shareholder who votes on Proposal 3A or Proposal 9(c) is treated as having a personal interest only if that interest results from a relationship with a controlling shareholder.

 

Confirmation by voting shareholders. Under the Companies Law, a shareholder voting on a proposal that requires a Special Majority must notify the Company before the vote whether or not he or she is a controlling shareholder or has a personal interest in the approval of the proposal. In reliance on Regulation 3A of the Israeli Companies Regulations (Reliefs for Companies with Securities Listed on an Exchange Outside of Israel), 5760-2000 (the “Reliefs Regulations”), by signing and returning the proxy card, or by voting online before or at the Meeting, a shareholder confirms to the Company that such shareholder is NOT a controlling shareholder of the Company and does NOT have a personal interest in the approval of any of Proposals 3A(a), 3A(b), 8, 9(a), 9(b), 9(c) or 9(d), unless such shareholder has delivered to the Company a notice in writing stating otherwise, no later than December 20, 2026 at 10:00 a.m. Eastern Time, to the attention of the Company’s Chief Financial Officer, Tim Hayden, at 7111 Syntex Drive, 3rd Floor, Mississauga, Ontario, Canada or by e-mail to ir@mbody.ai, or has so indicated on the proxy card. A shareholder who so indicates without specifying a proposal will have his, her or its vote excluded from the second count on all of those proposals. If you hold your shares in “street name” (through a bank, broker or other nominee) and believe that you are a controlling shareholder or have a personal interest in the approval of any of those proposals, you may also contact the representative managing your account, who can contact the Company’s Chief Financial Officer on your behalf. A shareholder who is a controlling shareholder or has a personal interest and who does not so notify the Company will have his, her or its vote counted as if the shareholder were not a controlling shareholder and had no personal interest, in reliance on the deemed confirmation.

 

Holders of 5% or more. The proxy card also asks a shareholder who holds 5% or more of the outstanding Ordinary Shares or of the voting rights of the Company to so indicate. This information assists the Company in administering the Special Majority counts and does not by itself exclude the shareholder’s vote from the second count.

 

If you have any question as to whether you are a controlling shareholder or have a personal interest in any proposal, please contact the Company at ir@mbody.ai or (702) 793-4300.

 

7

 

 

Recommendation of the Board of Directors

 

THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE “FOR” EACH OF THE PROPOSALS DESCRIBED IN THIS NOTICE, INCLUDING “FOR” THE ELECTION OF EACH DIRECTOR NOMINEE UNDER PROPOSAL 3 AND EACH EXTERNAL DIRECTOR CANDIDATE UNDER PROPOSAL 3A, AT BOTH SESSIONS OF THE MEETING.

 

Detailed voting instructions are provided both in the Proxy Statement and in the accompanying proxy card, which were furnished to the SEC on a Report on Form 6-K on or about November 17, 2026 and are available on the SEC’s website at www.sec.gov and on the Company’s website at ir.mbody.ai.

 

If you have any questions or need assistance with voting at the Meeting, please contact our proxy solicitor:

 

MacKenzie Partners

1-800-322-2885 (shareholders)

1-212-929-5500 (banks and brokers)

 

On behalf of the Board of Directors, I thank you for your support and appreciate your consideration of these matters.

 

Sincerely,

 

Regan McGee

 

Chairman of the Board of Directors

 

November 17, 2026

 

8

 

Exhibit 99.2

 

MBODY AI LTD.

 

7111 Syntex Drive, 3rd floor

Mississauga, Ontario

Canada

 

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

 

To be held on December 22, 2026 in two sessions, at 10:00 a.m. Eastern Time and, by adjournment, at 2:00 p.m. Eastern Time

 

Dear Shareholder:

 

We cordially invite you to attend the Annual General Meeting of Shareholders (the “Meeting”) of MBody AI Ltd. (formerly Check-Cap Ltd.) (“MBody AI,” the “Company,” “we,” “us” or “our”) to be held on December 22, 2026 in two sessions: the first at 10:00 a.m. Eastern Time, and the second, to which the first session will be adjourned, at 2:00 p.m. Eastern Time on the same day, in each case as a virtual meeting held exclusively by live audio webcast at https://edge.media-server.com/mmc/p/im8ebjko (password: mbodyai2026). There will be no physical meeting location. Shareholders of record and holders of a legal proxy may attend, ask questions and vote at the Meeting online.

 

At the Meeting, you will be asked to consider and vote on the following proposals. The proposal numbers are the item numbers on the enclosed proxy card.

 

At the first session (10:00 a.m. Eastern Time):

 

  4. to appoint SIMON & EDWARD, LLP, the successor by merger to BCRG LLP, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 and until the next annual general meeting of shareholders, and to authorize the Board of Directors, upon the recommendation of the Audit Committee, to fix its compensation (the “Auditor Proposal” or “Proposal 4”);

 

  3. to elect each of Regan McGee, John Fowler and David Lontini as a director of the Company, each to serve until the next annual general meeting of shareholders, unless his office is vacated earlier in accordance with the Articles of Association or the Israeli Companies Law, 5759-1999 (the “Companies Law”) (the “Director Election Proposal” or “Proposal 3”);

 

  3A. to elect each of Fiona George and Daniel Kokiw as an external director of the Company, within the meaning of the Companies Law, each for a three-year term commencing on the date of the Meeting (the election of Daniel Kokiw being conditional upon the election of Fiona George) (the “External Director Proposal” or “Proposal 3A”);

 

  6. to approve the adoption of a new Article 42A of the Articles of Association, in the form set out in Part D of Appendix D, confirming that the powers of the Board and of the continuing directors under Article 42 to appoint directors do not include the power to appoint external directors, who may be elected only by the general meeting, and that if the office of an external director becomes vacant the Board will convene a general meeting to elect an external director in accordance with the Companies Law (the “External Director Vacancies Proposal” or “Proposal 6”);

 

  7. to authorize the Board of Directors, in its discretion and at any time within 24 months after the date of the Meeting, to change the name of the Company from “MBody AI Ltd.” to “MBody SI Ltd.”, or to such similar name as the Registrar of Companies may approve, and to approve the corresponding amendment of the Articles of Association of the Company, in the form set out in Part A of Appendix D, effective upon the determination of the Board of Directors and the approval of the Registrar of Companies (the “Name Change Authority Proposal” or “Proposal 7”);

  

1

 

 

1.

to approve an amendment to the Company’s Articles of Association, in the form set out in Part B of Appendix D, so that all of the Company’s authorized and issued Ordinary Shares, currently of nominal value NIS 48.00 each, are re-designated as Ordinary Shares of no par value, together with conforming amendments to Articles 2, 6, 7, 9, 12, 14, 53, 55 and 69 of the Articles of Association, including concerning the consolidation and division of shares and fractional shares, and to confirm that the Company shall not seek payment of any unpaid nominal value from any holder of Ordinary Shares issued before the effective time of the amendment (the “No Par Value Proposal” or “Proposal 1”); and

 

2. subject to and conditional upon Proposal 1 becoming effective, to approve an increase in the Company’s authorized share capital from 18,000,000 Ordinary Shares to 175,000,000 Ordinary Shares of no par value, and the corresponding amendment of the Articles of Association in the form set out in Part C of Appendix D (the “Authorized Share Capital Proposal” or “Proposal 2”).

 

At the second session (2:00 p.m. Eastern Time the same day), to which the first session will be adjourned:

 

5.

to approve the MBody AI Ltd. 2026 Equity Incentive Plan, including its Israeli, United States and Canadian appendices, in the form attached as Appendix B, with a reserve of 1,841,517 Ordinary Shares, and to acknowledge that the Check-Cap Ltd. 2015 Equity Incentive Plan expired by its terms on June 23, 2025, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to it, including the Interval Approvals (the “Equity Plan Proposal” or “Proposal 5”);

 

8.to approve the Company’s amended and restated compensation policy (the “Compensation Policy”) for Executive Officers and Directors, including amendments to its compensation caps and ratios, in the form attached as Appendix A, for a period of three years from the date of the Meeting (the “Compensation Policy Proposal” or “Proposal 8”);

 

9(a).to approve the terms of office and engagement of John Fowler as Chief Executive Officer of the Company, as described in the Proxy Statement, including the guarantee by the Company of the obligations of MBody AI Corp. to Mr. Fowler under his employment agreement, the indemnification and exculpation undertaking in the form attached as Appendix C and the amended and restated indemnification agreement between MBody AI Corp. and Mr. Fowler (the “CEO Compensation Proposal” or “Proposal 9(a)”);

 

9(b).to approve the compensation of the non-employee directors of the Company, other than the external directors and any director who is a controlling shareholder of the Company (the “Director Compensation Proposal” or “Proposal 9(b)”);

 

9(c).to approve, in accordance with Regulation 5(f) of the Israeli Companies Regulations (Reliefs for Companies with Securities Listed on an Exchange Outside of Israel), 5760-2000, and Regulations 8A and 8B of the Companies Regulations (Rules Regarding Compensation and Expenses of External Directors), 5760-2000 (the “External Director Regulations”), the compensation of the external directors in excess of the amounts otherwise prescribed by those regulations (the “External Director Compensation Proposal” or “Proposal 9(c)”); and

 

9(d).to approve the grant of indemnification and exculpation undertakings to the directors of the Company, other than the Chief Executive Officer and any director who is a controlling shareholder of the Company, in the form attached as Appendix C (the “Indemnification Proposal” or “Proposal 9(d)”).

 

2

 

 

Proposals 4, 3, 3A, 6, 7, 1 and 2 will be voted on at the first session of the Meeting, at 10:00 a.m. Eastern Time. Proposals 5, 8, 9(a), 9(b), 9(c) and 9(d) will be voted on at the second session, at 2:00 p.m. Eastern Time on the same day. The Meeting will be adjourned at the close of the first session and will reconvene for the second session. The reason for the two sessions is explained under “Background of the Meeting” and “Why the Meeting is held in two sessions on the same day” below. A single proxy card covers both sessions.

 

In addition, at the first session of the Meeting, representatives of management will present and discuss with shareholders the Company’s audited consolidated financial statements for the year ended December 31, 2025. The financial statements are included in the Company’s Annual Report on Form 20-F for that year, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 27, 2026, under the Company’s former name, Check-Cap Ltd. (the “2025 Annual Report”). The 2025 Annual Report is available on the SEC’s website at www.sec.gov and on the Company’s website at ir.mbody.ai. It is not part of the proxy solicitation material. No vote is required on this item.

 

We are not aware of any other matters that will come before the Meeting. If any other matters properly come before the Meeting, the persons designated as proxies intend to vote on such matters in accordance with the judgment and recommendation of the Board of Directors.

 

Background of the Meeting

 

On August 26, 2026, the Company completed its business combination with MBody AI Corp., a Nevada corporation (the “Business Combination”), following which MBody AI Corp. became a wholly-owned subsidiary of the Company and the Company changed its name from Check-Cap Ltd. to MBody AI Ltd. Our Ordinary Shares continue to trade on the Nasdaq Capital Market under the symbol “MBAI.” The Company remains incorporated in the State of Israel and is governed by the Companies Law.

 

The Business Combination changed the Company’s business, its board of directors and its shareholder base. This Meeting is the first annual general meeting since the Business Combination. Several of the proposals address matters that follow directly from it: the re-designation of our shares as no par value shares, which we undertook to bring to this Meeting in our prospectus dated August 27, 2026; the election of directors; the election of two external directors, as required under the Companies Law now that the Company has a controlling shareholder; the approval and updating of our Compensation Policy; and the adoption of a new equity incentive plan for the combined company.

 

The Company’s current Compensation Policy was approved by shareholders on December 18, 2023. Under Section 267A of the Companies Law, a compensation policy must be approved by shareholders at least once every three years. The current Compensation Policy will therefore cease to be in effect on December 18, 2026, four days before the Meeting. Under the Companies Law, a new compensation policy must first be recommended by a compensation committee that includes the external directors, who are to be elected at the first session of the Meeting. Proposal 8 asks shareholders to approve an amended and restated Compensation Policy for a period of three years from the date of the Meeting. See “Proposal 8” for the consequences if Proposal 8 is not approved.

 

Following the Business Combination, Regan McGee, the Chairman of the Board, is a controlling shareholder of the Company under the Companies Law. As a result, the exemption from the requirement to appoint external directors on which the Company previously relied ceased to apply at the closing, and the Company is required to elect two external directors. The Company is doing so at this Meeting, which is the earliest practicable general meeting following the closing. Until the external directors are elected, the Company’s Compensation Committee does not meet the composition requirements of the Companies Law for the approval of office holder compensation. See “Why the Meeting is held in two sessions on the same day.”

 

3

 

 

Why the Meeting is held in two sessions on the same day

 

Under the Companies Law, the compensation policy and the terms of office and engagement of the Company’s office holders must be approved by a compensation committee that includes the external directors, then by the Board, and then by shareholders. The Company’s current compensation committee (the “Current Compensation Committee”), none of whose members is an external director, does not meet that requirement. Because the external directors are elected at this Meeting, the Board has structured the Meeting in two sessions on the same day. At the first session, at 10:00 a.m. Eastern Time, shareholders will vote on the proposals that do not depend on the composition of the Compensation Committee, including the election of the external directors. The first session will then be adjourned. In the interval, the external directors take office, the Board will reconstitute the Compensation Committee to include the external directors as required by the Companies Law (as reconstituted, the “Reconstituted Compensation Committee”), and the Reconstituted Compensation Committee and then the Board will meet to consider and, if they see fit, approve and recommend the 2026 Equity Incentive Plan described in Proposal 5 and the compensation matters described in Proposals 8 and 9 (the “Interval Approvals”). References in this Notice and the Proxy Statement to the “Compensation Committee” without qualification are to the compensation committee of the Board as constituted from time to time. The Meeting will reconvene at 2:00 p.m. Eastern Time for the second session, at which shareholders will vote on those proposals. The terms of the compensation proposals, as approved by the Board for submission to the shareholders, are described in the Proxy Statement; if the Reconstituted Compensation Committee or the Board makes any change as part of the Interval Approvals, the chairman of the Meeting will announce the change at the second session before the vote, and the Company will furnish a report on Form 6-K that describes the change as soon as practicable.

 

Who Can Vote

 

You are entitled to notice of, and to vote in person or by proxy at, the Meeting if you are a holder of record of Ordinary Shares as of the close of business on November 20, 2026 (the “Record Date”). As of November 13, 2026, the latest practicable date before the date of this Notice and the Proxy Statement (the “Reference Date”), there were 15,345,971 Ordinary Shares outstanding. You are also entitled to notice of the Meeting and to vote at the Meeting if you held Ordinary Shares through a bank, broker or other nominee that is one of the Company’s shareholders of record at the close of business on the Record Date, or which appeared in the participant listing of a securities depository on that date. The Record Date applies to both sessions of the Meeting.

 

How You Can Vote

 

●Voting at the virtual Meeting. If you are a shareholder of record, that is, your shares are registered directly in your name with the Company’s transfer agent, Equiniti Trust Company, LLC, you may attend and vote at the virtual Meeting by logging on to https://edge.media-server.com/mmc/p/im8ebjko, entering the password mbodyai2026 and entering your control number. If you are a beneficial owner of shares registered in the name of your broker, bank, trustee or nominee (that is, your shares are held in “street name”), you are also invited to attend the Meeting; however, to vote at the virtual Meeting as a beneficial owner, you must first obtain a “legal proxy” from your broker, bank, trustee or nominee giving you the right to vote the shares at the Meeting.

 

●Voting by mail. If you are a shareholder of record, you may submit your proxy by completing, signing and mailing the enclosed proxy card in the enclosed postage-paid envelope. If your Ordinary Shares are held in street name, please follow the voting instructions provided by your broker, trustee or nominee. Proxies must be received by the Company’s transfer agent, Equiniti Trust Company, LLC, Attn: Proxy Department, 1110 Centre Pointe Curve, Suite 101, Mendota Heights, MN 55120-4100, no later than December 20, 2026 at 10:00 a.m. Eastern Time. Proxies received by the transfer agent after that time and before the first session will be presented to the chairman of the Meeting and, at his discretion, may be voted as marked if received before the vote on the relevant matter. A proxy received by that deadline is valid for both sessions and carries to the second session.

 

4

 

 

●Voting by Internet. If you are a shareholder of record, you can submit a proxy over the Internet by logging on to the website listed on the enclosed proxy card, entering your control number and following the on-screen prompts. If you hold shares in street name, you may vote by the methods described in the instructions provided by your broker, bank, trustee or nominee. Submitting an Internet proxy will not affect your right to vote at the Meeting should you decide to attend.

 

The persons named as proxies on the enclosed proxy card are Sean Donahue and Carl Sherer, neither of whom is an office holder of the Company or has a personal interest in any proposal.

 

Change or Revocation of Proxy

 

If you are a shareholder of record, you may change or revoke your proxy in one of the following ways: (i) deliver a written notice of revocation to the Company’s Chief Financial Officer, Tim Hayden, at the address above; (ii) grant a new proxy that bears a later date; (iii) vote again via the Internet; or (iv) attend the virtual Meeting and vote online. A notice of revocation or a new proxy under (i), (ii) or (iii) is effective only if the Company or its transfer agent receives it by the proxy deadline stated above. Attendance at the Meeting will not by itself revoke a previously granted proxy. A proxy given for the first session carries to the second session, and the proxy deadline applies to both sessions. 1 If your shares are held in street name, you may change your vote by submitting new voting instructions to your broker, bank, trustee or nominee or, if you have obtained a legal proxy, by attending the virtual Meeting and voting online.

 

Quorum

 

The presence, in person or by proxy, of two or more shareholders holding or representing, in the aggregate, at least twenty-five percent (25%) of the Company’s voting rights will constitute a quorum at the Meeting. A shareholder attending the virtual Meeting online is treated as present in person. No business will be considered or determined at the Meeting unless the requisite quorum is present within half an hour from the time designated for the Meeting. If a quorum is not present within that time, the Meeting will stand adjourned to Tuesday, December 29, 2026, at the same times, in the same virtual format. At the adjourned meeting, any two (2) shareholders present in person or by proxy will constitute a quorum. The same 25% quorum requirement applies at the second session of the Meeting on the same day.

 

Abstentions and broker non-votes will be counted towards the quorum. A broker non-vote occurs when a broker holding shares in street name submits a proxy for those shares (in which case the shares are considered present for the purposes of determining presence of a quorum at the Meeting) but does not have the discretionary authority to vote on a particular proposal. This occurs when brokers have not received voting instructions from their customers, in which case the brokers, as the holders of record, are permitted to vote on “routine” matters, but not on non-routine matters. The proposals described in this Notice are non-routine matters except for the Auditor Proposal (Proposal 4) and, we expect, the No Par Value Proposal (Proposal 1) and the Authorized Share Capital Proposal (Proposal 2); therefore, it is important that you vote your shares, either by proxy or at the virtual Meeting.

 

Unsigned or unreturned proxies, including those not returned by banks, brokers or other record holders, will not be counted for quorum or voting purposes.

 

 

 

1The two sessions of the Meeting are held on the same day, and the proxies for both sessions are tabulated on the basis of proxies received by the proxy deadline. For that reason, a proxy, notice of revocation or new proxy received after the proxy deadline will not change a vote at the second session, except that a shareholder of record may attend the virtual Meeting and vote online. The Company does not expect any change between the sessions to the matters to be voted on at the second session. If a material change is made, the Company will announce it at the second session before the vote and furnish a report on Form 6-K describing the change as soon as practicable.

 

5

 

 

Vote Required for Approval of the Proposals

 

Your vote is very important, regardless of the number of Ordinary Shares that you own. Each Ordinary Share entitles the holder to one vote.

 

Ordinary majority. Proposals 1, 2, 3 (each nominee voted on separately), 4, 5, 6 and 7 each require the affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter (an “Ordinary Majority”). Abstentions and broker non-votes are not considered votes cast and have no effect on the result.

 

Special majority. Proposals 3A(a), 3A(b), 8, 9(a), 9(b), 9(c) and 9(d) each require an Ordinary Majority, and in addition require that either: (i) the majority of the votes cast in favor of the proposal includes at least a majority of the votes cast by shareholders who are not controlling shareholders of the Company and who do not have a personal interest in the approval of the proposal (in the case of Proposals 3A(a), 3A(b) and 9(c), only a personal interest arising from a relationship with the controlling shareholder), excluding abstentions; or (ii) the total number of votes cast against the proposal by the shareholders described in clause (i) does not exceed two percent (2%) of the total voting rights in the Company (a “Special Majority”). Because the current Compensation Policy will cease to be in effect on December 18, 2026, before the Meeting, the Company is submitting Proposals 9(b) and 9(d) for approval by a Special Majority, whether or not Proposal 8 is approved. The terms “controlling shareholder” and “personal interest” are explained under “Controlling Shareholders and Personal Interests” below.

 

Board override. If shareholders do not approve Proposal 8 by the required Special Majority, the Compensation Committee and the Board may nonetheless approve the Compensation Policy under Section 267A(c) of the Companies Law, following further discussion and on the basis of detailed reasons, if they determine that approval is in the best interests of the Company. If shareholders do not approve Proposal 9(a), the Compensation Committee and the Board may approve the Chief Executive Officer’s terms under Section 272(c1)(2) of the Companies Law on the same basis, to the extent that the Companies Law permits for an office holder who is also a director. No such override is available for Proposals 3A(a), 3A(b) or 9(c).

 

Conditional proposals. Proposal 2 is conditional upon Proposal 1 becoming effective. The election of Daniel Kokiw under Proposal 3A(b) is conditional upon the election of Fiona George under Proposal 3A(a). Proposals 8, 9(a), 9(b), 9(c) and 9(d) will be voted on at the second session only if both external directors are elected under Proposal 3A at the first session. Proposal 5 will be voted on at the second session whether or not the external directors are elected, because Israeli law does not require a compensation committee that includes the external directors to approve an equity incentive plan; if the Compensation Committee cannot be reconstituted, the Board will consider the Interval Approvals for Proposal 5. The equity components of Proposal 9(b) and 9(c) are conditional upon the approval of Proposal 5, and Proposal 9(c) is conditional upon the approval of Proposal 9(b). Proposal 7 is not conditional on any other proposal; the Part A regularization in Appendix D is drafted so that the Articles carry the current name if the Board does not use the authority. Otherwise, each proposal stands on its own and the approval of one proposal is not conditioned on the approval of any other.

 

Controlling Shareholders and Personal Interests

 

Under the Companies Law, in counting the Special Majority the votes of a “controlling shareholder” and of any shareholder having a “personal interest” in the approval of the proposal are excluded from the second count described in clause (i) above and are not counted toward the two percent threshold in clause (ii). In this Notice and the Proxy Statement, the “second count” means that separate count of the votes of shareholders who are not controlling shareholders and do not have a personal interest; it does not refer to the second session of the Meeting.

 

A “controlling shareholder” is a shareholder who has the ability to direct the activities of the Company, other than by virtue of being a director or other office holder. A person is presumed to be a controlling shareholder if he or she holds fifty percent (50%) or more of the voting rights in the Company or the right to appoint a majority of its directors or its chief executive officer. For the purposes of approving the terms of office and engagement of office holders and transactions with interested parties, a controlling shareholder also includes any shareholder who holds twenty-five percent (25%) or more of the voting rights in the Company if no other shareholder holds more than fifty percent (50%) of the voting rights, and two or more shareholders who each have a personal interest in the approval of the same transaction are treated as joint holders for this purpose. Regan McGee, the Chairman of our Board of Directors, beneficially owns approximately 45% of our outstanding Ordinary Shares and is a controlling shareholder of the Company for the purposes of the Companies Law.

 

6

 

 

A “personal interest” of a shareholder in an action or transaction of the Company includes a personal interest of any member of the shareholder’s immediate family (including a spouse, sibling, parent, grandparent, descendant, or spouse’s descendant, sibling or parent, or the spouse of any of these) or of any entity in which the shareholder or any such family member serves as a director or chief executive officer, owns at least five percent (5%) of the outstanding shares or voting rights, or has the right to appoint a director or the chief executive officer. A personal interest also includes the interest of a person voting under a proxy given by another person, whether or not the person granting the proxy has a personal interest. A vote cast by a proxy holder on behalf of a shareholder who has a personal interest is also treated as a vote of a person with a personal interest. A personal interest does not include an interest arising solely from the ownership of Ordinary Shares. A shareholder who votes on Proposal 3A or Proposal 9(c) is treated as having a personal interest only if that interest results from a relationship with a controlling shareholder.

 

Confirmation by voting shareholders. Under the Companies Law, a shareholder voting on a proposal that requires a Special Majority must notify the Company before the vote whether or not he or she is a controlling shareholder or has a personal interest in the approval of the proposal. In reliance on Regulation 3A of the Israeli Companies Regulations (Reliefs for Companies with Securities Listed on an Exchange Outside of Israel), 5760-2000 (the “Reliefs Regulations”), by signing and returning the proxy card, or by voting online before or at the Meeting, a shareholder confirms to the Company that such shareholder is NOT a controlling shareholder of the Company and does NOT have a personal interest in the approval of any of Proposals 3A(a), 3A(b), 8, 9(a), 9(b), 9(c) or 9(d), unless such shareholder has delivered to the Company a notice in writing stating otherwise, no later than December 20, 2026 at 10:00 a.m. Eastern Time, to the attention of the Company’s Chief Financial Officer, Tim Hayden, at 7111 Syntex Drive, 3rd Floor, Mississauga, Ontario, Canada or by e-mail to ir@mbody.ai, or has so indicated on the proxy card. A shareholder who so indicates without specifying a proposal will have his, her or its vote excluded from the second count on all of those proposals. If you hold your shares in “street name” (through a bank, broker or other nominee) and believe that you are a controlling shareholder or have a personal interest in the approval of any of those proposals, you may also contact the representative managing your account, who can contact the Company’s Chief Financial Officer on your behalf. A shareholder who is a controlling shareholder or has a personal interest and who does not so notify the Company will have his, her or its vote counted as if the shareholder were not a controlling shareholder and had no personal interest, in reliance on the deemed confirmation.

 

Holders of 5% or more. The proxy card also asks a shareholder who holds 5% or more of the outstanding Ordinary Shares or of the voting rights of the Company to so indicate. This information assists the Company in administering the Special Majority counts and does not by itself exclude the shareholder’s vote from the second count.

 

If you have any question as to whether you are a controlling shareholder or have a personal interest in any proposal, please contact the Company at ir@mbody.ai or (702) 793-4300.

 

7

 

 

Recommendation of the Board of Directors

 

THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE “FOR” EACH OF THE PROPOSALS DESCRIBED IN THIS NOTICE, INCLUDING “FOR” THE ELECTION OF EACH DIRECTOR NOMINEE UNDER PROPOSAL 3 AND EACH EXTERNAL DIRECTOR CANDIDATE UNDER PROPOSAL 3A, AT BOTH SESSIONS OF THE MEETING.

 

Detailed voting instructions are provided both in the Proxy Statement and in the accompanying proxy card, which were furnished to the SEC on a Report on Form 6-K on or about November 17, 2026 and are available on the SEC’s website at www.sec.gov and on the Company’s website at ir.mbody.ai.

 

If you have any questions or need assistance with voting at the Meeting, please contact our proxy solicitor:

 

MacKenzie Partners

1-800-322-2885 (shareholders)

1-212-929-5500 (banks and brokers)

 

On behalf of the Board of Directors, I thank you for your support and appreciate your consideration of these matters.

 

Sincerely,

 

Regan McGee

 

Chairman of the Board of Directors

 

November 17, 2026

 

8

 

 

MBODY AI LTD.

 

PROXY STATEMENT

 

ANNUAL GENERAL MEETING OF SHAREHOLDERS

 

To be held on December 22, 2026 in two sessions, at 10:00 a.m. Eastern Time and, by adjournment, at 2:00 p.m. Eastern Time

 

This Proxy Statement is being furnished in connection with the solicitation of proxies on behalf of the Board of Directors (the “Board”) of MBody AI Ltd. (formerly Check-Cap Ltd.) (“MBody AI,” the “Company,” “we,” “us” or “our”) to be voted at the Annual General Meeting of Shareholders (the “Meeting”), and at any adjournment or postponement thereof, pursuant to the accompanying Notice of Annual General Meeting of Shareholders (the “Notice”). The Meeting will be held on December 22, 2026 in two sessions, the first at 10:00 a.m. Eastern Time and the second, by adjournment of the first, at 2:00 p.m. Eastern Time on the same day, in each case as a virtual meeting held exclusively by live audio webcast at https://edge.media-server.com/mmc/p/im8ebjko (password: mbodyai2026).

 

Capitalized terms used in this Proxy Statement and not otherwise defined have the meanings given to them in the Notice.

 

The Company published the Notice on November 17, 2026 and furnished the Notice, this Proxy Statement and the proxy card to the SEC on a Report on Form 6-K on or about the same date. On or about November 26, 2026, the Company is mailing the Notice, this Proxy Statement, and the proxy card to shareholders of record and, through their brokers, banks and other nominees, to beneficial owners, in each case as of the Record Date. The Notice, this Proxy Statement and the proxy card are also available on the SEC’s website at www.sec.gov and on the Company’s website at ir.mbody.ai.

 

Mailing. This Proxy Statement, the Notice and the proxy card are first being mailed to shareholders on or about November 26, 2026. The Company is not using the “notice and access” model for this Meeting.

 

Additional copies. A shareholder may request a copy of the proxy materials, free of charge, from the Company by e-mail to ir@mbody.ai or by telephone at (702) 793-4300. Shareholders holding through a bank, broker or other nominee should follow the instructions provided by that nominee.

 

As a foreign private issuer, the Company is exempt from the rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), related to the furnishing and content of proxy statements. The circulation of this Proxy Statement should not be taken as an admission that the Company is subject to those proxy rules. The votes on the compensation-related proposals at the Meeting are binding under the Companies Law and are not advisory “say-on-pay” votes of the kind held by U.S. domestic issuers.

 

Purpose of the Meeting

 

At the Meeting, shareholders will be asked to consider and vote on the proposals set out in the Notice. Each proposal is described in detail in this Proxy Statement under the heading bearing its number, which is also the item number under which it appears on the proxy card.

 

9

 

 

Summary of Proposals, Card Items and Votes Required

 

The following table summarizes the proposals, the corresponding items on the proxy card, the session at which each is voted, and the vote required. See “Vote Required for Approval of the Proposals” and “Controlling Shareholders and Personal Interests” in the Notice for the full explanation, including the Board override (where applicable) and the persons excluded from the second count.

 

Proposal Subject Items on proxy card;
session
Vote required
4 Appointment of SIMON & EDWARD, LLP (successor by merger to BCRG LLP) as independent auditor; Board authority to fix compensation. Item 4; first Ordinary Majority
3 Election of 3 directors (one vote per nominee). Items 3(a) to 3(c); first Ordinary Majority
3A Election of 2 external directors for three-year terms (one vote per candidate). Items 3A(a) and 3A(b); first Special Majority (Section 239(b))
6 New Article 42A: external directors may not be appointed by the Board under Article 42. Item 6; first Ordinary Majority
7

Regularization of the Company’s name in the Articles; authority to the Board to change the Company’s name to MBody SI Ltd. (24 months).

Item 7; first Ordinary Majority
1 Re-designation of Ordinary Shares as no par value shares; confirmation of no call on unpaid nominal value. Item 1; first Ordinary Majority
2 Increase in authorized share capital to 175,000,000 Ordinary Shares (conditional on Proposal 1). Item 2; first Ordinary Majority
5

2026 Equity Incentive Plan with Israeli, U.S. and Canadian appendices; reserve of 1,841,517 shares.

Item 5; second Ordinary Majority
8 Amended and restated Compensation Policy, including amended caps and ratios (three years). Item 8; second Special Majority (Section 267A)
9(a) Terms of office and engagement of John Fowler as Chief Executive Officer, including the Company guarantee, the indemnification undertaking and the MBody AI Corp. indemnification agreement. Item 9(a); second Special Majority (Section 272(c1))
9(b)

Compensation of non-employee directors other than the external directors and any controlling shareholder: US$40,000 cash and US$60,000 equity per year, identical to the external directors (equity conditional on Proposal 5); if Proposal 9(c) is not approved, the amounts prescribed by the External Director Regulations, without equity, while serving on the Compensation Committee.

Item 9(b); second Special Majority (Section 273; policy lapses before the Meeting)
9(c) Compensation of the external directors under Regulation 5(f) of the Reliefs Regulations and Regulations 8A and 8B of the External Director Regulations: US$40,000 cash and US$60,000 equity per year (equity conditional on Proposal 5) Item 9(c); second Special Majority (Section 239(b) majority, under Regulation 8B)
9(d) Indemnification and exculpation undertakings for directors other than the Chief Executive Officer and any controlling shareholder (Appendix C form). Item 9(d); second Special Majority (Section 273; policy lapses before the Meeting)

  

THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE “FOR” EACH OF THE PROPOSALS.

 

10

 

 

QUESTIONS AND ANSWERS ABOUT THE MEETING

 

The following questions and answers address briefly some questions you may have about the Meeting. They may not address all questions that may be important to you as a shareholder. Please refer to the more detailed information contained elsewhere in this Proxy Statement and its appendices.

 

Q: Why am I receiving these materials?

 

A: The Company is soliciting proxies for its Annual General Meeting of Shareholders. You are receiving these materials because you owned Ordinary Shares of the Company on November 20, 2026, the Record Date for the Meeting, and that ownership entitles you to vote at the Meeting. By use of a proxy, you can vote your shares whether or not you attend the Meeting.

 

Q: What am I being asked to vote on?

 

A: 10 proposals, comprising 16 separate votes on the proxy card: the appointment of SIMON & EDWARD, LLP (the successor by merger to BCRG LLP) as our independent auditor (Proposal 4); the election of 3 directors, voted on individually (Proposal 3); the election of 2 external directors, voted on individually (Proposal 3A); a new Article 42A of our Articles of Association (Proposal 6); an optional authority to the Board to change the Company’s name (Proposal 7); the re-designation of our shares as no par value shares (Proposal 1); an increase in our authorized share capital (Proposal 2); a new equity incentive plan (Proposal 5); the approval of our amended and restated Compensation Policy, including amendments to its caps and ratios (Proposal 8); the terms of office of our Chief Executive Officer (Proposal 9(a)); the compensation of our non-employee directors (Proposal 9(b)); the compensation of our external directors (Proposal 9(c)); and indemnification and exculpation undertakings for our directors (Proposal 9(d)). You will also have the opportunity to discuss our audited financial statements for 2025, on which no vote is taken.

 

Q: Why is the Meeting held in two sessions on the same day?

 

A: The Companies Law requires that compensation matters be approved by a compensation committee that includes the external directors before shareholders vote on them. The external directors are elected at the first session, at 10:00 a.m. Eastern Time. The Board will reconstitute the Compensation Committee immediately afterwards, the reconstituted Committee and the Board will meet in the interval to consider and, if they see fit, approve the equity incentive plan and the compensation matters, and shareholders will vote on them at the second session, at 2:00 p.m. Eastern Time the same day. One proxy card covers both sessions; you do not need to vote twice. See “Why the Meeting is held in two sessions on the same day” in the Notice.

 

Q: Why are there so many items on the ballot?

 

A: The Meeting is the first annual general meeting following the Business Combination, and the Companies Law requires shareholder approval for a number of matters that arise from it. Directors elected under the Companies Law are voted on one at a time. The compensation matters are presented as separate votes so that shareholders can vote on each one separately; the Company has not bundled unrelated matters into a single vote.

 

Q: Who will serve on the Board after the Meeting?

 

A: If all nominees are elected, the Board will consist of 5 directors: Regan McGee, John Fowler and David Lontini (Proposal 3) and Fiona George and Daniel Kokiw as external directors (Proposal 3A). The election of Mr. Kokiw is conditional upon the election of Ms. George, because the Companies Law requires that where all directors are of one gender, the external director appointed must be of the other gender. Kai Sorensen, Ghaleb El Masri and Anurag Sharma, who are current directors, are not standing for re-election, and their terms of office will end at the conclusion of the Meeting, which will be the end of the second session. See “The Board of Directors and Corporate Governance.”

 

11

 

 

Q: Why is the Company asking shareholders to elect external directors?

 

A: The Companies Law requires an Israeli public company to have at least two external directors, who are independent directors elected by a Special Majority for fixed three-year terms and who sit on the audit and compensation committees. Before the Business Combination, the Company relied on an exemption available to companies listed on Nasdaq that have no controlling shareholder. Following the Business Combination, Regan McGee is a controlling shareholder of the Company, so the exemption ceased to apply at the closing on August 26, 2026 and the Company is required to elect two external directors. The Company is doing so at this Meeting. See “Proposal 3A.”

 

Q: What is a controlling shareholder and what is a personal interest, and why do they matter?

 

A: Several proposals require a Special Majority under the Companies Law. In counting a Special Majority, the votes of a controlling shareholder and of shareholders with a personal interest in the proposal are set aside, and the proposal must be supported by a majority of the remaining votes (or opposed by no more than 2% of the total voting rights). Regan McGee, our Chairman, is a controlling shareholder. If you are not a controlling shareholder and have no personal interest in a proposal, your vote counts in both tallies. See “Controlling Shareholders and Personal Interests” in the Notice.

 

Q: Do I need to do anything to confirm that I am not a controlling shareholder or do not have a personal interest?

 

A: No, unless you are one. By signing and returning the proxy card, or by voting online before or at the Meeting, you confirm that you are not a controlling shareholder and do not have a personal interest in Proposals 3A(a), 3A(b), 8, 9(a), 9(b), 9(c) and 9(d). If you are a controlling shareholder or have a personal interest, you must notify the Company’s Chief Financial Officer in writing by the proxy deadline, or so indicate on the proxy card where provided. Street-name holders may do so through their broker. If you hold 5% or more of our Ordinary Shares, please also check the box provided for that purpose.

 

Q: Who can vote at the Meeting?

 

A: All holders of record of Ordinary Shares as of the close of business on November 20, 2026 are entitled to vote at the Meeting. Each Ordinary Share is entitled to one vote on each matter. As of the Reference Date, November 13, 2026, there were 15,345,971 Ordinary Shares outstanding.

 

Q: What constitutes a quorum?

 

A: Two or more shareholders present in person or by proxy holding at least 25% of the Company’s voting rights. Abstentions and broker non-votes count toward the quorum. If a quorum is not present within half an hour, the Meeting will be adjourned to December 29, 2026, and any two shareholders present in person or by proxy will then constitute a quorum.

 

Q: How do I vote?

 

A: You may vote at the virtual Meeting, by mailing the enclosed proxy card, or by Internet. If you hold your shares in street name, follow the instructions from your broker, bank or nominee. See “How You Can Vote” in the Notice.

 

Q: What happens if I do not vote, or return a proxy card without marking it?

 

A: If you are a shareholder of record and do not vote, your shares will not be voted. If you hold your shares in street name and do not instruct your broker, your shares will not be voted on any proposal except proposals on which brokers may vote uninstructed shares. See “Quorum” in the Notice. If you return a signed proxy card without marking a choice on a proposal, your shares will be voted “FOR” that proposal, subject to the confirmation described above.

 

12

 

 

Q: Can I change my vote after I have submitted a proxy?

 

A: Yes, until the proxy deadline. See “Change or Revocation of Proxy” in the Notice. Your proxy carries to the second session, and the proxy deadline applies to both sessions.

 

Q: What is the effect of the proposals being conditional on one another?

 

A: Proposal 2 (the increase in authorized share capital) will not take effect unless Proposal 1 (no par value) is approved and becomes effective, because the increase is expressed as a number of shares of no par value. The election of Daniel Kokiw (Proposal 3A(b)) is conditional upon the election of Fiona George (Proposal 3A(a)); see “Proposal 3A.” Proposals 8 and 9 will be voted on at the second session only if both external directors are elected under Proposal 3A at the first session. Proposal 5 (the equity plan) will be voted on at the second session whether or not the external directors are elected. The equity components of the non-employee director compensation and the external director compensation (Proposals 9(b) and 9(c)) will not take effect unless Proposal 5 (the equity plan) is approved. The external director compensation (Proposal 9(c)) will not take effect unless the non-employee director compensation (Proposal 9(b)) is approved. Proposal 7 (the name change authority) is not conditional on any other proposal.

 

Q: What happens if a compensation proposal is not approved?

 

A: It depends on the proposal. If shareholders do not approve the Compensation Policy (Proposal 8), the Compensation Committee and the Board may nonetheless approve it under Section 267A(c) of the Companies Law, following further discussion and on the basis of detailed reasons, if they determine that approval is in the best interests of the Company. The same applies to the Chief Executive Officer’s terms (Proposal 9(a)) under Section 272(c1)(2), to the extent that the Companies Law permits for an office holder who is also a director. No such override exists for any other proposal. The consequences for each proposal are described under that proposal.

 

Q: What is Proposal 6?

 

A: Proposal 6 adds a new Article 42A to our Articles of Association. Article 42 of our Articles of Association permits the Board to appoint directors to fill vacancies and, if the number of directors falls below the minimum of four, limits the continuing directors to acting in an emergency, filling vacancies up to that minimum or calling a general meeting. Article 42A confirms that none of those powers extends to the appointment of external directors, who may be elected only by the general meeting under the Companies Law, and that if the office of an external director becomes vacant the Board will convene a general meeting to elect an external director in accordance with the Companies Law. It does not otherwise change Article 42 or the Board’s size limits in Article 39. See “Proposal 6.”

 

Q: What is Proposal 7?

 

A: Proposal 7 authorizes the Board, at its discretion and within 24 months after the Meeting, to change the Company’s name from MBody AI Ltd. to MBody SI Ltd. (or a similar name the Registrar of Companies approves) and to amend the Articles of Association accordingly. The Board may decide not to use the authority. The authority does not change the Company’s ticker symbol, share capital, business, management or any right of shareholders. Proposal 7 also amends the Articles, with effect from the Meeting, to reflect the Company’s current name, MBody AI Ltd., because the Articles on file were not updated when the name changed. See “Proposal 7.”

 

Q: Who is paying for this proxy solicitation?

 

A: The Company will bear the cost of soliciting proxies, including the reasonable expenses of brokers and nominees in forwarding proxy materials to beneficial owners. In addition to solicitation by mail, our directors, officers and employees may solicit proxies personally or by telephone or electronic means, without additional compensation. We have retained MacKenzie Partners, Inc. to assist in the solicitation for a fee of approximately $12,500 plus reimbursement of expenses.

 

Q: Whom should I contact with questions?

 

A: MacKenzie Partners, Inc. at 1-800-322-2885 (Shareholders) or 1-212-929-5500 (banks and brokers), or the Company at ir@mbody.ai

 

13

 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

This Proxy Statement contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans, objectives, expectations and intentions with respect to the matters to be voted on at the Meeting, the intended uses of authorized share capital, the anticipated benefits of the Compensation Policy and the equity incentive plan, and the composition and operation of the Board and its committees. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including the risks described under “Risk Factors” in the Company’s prospectus dated August 27, 2026 and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statement, except as required by law. Nothing in this Proxy Statement constitutes an offer to sell or the solicitation of an offer to buy any securities.

 

14

 

 

THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE

 

Composition of the Board

 

Under our Articles of Association, the Board must consist of not fewer than 4 and not more than 11 directors. At the closing of the Business Combination, the Board was reconstituted and the following 7 directors were appointed under Article 42 of the Articles of Association: Regan McGee (Chairman), John Fowler (Chief Executive Officer), David Lontini, Scott Walters, Kai Sorensen, Ghaleb El Masri and Anurag Sharma. Scott Walters passed away on October 10, 2026. The Board records its gratitude for his service to the Company. Each of the other 6 directors holds office until the conclusion of this Meeting.

 

Three (3) of the current directors, Regan McGee, John Fowler and David Lontini, are standing for election under Proposal 3. Kai Sorensen, Ghaleb El Masri and Anurag Sharma are not standing for re-election. Under Articles 40(a) and 42 of our Articles of Association, the term of office of each of them will end at the conclusion of the Meeting, which will be the end of the second session, and the Company thanks each of them for his service. Accordingly, each of them will remain a director in the interval between the first session and the second session, and the Board will consist of 8 directors. Two (2) candidates who are not currently directors, Fiona George and Daniel Kokiw, are standing for election as external directors under Proposal 3A. If the nominees under Proposals 3 and 3A are elected, the Board will consist of 5 directors following the Meeting: Regan McGee, John Fowler, David Lontini, Fiona George and Daniel Kokiw.

 

Other than external directors, each of our directors holds office until the next annual general meeting of shareholders following his or her election, unless the director’s office is vacated earlier in accordance with the Companies Law or the Articles of Association. A director appointed by the Board to fill a vacancy holds office for the remainder of the term of the director whose office was vacated. External directors serve fixed three-year terms under the Companies Law.

 

Director Independence

 

The Board has affirmatively determined that David Lontini and each of the external director candidates, Fiona George and Daniel Kokiw, is an “independent director” within the meaning of the Nasdaq Listing Rules, and that each of them also satisfies the independence requirements of Rule 10A-3 under the Exchange Act for audit committee membership. Each of Kai Sorensen, Ghaleb El Masri and Anurag Sharma, who serve until the conclusion of the Meeting, is also an independent director under the Nasdaq Listing Rules. Regan McGee (a controlling shareholder and the Chairman of the Board) and John Fowler (our Chief Executive Officer) are not independent under the Nasdaq Listing Rules. If the nominees under Proposals 3 and 3A are elected, the Board will consist of 5 directors, 3 of whom are independent under the Nasdaq Listing Rules, of whom Fiona George and Daniel Kokiw will also serve as external directors under the Companies Law.

 

Board and committee independence. Nasdaq Listing Rule 5605(b)(1) requires that a majority of the board of directors of a listed company be composed of independent directors. Following the Meeting, if all nominees are elected, 3 of the Company’s 5 directors will be independent under the Nasdaq Listing Rules: David Lontini, Fiona George and Daniel Kokiw. Each of the Audit Committee and the Compensation Committee will consist of those 3 independent directors. Each member of the Audit Committee will also satisfy the independence requirements of Rule 10A-3 under the Exchange Act. Accordingly, the Company will not rely on home country practice in lieu of the board and committee independence requirements of Nasdaq Listing Rules 5605(b)(1), 5605(c)(2)(A) and 5605(d)(2). The Company does not rely on the controlled company exemption under Nasdaq Listing Rule 5615(c). Other home country practices described in this Proxy Statement are unaffected.

 

15

 

 

Committees of the Board

 

The Board has an Audit Committee, a Compensation Committee and a Nominating Committee. Each committee is currently composed entirely of independent directors under the Nasdaq Listing Rules. The current members of the Audit Committee are Ghaleb El Masri (Chair), Kai Sorensen and Anurag Sharma; the current members of the Compensation Committee are Kai Sorensen (Chair), Ghaleb El Masri and Anurag Sharma; and the current members of the Nominating Committee are Kai Sorensen (Chair), Ghaleb El Masri and Anurag Sharma.

 

Under the Companies Law, the audit committee (Section 115) of a public company that has external directors must include all of the external directors, must have a majority of independent directors and must be chaired by an external director; the compensation committee (Section 118A) must include all of the external directors, who must constitute a majority of its members, and must be chaired by an external director. Upon the election of the external directors under Proposal 3A at the first session, and because the current committee members are not standing for re-election, the Board intends to reconstitute the committees as follows: Audit Committee: Fiona George (Chair), Daniel Kokiw and David Lontini; Compensation Committee: Fiona George (Chair), Daniel Kokiw and David Lontini. Following the Meeting, the Board will not maintain a separate Nominating Committee. Director nominees will be selected, or recommended for the Board’s selection, by independent directors constituting a majority of the Board’s independent directors in a vote in which only independent directors participate, as permitted by Nasdaq Listing Rule 5605(e)(1)(A). The Board will adopt the resolution addressing the nominations process required by Nasdaq Listing Rule 5605(e)(2). The Board has determined that Fiona George qualifies as an “audit committee financial expert” as defined by SEC rules and has “accounting and financial expertise” within the meaning of Section 240(a1) of the Companies Law and the regulations thereunder.

 

Under Section 118A of the Companies Law, the members of the compensation committee who are not external directors must receive compensation in accordance with the regulations governing the compensation of external directors. Because the Company has a controlling shareholder, the exemption from this requirement in Regulation 5D of the Reliefs Regulations is not available to the Company, including following the amendment of the Reliefs Regulations in March 2024. The compensation of Mr. Lontini under Proposal 9(b) is identical in all respects to the compensation of the external directors under Proposal 9(c), which is determined under the External Director Regulations, and its cash and equity components cannot be reallocated. If Proposal 9(c) is not approved, Mr. Lontini will receive, for as long as he serves on the Compensation Committee, the amounts prescribed by the External Director Regulations. There can be no assurance that a court or regulatory authority would agree with that approach.

 

The Board has approved the compensation-related proposals described in this Proxy Statement (Proposals 8, 9(a), 9(b), 9(c) and 9(d)) for submission to shareholders, and has approved the submission of the 2026 Equity Incentive Plan (Proposal 5) to shareholders, subject to the Interval Approvals. The adoption of the 2026 Equity Incentive Plan and any grants under it will be approved by the Board as constituted following the Meeting. Because the Companies Law requires the compensation matters to be approved by a compensation committee that includes the external directors, the Reconstituted Compensation Committee will consider and, if it sees fit, approve the compensation matters and the 2026 Equity Incentive Plan and, in respect of the Chief Executive Officer’s terms, consider the matters required by Section 267B and the Compensation Policy, determine whether the terms conform to the proposed Compensation Policy and record its reasons, followed by the Board, as part of the Interval Approvals. Each compensation proposal and Proposal 5 also includes the approval, to the extent required under the Companies Law, of the approvals of the Compensation Committee and the Board, including the Interval Approvals. The Reconstituted Compensation Committee will also ratify the Company’s directors’ and officers’ liability insurance and other matters approved by the Current Compensation Committee since the closing of the Business Combination.

 

Controlling Shareholder

 

As described in the Notice, as of the Reference Date, Regan McGee beneficially owns approximately 45% of our outstanding Ordinary Shares and is a controlling shareholder of the Company under the Companies Law. As a result, transactions between the Company and Mr. McGee, including the terms of his office and engagement, require the approval of the Compensation Committee (or, in the case of transactions other than compensation, the Audit Committee), the Board and the shareholders by a Special Majority, and the terms of his engagement must be re-approved every three years. Mr. McGee serves as Chairman of the Board. No compensation for his service as a director and no indemnification undertaking to him is proposed at this Meeting, and he is excluded from Proposals 9(b) and 9(d).

 

16

 

 

Executive Officers

 

Our executive officers are:

 

Name  Age   Position
John Fowler  38   Chief Executive Officer and director
Tim Hayden  44   Chief Financial Officer

 

John Fowler. Mr. Fowler’s biography appears under “Proposal 3.” See “Proposal 3” and “Proposal 9(a).”

 

Tim Hayden. Mr. Hayden has served as Chief Financial Officer since the closing of the Business Combination. He is a Certified Public Accountant and a Chartered Accountant (Ontario, Canada) with over 20 years of experience across corporate finance, business development, operations and M&A. He served at Agrify Corporation (Nasdaq: AGFY) as Senior Vice President of Corporate Development beginning in July 2022, subsequently as Chief Revenue Officer, and as Interim Chief Financial Officer and principal financial and accounting officer effective March 1, 2023. From 2019 to 2022, he held several roles at a Canadian pharmaceutical producer, including Vice President of Corporate Development, Chief Business Development Officer and Chief Operating Officer. Earlier, he served as M&A Senior Manager at Deloitte Canada (2017 to 2019) and as Corporate Finance Manager, Deal Advisory at KPMG UK LLP (2015 to 2017), and held positions at BDO UK LLP, National Health Service Improvement, the HDI Group and Deloitte South Africa. He holds a B.A. in Accounting from Rhodes University.

 

Security Ownership of Certain Beneficial Owners and Management

 

The following table sets forth information regarding the beneficial ownership of our Ordinary Shares as of the Reference Date by (i) each person known to us to beneficially own more than 5% of our outstanding Ordinary Shares, (ii) each of our directors and director nominees, (iii) each of our executive officers, and (iv) all of our directors and executive officers as a group. Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. Except as indicated in the footnotes, we believe that each person named has sole voting and investment power over the shares shown. Percentages are based on 15,345,971 Ordinary Shares outstanding as of the Reference Date. There are no options or other convertible securities outstanding. Ordinary Shares that a person has the right to acquire within 60 days after the Reference Date are deemed outstanding for the purpose of computing the percentage ownership of that person, but not for the purpose of computing the percentage ownership of any other person.

 

Name of beneficial owner  Number of
Ordinary
Shares
beneficially
owned
   Percentage of
class
 
5% or greater holders        
Regan McGee(1)   6,860,097    44.7%
Directors, nominees and executive officers          
Regan McGee(1)   6,860,097    44.7%
John Fowler(2)   670,064    4.4%
David Lontini   -    - 
Kai Sorensen (director until the Meeting) (3)   3,587    * 
Ghaleb El Masri (director until the Meeting)   -    - 
Anurag Sharma (director until the Meeting)   -    - 
Fiona George (external director candidate) (4)   79,717    * 
Daniel Kokiw (external director candidate)   nil    - 
Tim Hayden (5)   79,717    * 
All directors, nominees and executive officers as a group (9 persons)   7,693,182    50.1%

 

(1)Held through entities controlled by Mr. McGee. Mr. McGee is a controlling shareholder of the Company under the Companies Law.

(2)Held through Fowler Family Holdings Corp.

(3)Held through Toft Holdings, Inc.

(4)Held by the estate of Scott Walters, the deceased spouse of Ms. George. Ms. George is the executor and beneficiary of the estate.

(5)Held by Gerda Hayden, the spouse of Mr. Hayden.

*Less than 1%.

 

To the Company’s knowledge, no person other than Mr. McGee beneficially owns more than 5% of the outstanding Ordinary Shares.

 

17

 

 

PROPOSAL 1

 

RE-DESIGNATION OF THE ORDINARY SHARES AS NO PAR VALUE SHARES

 

(Item 1 on the Proxy Card; first session)

 

Background

 

Our Ordinary Shares currently have a nominal (par) value of NIS 48.00 per share. The nominal value is the historical result of a series of reverse share splits effected by Check-Cap Ltd. before the Business Combination, each of which multiplied the nominal value per share by the split ratio. It bears no relationship to the current trading price of our Ordinary Shares, which has at all relevant times been substantially below NIS 48.00 (approximately US$15.00, based on the exchange rate published by the Bank of Israel on November 13, 2026).

 

The Companies Law permits the shares of an Israeli company to have no nominal value. A company whose shares have no nominal value states its authorized share capital as a number of shares rather than as an amount in New Israeli Shekels, and the issue price of its shares is not constrained by any nominal value. Many Israeli companies listed on Nasdaq have shares of no nominal value.

 

In connection with the Company’s public offering of Ordinary Shares completed in August 2026 at a price of US$6.50 per share, which was below the nominal value of NIS 48.00 per share, the Board undertook that the Company will not make calls on, or forfeit, the shares offered in that offering at any time on account of any unpaid nominal value. The Ordinary Shares issued to the former shareholders of MBody AI Corp. at the closing of the Business Combination on August 26, 2026 were also issued at a value per share below NIS 48.00. The confirmation in Proposal 1 applies to those shares, to the shares sold in the August 2026 offering, and to any other Ordinary Shares issued before the amendment takes effect at a price per share below NIS 48.00. The Company also undertook, in its prospectus dated August 27, 2026, to include on the agenda of its next annual general meeting a proposal to amend its Articles of Association to re-designate the Ordinary Shares as no par value shares, subject to applicable law and shareholder approval. Proposal 1 fulfills that undertaking.

 

Reasons for the Proposal

 

The Board believes that the re-designation is in the best interests of the Company and its shareholders for the following reasons:

 

●It removes a constraint on future issuances. Under the Companies Law, shares may not ordinarily be issued at a discount to their nominal value. With a nominal value of approximately US$15.00 per share and a trading price well below that level, any future issuance of Ordinary Shares, whether in a financing, an acquisition or under an equity incentive plan, would otherwise require the same no-call structure used in the August 2026 offering.

 

●It simplifies our capital structure. The authorized share capital will be expressed as a number of Ordinary Shares (see Proposal 2) rather than as an amount in New Israeli Shekels divided into shares of NIS 48.00 each.

 

●It aligns the Company’s constitutional documents with the economic reality of its share capital. The nominal value serves no economic function for the Company or its shareholders.

 

The re-designation will not change the number of Ordinary Shares held by any shareholder, the rights attached to the Ordinary Shares, or any shareholder’s proportionate interest in the Company. It does not involve any distribution to shareholders, any reduction of the Company’s capital or any court approval. The amendment will take effect upon its adoption by the shareholders. Under Section 21(b) of the Companies Law, the Company will file the text of the resolution with the Israeli Registrar of Companies within 14 days after the Meeting, which the Company expects to do by January 5, 2027. The text of the amendment is set out in Part B of Appendix D. Part B also makes conforming changes to Articles 2, 6, 7, 12, 14, 53, 55 and 69 of the Articles of Association to remove references to nominal value, including by limiting the liability of shareholders under Article 2 to the unpaid issue price of their shares and by providing for pro rata allocations by number of shares rather than by nominal value. Part B also makes conforming changes to Article 9 of the Articles of Association, so that the Company’s existing authority to consolidate and divide its shares, and the Board’s powers in respect of fractional shares, apply to shares of no par value, and so that the Board may cause fractional shares resulting from a consolidation to be aggregated and sold by the Company’s transfer agent on behalf of the holders entitled to them, including to purchasers who are not existing shareholders (Article 9(b)(v) currently refers to transfers to other shareholders), and Article 9(a), which refers to consolidation into shares of a larger nominal value, will be amended to apply to shares of no par value. The other Articles amendments at this Meeting are the increase in authorized share capital (Proposal 2, Part C of Appendix D), new Article 42A (Proposal 6, Part D of Appendix D) and the regularization of the Company’s name and, if and when the Board exercises the authority under Proposal 7, the change of the Company’s name (Part A of Appendix D).

 

18

 

 

The proposed resolution also confirms that the Company will not seek payment of any unpaid nominal value from holders of Ordinary Shares issued before the amendment becomes effective at a price below NIS 48.00 per share. This confirms, at the shareholder level, the undertaking already given by the Board in connection with the August 2026 offering, and it applies also to the Ordinary Shares issued at the closing of the Business Combination.

 

Approval Requirements under Israeli Law

 

The re-designation is an amendment to the Company’s Articles of Association. Under the Companies Law and our Articles of Association, an amendment to the Articles of Association requires the approval of shareholders by an Ordinary Majority. Israeli counsel has advised the Company that the re-designation does not constitute a distribution, does not involve a reduction of capital, and does not require court approval under Sections 301 to 303 of the Companies Law, and that no separate capitalization resolution under Section 304 of the Companies Law is required by reason of the re-designation.

 

Proposed Resolution

 

It is proposed that the following resolution be adopted at the Meeting:

 

“RESOLVED, to approve the amendment of the Company’s Articles of Association so that all authorized and issued Ordinary Shares of the Company, currently of nominal value NIS 48.00 each, are re-designated as Ordinary Shares of no par value, such that the authorized share capital of the Company shall consist of 18,000,000 Ordinary Shares of no par value, together with conforming amendments to Articles 2, 6, 7, 9, 12, 14, 53, 55 and 69 of the Articles of Association, in each case in the form set out in Part B of Appendix D to the Proxy Statement, and to confirm that the Company shall not seek payment of any unpaid nominal value from any holder of Ordinary Shares issued before the effective time of the amendment at a price per share below NIS 48.00, all as described in the Proxy Statement.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal. We expect that this proposal will be a routine matter on which brokers may vote uninstructed shares. Abstentions and broker non-votes are not considered votes cast and will have no effect on the result.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” the No Par Value Proposal.

 

19

 

 

PROPOSAL 2

 

INCREASE IN AUTHORIZED SHARE CAPITAL

 

(Item 2 on the Proxy Card; first session)

 

Background

 

Our authorized share capital currently consists of 18,000,000 Ordinary Shares, of which 15,345,971 were issued and outstanding as of the Reference Date and 160,429 were reserved for issuance under the Company’s existing equity line arrangement. Accordingly, approximately 2.5 million Ordinary Shares remain available for issuance. The Board believes that this does not meet the Company’s anticipated needs following the Business Combination, including the reserve of 1,841,517 Ordinary Shares under the 2026 Equity Incentive Plan described under Proposal 5.

 

The Board has approved, and recommends that shareholders approve, an increase in the authorized share capital to 175,000,000 Ordinary Shares of no par value. Because the increase is expressed as a number of shares of no par value, Proposal 2 is conditional upon Proposal 1 becoming effective. If Proposal 1 is not approved, Proposal 2 will not be implemented even if approved.

 

Purpose and Effect of the Increase

 

The purpose of the increase is to provide the Company with the flexibility to issue Ordinary Shares for general corporate purposes as the Board may determine from time to time, including in connection with future equity financings, acquisitions of businesses or assets, strategic transactions, and equity-based compensation under the equity incentive plan described under Proposal 5. The Company is a growth company whose business plan contemplates the deployment of capital in fleet expansion and, potentially, acquisitions, and the Board considers it prudent to have authorized but unissued share capital available so that opportunities can be pursued without the delay and expense of convening a general meeting on each occasion. Other than as disclosed in the Company’s filings with the SEC, the Company has no current agreement, arrangement or understanding to issue any of the additional Ordinary Shares that would be authorized by this proposal.

 

The additional Ordinary Shares would have the same rights as the currently outstanding Ordinary Shares. Shareholders do not have pre-emptive rights under our Articles of Association or the Companies Law, and the issuance of additional Ordinary Shares would dilute the ownership and voting interests of existing shareholders and could dilute earnings per share and book value per share. The Board will continue to be subject to the requirements of the Companies Law, the Nasdaq Listing Rules (including the shareholder approval requirements that apply to certain issuances of 20% or more of the outstanding shares and to issuances to related parties, to the extent that they apply to the Company as a foreign private issuer) and applicable securities laws in connection with any issuance. The increase in authorized share capital is not being proposed in response to any effort to accumulate the Company’s shares or to obtain control of the Company, and the Board is not aware of any such effort.

 

The size of the increase reflects the Board’s judgment that the authorized capital should cover a period of several years across a range of possible share prices, to provide substantial capacity for capital raising and significant acquisitions in support of the Company’s long-term growth, while reducing the need to seek further increases when financing or acquisition opportunities arise. The authorization does not itself approve any particular financing or acquisition or eliminate any separate approvals required for a future transaction. A further increase may still be needed depending on future circumstances. If Proposal 2 is approved, approximately 157.7 million Ordinary Shares would be authorized but unissued and unreserved following the Meeting. The text of the amendment is set out in Part C of Appendix D.

 

Approval Requirements under Israeli Law

 

An increase in authorized share capital is an amendment to the Articles of Association and requires the approval of shareholders by an Ordinary Majority.

 

Proposed Resolution

 

It is proposed that the following resolution be adopted at the Meeting:

 

“RESOLVED, subject to and conditional upon Proposal 1 becoming effective, to approve the increase of the authorized share capital of the Company from 18,000,000 Ordinary Shares of no par value to 175,000,000 Ordinary Shares of no par value, by the creation of 157,000,000 additional Ordinary Shares of no par value ranking pari passu in all respects with the existing Ordinary Shares, and the corresponding amendment of the Articles of Association in the form set out in Part C of Appendix D to the Proxy Statement, as described in the Proxy Statement.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal. We expect that this proposal will be a routine matter on which brokers may vote uninstructed shares. Abstentions and broker non-votes are not considered votes cast and will have no effect on the result.

 

Board Recommendation

 

The Board of Directors unanimously recommends a vote “FOR” the Authorized Share Capital Proposal.

 

20

 

 

PROPOSAL 3

 

ELECTION OF DIRECTORS

 

(Items 3(a) to 3(c) on the Proxy Card; first session)

 

Background

 

Under our Articles of Association, our Board must consist of at least 4 and not more than 11 directors. Other than external directors, each of our directors holds office until the next annual general meeting of shareholders following his or her election, unless his or her office is vacated earlier. Seven (7) directors were appointed to the Board under Article 42 of the Articles of Association at the closing of the Business Combination. Scott Walters, 1 of the 7, passed away on October 10, 2026. Three (3) of the remaining directors, Regan McGee, John Fowler and David Lontini, are standing for election at the Meeting under this Proposal 3. Kai Sorensen, Ghaleb El Masri and Anurag Sharma are not standing for re-election, and their terms of office will end at the conclusion of the Meeting. The 2 candidates for election as external directors under Proposal 3A are not currently directors and are not nominated under this Proposal 3.

 

The Board has reviewed and evaluated the qualifications and suitability of each nominee. In accordance with the Companies Law, each nominee has certified to us that he meets all the requirements of the Companies Law for election as a director of a public company, possesses the necessary qualifications and is able to dedicate the time required to fulfil his duties as a director, taking into consideration the Company’s size and special needs. The Board has nominated the 3 individuals named below for election, each to hold office until the next annual general meeting of shareholders, or until his earlier resignation, removal or other vacation of office.

 

Regan McGee and John Fowler are not independent under the Nasdaq Listing Rules. David Lontini is an independent director under the Nasdaq Listing Rules. See “The Board of Directors and Corporate Governance - Director Independence.”

 

Nominees for Director

 

The following biographical information is provided with respect to each nominee, based on our records and information provided to us by the nominee.

 

Regan McGee (Item 3(a))

 

Regan McGee has served as Chairman of the Board since the closing of the Business Combination on August 26, 2026. Mr. McGee is the Company’s largest shareholder. He is also Chairman and Chief Executive Officer of Apollo Technology Capital Corporation, an investment and governance platform focused on founder-led companies, and is the Founder, Chairman and Chief Executive Officer of Nobul Technologies, a real estate financial technology company. Mr. McGee is a named inventor on multiple patents, including in artificial intelligence and AI-driven robotics systems. He has served as a corporate director across private, public and nonprofit organizations, including eight years on the board of Daily Bread Food Bank, and earlier in his career held roles at Brookfield Asset Management, CI Financial and BMO Financial Group. He holds a B.A. in Economics from Queen’s University and the Chartered Investment Manager designation, and completed the ICD.D Directors’ Education Program at the University of Toronto’s Rotman School of Management. Age: 46. Mr. McGee is a controlling shareholder of the Company.

 

John Fowler (Item 3(b))

 

John Fowler has served as Chief Executive Officer and a director of the Company since the closing of the Business Combination on August 26, 2026. Mr. Fowler is a corporate lawyer and public-company chief executive officer. He served as President and Chief Executive Officer of a Canadian consumer packaged goods company listed on the TSX and TSX-V from 2014 to 2019, where he built the business into a nationally recognized brand and raised over C$250 million in capital. That company was subsequently acquired for approximately C$430 million in 2021. Mr. Fowler has been a member of the Toronto Chapter of the Young Presidents’ Organization (YPO) since 2019. Licensed to practice law in Ontario since 2013, Mr. Fowler holds a J.D. from the University of Ottawa and a B.A. from the University of Toronto. Age: 38. See “Proposal 9(a)” regarding the proposed terms of his engagement.

 

21

 

 

David Lontini (Item 3(c))

 

David Lontini has served as a director of the Company since January 2024. Mr. Lontini served as Chairman of the Board from July 2024 until the closing of the Business Combination, and as Interim Chief Executive Officer of Check-Cap Ltd. from July 2025 until the closing of the Business Combination. He is an experienced business owner and operator who has completed M&A transactions and held senior leadership positions at organizations including Pointstreak Sports Technologies, Maru/Matchbox and the Toronto Argonauts Football Club. He holds a B.A. in Liberal Arts and Political Science from York University. Age: 44.

 

The Company is not aware of any reason why any nominee, if elected, would be unable or unwilling to serve as a director. There are no family relationships among any of the nominees or executive officers of the Company. Other than as described in this Proxy Statement, none of the nominees has any arrangement or understanding with any other person pursuant to which he was selected as a nominee.

 

Compensation of Nominees

 

No compensation for Mr. McGee’s service as a director is proposed at this Meeting. The compensation of Mr. Fowler as Chief Executive Officer is the subject of Proposal 9(a). The compensation of Mr. Lontini, as a non-employee director, is the subject of Proposal 9(b). Mr. McGee and Mr. Fowler will not receive the director compensation under Proposals 9(b) and 9(c). Indemnification and exculpation undertakings for the directors other than a controlling shareholder are the subject of Proposal 9(d); no undertaking to Mr. McGee is proposed at this Meeting.

 

Proposed Resolutions

 

It is proposed that the following resolutions be adopted at the Meeting, each to be voted on separately:

 

“RESOLVED, to elect Regan McGee as a director of the Company, to serve until the next annual general meeting of shareholders, unless his office is vacated earlier in accordance with the Articles of Association or the Companies Law.”

 

“RESOLVED, to elect John Fowler as a director of the Company, to serve until the next annual general meeting of shareholders, unless his office is vacated earlier in accordance with the Articles of Association or the Companies Law.”

 

“RESOLVED, to elect David Lontini as a director of the Company, to serve until the next annual general meeting of shareholders, unless his office is vacated earlier in accordance with the Articles of Association or the Companies Law.”

 

Vote Required

 

Each nominee will be voted on separately. The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal. Abstentions and broker non-votes are not considered votes cast and will have no effect on the result.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” the election of each of the nominees named above.

 

22

 

 

PROPOSAL 3A

 

ELECTION OF EXTERNAL DIRECTORS

 

(Items 3A(a) and 3A(b) on the Proxy Card; first session)

 

Background

 

Under the Companies Law, an Israeli public company is generally required to have at least two “external directors.” External directors are independent directors who meet detailed qualification and independence requirements set out in the Companies Law, are elected by shareholders by a Special Majority, serve for fixed three-year terms (which may be extended for additional three-year terms, subject to conditions under the Companies Law and regulations), may be removed only in limited circumstances, and are entitled to compensation only in the amounts and manner prescribed by regulations under the Companies Law. At least one external director must have “accounting and financial expertise,” and the others must have “professional qualifications,” each as determined by the Board in accordance with regulations under the Companies Law. External directors must be members of the audit committee and the compensation committee, which must be chaired by an external director.

 

The Reliefs Regulations exempt a company whose shares are listed on certain foreign exchanges, including Nasdaq, from the requirement to appoint external directors, provided that the company has no controlling shareholder and complies with the director independence and committee composition requirements applicable to U.S. domestic companies under the rules of the exchange. Before the Business Combination, Check-Cap Ltd. had no controlling shareholder and relied on that exemption. Upon the closing of the Business Combination on August 26, 2026, Regan McGee became a controlling shareholder of the Company, and the exemption ceased to apply. The Company is accordingly required to elect two external directors, and is doing so at this Meeting. The Board is proposing the election of Fiona George and Daniel Kokiw, neither of whom currently serves as a director of the Company. Each is elected fresh at the Meeting and has not been appointed to the Board beforehand.

 

Under the Companies Law, where at the time of the appointment of an external director all members of the board of directors are of the same gender, the external director appointed must be of the other gender. All of the Company’s current directors are men. Fiona George is a woman, and her election satisfies that requirement. For that reason the election of Ms. George under Proposal 3A(a) is put to the vote first, and the election of Mr. Kokiw under Proposal 3A(b) is subject to and conditional upon her election: under Section 239(d) of the Companies Law, if Ms. George is not elected, the external director then appointed must be a woman and Mr. Kokiw cannot be elected.

 

Qualifications of the Candidates

 

Neither candidate has previously served as a director or office holder of MBody AI Corp. or MBody AI Canada Corp. Mr. Kokiw served as a director of Check-Cap Ltd. from January 25, 2024 until the closing of the Business Combination on August 26, 2026, when he resigned. Service as an office holder of the Company within the two years before appointment would ordinarily constitute an “affiliation” that disqualifies a candidate from serving as an external director under Section 240(b) of the Companies Law. The only statutory exception covers a director appointed to serve as an external director in a company about to offer its shares to the public for the first time, which does not apply to Mr. Kokiw. The Board has nonetheless concluded that Mr. Kokiw may be elected as an external director, having regard to the following: (i) throughout Mr. Kokiw’s service as a director, the Company had no controlling shareholder and relied on the exemption under the Reliefs Regulations, so that it was not required to have external directors; (ii) the Company became subject to the external director requirement only upon the closing of the Business Combination, when Mr. McGee became a controlling shareholder, and Mr. Kokiw ceased to serve as a director at that time; (iii) Mr. Kokiw has no employment, business or professional relationship with, and has not been subject to the control of, Mr. McGee, MBody AI Corp. or MBody AI Canada Corp.; and (iv) the short period between the closing of the Business Combination and the Meeting. In reaching that conclusion, the Board considered the position of the Israeli Ministry of Justice in a comparable case disclosed by another Israeli company listed on Nasdaq. That company ceased to be entitled to the same exemption when a shareholder acquired more than 25% of its shares, and the Ministry of Justice informed it that there was no impediment to re-classifying as external directors two directors who had served on its board while it relied on the exemption, considering, among other things, the short time between the adoption of the exemption and the formation of a control interest and the absence of any affiliation between those directors and the new controlling shareholder. That case differs from Mr. Kokiw’s: the directors in that case had served as external directors of that company before it adopted the exemption, and the issue addressed by the Ministry of Justice was the change in their compensation while the company relied on the exemption, rather than prior service as a director who was not an external director. The Company has not sought the position of the Ministry of Justice with respect to Mr. Kokiw. There can be no assurance that a court or regulatory authority would reach the same conclusion as the Board. If Mr. Kokiw’s election were later found to be invalid, actions of the Audit Committee and the Reconstituted Compensation Committee, including the Interval Approvals, could be challenged. Article 49 of the Articles of Association provides that acts of the Board, its committees and any person acting as a director remain valid even if a defect in the appointment of a director is later discovered, but that provision applies subject to the Companies Law.

 

In addition, the Board considered the following:

 

Section 240(b) of the Companies Law excludes from the definition of “affiliation” service as a director by a person appointed in order to serve as an external director of a company that is about to offer its shares to the public for the first time. The purpose of this exception is that service on the board before a company becomes subject to the external director requirement should not disqualify a person from serving as an external director once the requirement applies. The Board believes that the same purpose applies to a company that becomes subject to that requirement when it first has a controlling shareholder. The pending bill to amend Section 242 of the Companies Law, described below under “Consequences if Proposal 3A is not Approved,” is consistent with this view.

 

Regulation 4 of the Israeli Companies Regulations (Matters That Do Not Constitute an Affiliation), 5767-2006, provides that a person who had an affiliation with a corporation controlled by a company’s controlling shareholder, only during a period in which the current controlling shareholder was not the controlling shareholder of that corporation, is not considered to have had an affiliation during the two years before the appointment. For this purpose, a corporation controlled by the controlling shareholder does not include the company itself or a corporation it controls. Although Regulation 4 therefore does not apply to Mr. Kokiw’s prior service on the Board, the Board believes that it reflects the same principle: a relationship that existed only before the current controlling shareholder obtained control should not, by itself, impair a director’s independence from that controlling shareholder.

 

23

 

 

Ms. George is the widow of Scott Walters. Mr. Walters served as a director of MBody AI Corp. from August 2025 until the closing of the Business Combination, and as a director of the Company from the closing on August 26, 2026 until his death on October 10, 2026. The Board has considered Section 240(b) of the Companies Law and has determined that Ms. George is eligible for election as an external director, for the following reasons: (i) Mr. Walters’s service ended on his death, and at the date of her appointment Ms. George has no relative who has an affiliation with the Company, with Mr. McGee or with any corporation that Mr. McGee controls; (ii) Mr. Walters served as a non-executive director and held no executive office in the Company or MBody AI Corp.; and (iii) Ms. George herself has no employment, business or professional relationship with the Company, MBody AI Corp., MBody AI Canada Corp. or Mr. McGee, and has never served as an office holder of any of them. However, Section 240(b) also takes into account an affiliation of a candidate’s relative during the two years before the appointment, and Mr. Walters served as a director of the Company and of MBody AI Corp. within that period. The Companies Law does not address whether a deceased spouse is treated as a relative for this purpose, and there can be no assurance that a court or regulatory authority would agree with the Board’s determination.

 

Each candidate has delivered to the Company the declaration required under Section 241 of the Companies Law, confirming that he or she meets all of the requirements applicable to external directors under the Companies Law.

 

Accounting and financial expertise. The Board has determined that Fiona George has “accounting and financial expertise” within the meaning of Section 240(a1) of the Companies Law and the regulations thereunder, based on her experience in senior business management positions, including as a Branch Administrator in the Private Client Division of BMO Nesbitt Burns, where she reviewed general ledgers and operating statements and managed payroll and commission accounting documentation, and as Regional Manager of a multi-location retail business, described below, and that Daniel Kokiw has “professional qualifications” within the meaning of those regulations, based on his experience as the owner and operator of businesses, in which he has been responsible for financial statements, budgets and financial controls, his experience in M&A transactions, and his service as a director and a member of the audit committee of Check-Cap Ltd., a Nasdaq-listed company, from January 2024 to August 2026, described below. 

The Candidates

 

Fiona George (Item 3A(a))

 

Fiona George, age 60, has served since 2020 as Regional Manager of a retail business with multiple locations in Canada. She was previously a Branch Administrator in the Private Client Division of BMO Nesbitt Burns in Toronto, where she managed more than 25 support staff, reviewed general ledgers and operating statements and managed payroll and commission accounting documentation. Ms. George holds a Bachelor of Arts degree from the University of Toronto. Ms. George does not serve on the board of any other public company. Ms. George has no prior relationship with the Company, Check-Cap Ltd., MBody AI Corp. or Mr. McGee.

 

24

 

 

Daniel Kokiw (Item 3A(b))

 

Daniel Kokiw served as a director of Check-Cap Ltd. from January 25, 2024 until the closing of the Business Combination. Mr. Kokiw is an experienced business owner and operator who has successfully completed M&A transactions. For over 8 years, Mr. Kokiw was in a senior operational role at Zodiac Recreational of North America, of Zodiac Nautic, and before that he ran the operations of Rokan Laminating. Mr. Kokiw currently owns and operates a business in food retail. He studied psychology at Carleton University. Age: 54. Mr. Kokiw has no employment, business or professional relationship with, and has not been subject to the control of, Mr. McGee, MBody AI Corp. or MBody AI Canada Corp.

 

Mr. Kokiw and Mr. Lontini, a nominee under Proposal 3, are among the respondents in a pending derivative proceeding described in the 2025 Annual Report, which the Company is defending and which is currently in mediation. The proceeding relates to their prior service as directors of Check-Cap Ltd. and does not relate to Mr. Kokiw’s qualifications to serve as an external director. If elected, each of Mr. Kokiw and Mr. Lontini will recuse himself from, and will not participate in any deliberation or vote of the Board or any committee of the Board on, any matter relating to the proceeding, including its defense, any mediation or settlement, and any claim for indemnification or insurance in connection with it. Following the Meeting, those matters will be considered by Fiona George, as the chair of the Audit Committee and the only member of the Audit Committee without a personal interest in them, and by the other directors who do not have a personal interest in them. To the extent that a majority of the members of the Audit Committee, the Compensation Committee or the Board has a personal interest in such a matter, the matter will be approved in accordance with Section 278(b) of the Companies Law, including, where required, by the shareholders. Any indemnification or insurance in connection with the proceeding will be approved in the manner required by the Companies Law. The Board has considered whether Mr. Kokiw’s status as a respondent creates, or may create, a conflict of interest with his duties as an external director, and has concluded that, in light of that recusal, it does not prevent his election. Any indemnification of Mr. Kokiw or Mr. Lontini in connection with the proceeding will be provided under his existing indemnification agreement with Check-Cap Ltd. relating to his prior service as a director and, in the case of Mr. Kokiw, not as compensation for his service as an external director. There can be no assurance that a court or regulatory authority would agree with the Board’s conclusion.

 

Term and Committee Service

 

If elected, each external director will serve for a three-year term commencing on the date of the Meeting. The election of Mr. Kokiw is conditional upon the election of Ms. George. Upon election, each will be appointed to the Audit Committee and the Compensation Committee, and Ms. George will serve as chair of both the Audit Committee and the Compensation Committee. Ms. George will also serve as the Audit Committee’s audit committee financial expert. See “The Board of Directors and Corporate Governance - Committees of the Board.”

 

Approval Requirements under Israeli Law

 

Under Section 239(b) of the Companies Law, the election of an external director requires a Special Majority in which the second count is made among shareholders who are not controlling shareholders and who do not have a personal interest in the appointment arising from a relationship with a controlling shareholder; a personal interest that does not arise from such a relationship is disregarded for this purpose. Accordingly, Mr. McGee’s Ordinary Shares will be excluded from the second count on each of Items 3A(a) and 3A(b); the Ordinary Shares held by other directors and officers of the Company will be counted unless the holder has a personal interest resulting from a relationship with Mr. McGee.

 

Proposed Resolutions

 

It is proposed that the following resolutions be adopted at the Meeting, each to be voted on separately:

 

“RESOLVED, to elect Fiona George as an external director of the Company for a three-year term commencing on the date of the Meeting, in accordance with the Israeli Companies Law, 5759-1999.”

 

“RESOLVED, subject to and conditional upon the election of Fiona George under Item 3A(a), to elect Daniel Kokiw as an external director of the Company for a three-year term commencing on the date of the Meeting, in accordance with the Israeli Companies Law, 5759-1999.”

 

Vote Required

 

Each candidate will be voted on separately. The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal, provided that either (i) the majority voted in favor includes at least a majority of the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in the approval of the proposal (in the case of this Proposal 3A, only a personal interest arising from a relationship with the controlling shareholder), excluding abstentions, or (ii) the total number of votes cast against the proposal by such shareholders does not exceed two percent (2%) of the total voting rights in the Company. See “Controlling Shareholders and Personal Interests” in the Notice. By signing and returning the proxy card, or by voting online before or at the Meeting, you confirm that you are not a controlling shareholder and do not have a personal interest in the approval of this proposal, unless you have notified the Company otherwise as described in the Notice.

 

25

 

 

Consequences if Proposal 3A is not Approved

 

There is no Board override for the election of an external director. If Fiona George is not elected under Proposal 3A(a), Daniel Kokiw cannot be elected under Proposal 3A(b). If either candidate is not elected, the Company will not have the two external directors that the Companies Law requires, the Compensation Committee cannot be reconstituted as the Companies Law requires, and Proposals 8 and 9 will not be voted on at the Meeting. Proposal 5 will still be voted on at the second session. The terms of office of Kai Sorensen, Ghaleb El Masri and Anurag Sharma will nevertheless end at the conclusion of the Meeting. If the nominees under Proposal 3 are elected, the Board would then consist of three directors, which is below the minimum of four directors under Article 39 of our Articles of Association. In that case, under Article 42 of our Articles of Association, the continuing directors may act only in an emergency, to fill vacancies up to the minimum number of directors, or to convene a general meeting for the purpose of electing directors. The Company will convene a further general meeting to elect external directors and to vote on Proposals 8 and 9, and the Company will not have a compensation policy in effect until one is approved, as the current Compensation Policy will cease to be in effect on December 18, 2026.

 

The Companies Law does not expressly provide a period within which an existing public company that ceases to be entitled to the exemption under the Reliefs Regulations must appoint external directors. Section 242(a) of the Companies Law allows a company three months after it becomes a public company to appoint its external directors, and a pending bill to amend Section 242 would expressly allow a public company that becomes a company with a controlling shareholder three months to do so, but that bill has not been enacted. The Meeting will be held more than three months after the closing of the Business Combination on August 26, 2026. Accordingly, the Company may be considered not to have complied with the external director requirements of the Companies Law from the closing, or from the end of that three-month period, until the external directors are elected.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” the election of each of Fiona George and Daniel Kokiw as an external director.

 

26

 

 

PROPOSAL 4

 

APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

(Item 4 on the Proxy Card; first session)

 

Background

 

Under the Companies Law, the shareholders of a public company appoint its independent auditor at each annual general meeting, and the Board reports to shareholders on the auditor’s compensation. BCRG LLP has served as the Company’s independent registered public accounting firm since 2025. On June 15, 2026, BCRG LLP merged with SIMON & EDWARD, LLP, and SIMON & EDWARD, LLP is the successor firm. The Audit Committee and the Board have recommended the appointment of SIMON & EDWARD, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 and until the next annual general meeting of shareholders.

 

The following table sets forth the fees billed to the Company by BCRG LLP and RBSM LLP for the fiscal years ended December 31, 2025 and 2024: 

 

   December 31,   
   2025   2024 
RBSM LLP          
Audit Fees (1)  $—   $150,000 
Tax Fees (2)  $—   $— 
Other Fees (3)  $—   $— 
Subtotal  $—   $150,000 
           
BCRG Group          
Audit Fees (1)  $30,000   $30,000 
Tax Fees (2)  $—   $— 
Other Fees (3)  $—   $— 
Subtotal  $30,000   $30,000 
           
Total  $30,000   $180,000 

 

(1)Audit fees represent fees for professional services rendered for the audit or re-audit of our consolidated financial statements, consents, and in connection with certain of our filings with the U.S. Securities and Exchange Commission. BCRG Group was appointed on December 19, 2025 as our independent registered public accounting firm for the year ended December 31, 2025, and subsequently re-audited and issued superseding unqualified opinions on our consolidated financial statements for the years ended December 31, 2024 and December 31, 2023. BCRG Group fees attributed to 2024 reflect re-audit services performed during 2025. RBSM LLP fees reflect their original audit of fiscal year 2024.
(2)No tax fees were incurred for the years ended December 31, 2025 and 2024.
(3)No other fees were incurred for the years ended December 31, 2025 and 2024.

 

The Audit Committee pre-approves all audit and permitted non-audit services provided by the independent auditor in accordance with its pre-approval policy. A representative of SIMON & EDWARD, LLP is not expected to be present at the Meeting.

 

Proposed Resolution

 

It is proposed that the following resolution be adopted at the Meeting:

 

“RESOLVED, to appoint SIMON & EDWARD, LLP, the successor by merger to BCRG LLP, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 and until the next annual general meeting of shareholders, and to authorize the Board of Directors, upon the recommendation of the Audit Committee, to fix its compensation.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal. Abstentions and broker non-votes are not considered votes cast and will have no effect on the result. This proposal is a routine matter on which brokers may vote uninstructed shares.

 

Board Recommendation

 

The Board of Directors unanimously recommends a vote “FOR” the Auditor Proposal.

 

27

 

 

PROPOSAL 5

 

APPROVAL OF THE 2026 EQUITY INCENTIVE PLAN

(Item 5 on the Proxy Card; second session)

 

Background

 

Shareholders are being asked to approve the MBody AI Ltd. 2026 Equity Incentive Plan (the “2026 Plan”), together with an Israeli appendix for awards under Section 102 and Section 3(i) of the Israeli Income Tax Ordinance, a United States appendix (the “U.S. Appendix”) for awards to U.S. taxpayers, including incentive stock options, and a Canadian appendix for awards to Canadian taxpayers. On November 17, 2026, the Board approved the submission of the 2026 Plan to shareholders. Because the 2026 Plan provides for equity compensation of the Company’s office holders, the Reconstituted Compensation Committee and the Board will consider and, if they see fit, approve the 2026 Plan as part of the Interval Approvals, after the external directors are elected at the first session, and Proposal 5 will be voted on at the second session. The Board as constituted after the Meeting will consider the adoption of the 2026 Plan, and any grant of awards under it, in accordance with the Companies Law and the Compensation Policy. The 2026 Plan and its appendices are attached as Appendix B. The Company’s predecessor plan, the Check-Cap Ltd. 2015 Equity Incentive Plan (including its United States Sub-Plan), expired by its terms on June 23, 2025, and no further awards may be granted under it. No awards remain outstanding under the 2015 plan. The 2026 Plan will be the Company’s only equity incentive plan.

 

Under Israeli law, the approval of the Board is enough for the adoption of an equity incentive plan, and as a foreign private issuer the Company may follow that home country practice in lieu of the Nasdaq requirement to obtain shareholder approval for equity compensation plans. The Company is nonetheless seeking shareholder approval of the 2026 Plan for two reasons. First, under Section 422 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), options granted to U.S. employees qualify as incentive stock options (“ISOs”), which confer certain U.S. tax benefits, only if granted under a plan approved by the shareholders of the granting company within 12 months before or after its adoption. Second, shareholder approval aligns the 2026 Plan with the Nasdaq Listing Rules applicable to U.S. domestic companies. If Proposal 5 is not approved, the Board may still adopt the 2026 Plan following the Meeting, but the Company will be unable to grant ISOs to its U.S. employees, and the equity component of the terms proposed under Proposals 9(b) and 9(c) will not take effect.

 

The Board believes that equity-based compensation is an important component of overall compensation to attract and retain the long-term service of the best personnel, while aligning their interests with those of shareholders. The Company competes for talent in the United States and Canada, where equity compensation is a standard component of executive and technical compensation.

 

Summary of the 2026 Plan

 

The following is a summary of the principal terms of the 2026 Plan. It is qualified in its entirety by the full text of the 2026 Plan and its appendices attached as Appendix B.

 

Shares subject to the plan. The aggregate number of Ordinary Shares that may be issued under the 2026 Plan is 1,841,517 Ordinary Shares, representing approximately 12% of the 15,345,971 Ordinary Shares outstanding as of the Reference Date. The reserve is a fixed number. The 2026 Plan has no “evergreen” or automatic annual increase, and any increase in the reserve (other than for the adjustments described below) requires shareholder approval. The maximum number of Ordinary Shares that may be issued upon the exercise of ISOs is also 1,841,517. Shares subject to awards that expire, are forfeited or cancelled, or are settled in cash will again be available for issuance. Shares withheld to satisfy tax withholding on any award, shares tendered or withheld to pay the exercise price of an option or share appreciation right, shares subject to a share appreciation right that are not issued on its net settlement, and shares repurchased with option proceeds will not be added back to the reserve. Awards granted in substitution for awards of a company that the Company acquires do not reduce the reserve. The reserve, the ISO limit and outstanding awards will be adjusted for share splits, share dividends, recapitalizations and similar events.

 

28

 

 

Eligibility. Employees, directors, officers and consultants of the Company and its subsidiaries are eligible to receive awards. Under the Israeli appendix, awards under Section 102 of the Israeli Income Tax Ordinance may be granted only to Israeli employees, officers and directors who are not controlling shareholders, and awards under Section 3(i) to Israeli participants who are controlling shareholders, consultants or otherwise not eligible for Section 102 awards. The 2026 Plan does not itself grant any award to any person. Any award to a director, to the Chief Executive Officer or to a controlling shareholder requires the separate approvals prescribed by the Companies Law, as described under Proposals 9(b) and 9(c).

 

Types of awards. Options (including ISOs and non-qualified options under the U.S. Appendix), share appreciation rights, restricted shares, restricted share units, performance awards and other share-based awards.

 

Administration. The 2026 Plan is administered by the Compensation Committee or, to the extent the Board so determines or the Committee is not constituted, by the Board (the “Administrator”). The Administrator determines the recipients, types, sizes and terms of awards, interprets the plan, and may adopt sub-plans and appendices to qualify awards for favorable tax treatment in other jurisdictions, in each case subject to the Companies Law and the Compensation Policy.

 

Exercise price and term. The exercise price of options and share appreciation rights may not be less than the fair market value of an Ordinary Share on the date of grant (110% of fair market value for ISOs granted to holders of more than 10% of the Company’s voting power). The maximum term of an option or share appreciation right is ten years (five years for ISOs granted to 10% holders).

 

Minimum vesting. Awards vest over a period of not less than one year from the date of grant, except for awards covering up to 5% of the reserve and awards granted in substitution for awards of an acquired company, except on death, disability or retirement, or in connection with a change in control to the extent described below, and except that awards to non-employee directors granted on the date of an annual general meeting may vest on the earlier of the first anniversary of the date of grant and the next annual general meeting, if at least 50 weeks have elapsed. The Compensation Policy separately requires a vesting period of at least three years for awards to Executives and, through Section 7.1.2, for awards to directors; the director awards under Proposals 9(b) and 9(c) vest over three years in equal annual instalments.

 

Non-employee director limit. The aggregate grant date fair value of awards granted to any non-employee director in any calendar year, together with cash fees for that year, may not exceed US$400,000 (US$600,000 in the calendar year in which the director first joins the Board). This limit is a ceiling in the 2026 Plan; the Compensation Policy imposes the lower cap of 400% of annual fees described under Proposals 9(b) and 9(c).

 

Change in control. A change in control means (i) a merger, consolidation, amalgamation or similar transaction involving the Company, unless the Company’s shareholders immediately before the transaction hold more than 50% of the voting power of the surviving or resulting entity (or its parent) in substantially the same proportions, or (ii) a sale or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than to an entity in which the Company’s shareholders hold more than 50% of the voting power in substantially the same proportions. An acquisition of shares, including an acquisition of more than 50% of the voting power by any person, and a change in the composition of the Board are not a change in control. A change in control also does not include a change of the Company’s jurisdiction of incorporation, the creation of a holding company owned in substantially the same proportions by the Company’s shareholders, an issuance of securities in a financing, or an internal reorganization. Where an award holder’s award agreement, or an employment or service agreement approved in accordance with the Companies Law, defines a change in control differently, that definition applies to that holder’s awards. No award will vest by reason of a change in control except to the extent the award holder’s award agreement or employment or service agreement so provides, and that agreement prevails over the 2026 Plan on the effect of a change in control. In a change in control, outstanding awards will be assumed or substituted by the successor unless the Administrator determines otherwise. If awards are not assumed or substituted, the Administrator may accelerate their vesting, permit their exercise before the change in control, or cancel them for a payment equal to the value of their vested portion and, if the Administrator so determines, their unvested portion. The director awards under Proposals 9(b) and 9(c) will not provide for vesting upon a change in control.

 

29

 

 

Death, disability and termination of service. On death or disability, unless the award agreement provides otherwise, time-based awards vest in full and performance awards vest pro rata based on actual performance. Where an approved employment or service agreement so provides, awards continue to vest for up to 12 months after a termination without cause or for good reason. Otherwise, unless the award agreement provides differently, vested options may be exercised for three months following termination of service (twelve months following death or disability), and unvested awards are forfeited.

 

No repricing. The Administrator may not, without shareholder approval, reduce the exercise price of outstanding options or share appreciation rights, cancel them in exchange for awards with a lower exercise price or for cash when the exercise price exceeds fair market value, or take any other action treated as a repricing under the Nasdaq Listing Rules.

 

Dividends. No dividends or dividend equivalents will be paid on unvested awards; any accrued dividend equivalents will be paid only if and when the underlying award vests.

 

Clawback. Awards are subject to the Company’s clawback policy adopted under Nasdaq Listing Rule 5608 and to Section 8 of the Compensation Policy.

 

Transferability. Awards are generally non-transferable other than by will or the laws of descent, and awards held by a trustee under Section 102 are subject to the trust and holding-period requirements of the Israeli Income Tax Ordinance.

 

Amendment and termination. The Board may amend, suspend or terminate the 2026 Plan at any time, provided that no amendment may materially impair the rights of a participant without consent. Shareholder approval is required for an increase in the reserve or the ISO limit (other than for adjustments), an expansion of eligibility, an extension of the term of the plan, a repricing, and any other amendment for which applicable law or the Nasdaq rules require it. The 2026 Plan will terminate 10 years after its adoption by the Board unless earlier terminated.

 

Israeli appendix. Awards to Israeli participants may be granted as trustee awards under the capital gains track or the ordinary income track of Section 102(b), as elected by the Company, held by a trustee for the required holding period, or as non-trustee awards under Section 102(c) or under Section 3(i) of the Israeli Income Tax Ordinance, as determined by the Administrator.

 

U.S. Appendix. The U.S. Appendix provides for ISOs and non-qualified options and for awards intended to comply with or be exempt from Section 409A of the Code, and carries forward the structure of the 2015 United States Sub-Plan updated for Section 422 of the Code and current Form S-8 practice.

 

Canadian appendix. The Canadian appendix provides that options granted to Canadian participants have an exercise price no lower than fair market value at grant, that restricted share units are settled no later than December 31 of the third calendar year after the year in which the services were rendered, and that awards are made in reliance on the employee, executive officer, director and consultant exemption under National Instrument 45-106.

 

30

 

 

U.S. Federal Income Tax Consequences

 

The following is a brief summary of the principal U.S. federal income tax consequences of awards under the U.S. Appendix. It is not a complete description and does not address state, local, Israeli or Canadian tax consequences. Incentive stock options. A participant recognizes no taxable income on the grant or exercise of an ISO (although the spread at exercise is an item of adjustment for alternative minimum tax purposes). If the shares are held for at least two years from grant and one year from exercise, gain on sale is long-term capital gain and the Company receives no deduction; if the shares are disposed of earlier, the participant recognizes ordinary income equal to the lesser of the spread at exercise or the gain on sale, and the Company is generally entitled to a corresponding deduction. Non-qualified options. A participant recognizes ordinary income at exercise equal to the excess of the fair market value of the shares over the exercise price, and the Company is generally entitled to a corresponding deduction. Restricted shares and restricted share units. A participant recognizes ordinary income when restricted shares vest (or at grant, if a Section 83(b) election is made) or when restricted share units are settled, in each case equal to the fair market value of the shares delivered, and the Company is generally entitled to a corresponding deduction. Section 409A. Awards are intended to be exempt from or to comply with Section 409A of the Code.

 

New Plan Benefits

 

The 2026 Plan fixes no grant to any person. The equity components of the terms proposed under Proposals 9(b) and 9(c) are described under those proposals and are conditional on the approval of this Proposal 5. No other awards have been granted or allocated under the 2026 Plan, and the awards that will be granted in the future are not determinable.

 

Proposed Resolution

 

“RESOLVED, to approve the MBody AI Ltd. 2026 Equity Incentive Plan, including its Israeli, United States and Canadian appendices, in the form attached as Appendix B to the Proxy Statement, with a reserve of 1,841,517 Ordinary Shares, and to acknowledge that the Check-Cap Ltd. 2015 Equity Incentive Plan expired by its terms on June 23, 2025, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to it, including the Interval Approvals.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal. Abstentions and broker non-votes are not considered votes cast and will have no effect on the result. Because the 2026 Plan does not fix any grant to any director or controlling shareholder, no shareholder is excluded from voting on this proposal.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” the Equity Plan Proposal.

 

31

 

 

PROPOSAL 6

 

AMENDMENT OF THE ARTICLES OF ASSOCIATION: EXTERNAL DIRECTORS NOT APPOINTED BY THE BOARD (NEW ARTICLE 42A)

(Item 6 on the Proxy Card; first session)

 

Background

 

Article 39 of our Articles of Association sets the minimum and maximum size of the Board at four and eleven directors, including any external directors. Article 42 permits the Board to appoint directors to fill vacancies and, if the number of directors in office falls below the minimum in Article 39, limits the continuing directors to acting in an emergency, filling vacancies up to that minimum or calling a general meeting to elect directors. Article 42 does not distinguish between external directors and other directors. Under the Companies Law, however, external directors may be elected only by the general meeting under Section 239 and cannot be appointed by the Board. Proposal 6 adds a new Article 42A to make that limitation express.

 

What Article 42A Does

 

●Article 42A provides that the powers of the Board and of the continuing directors under Article 42 to appoint directors, including to fill a vacancy and where the number of directors in office is less than the minimum in Article 39, do not include the power to appoint an external director, and that external directors may be elected only by the general meeting in accordance with Section 239 of the Companies Law. It also provides that if the office of an external director becomes vacant, the Board (or the continuing directors) will convene a general meeting to elect an external director in accordance with the Companies Law.

 

●What Article 42A Does Not Do

 

It does not change the Board’s power under Article 42 to appoint directors other than external directors, or the limits on the continuing directors under Article 42.

 

It does not change the Board’s size limits in Article 39.

 

Israeli counsel has advised the Company that Article 42A reflects the requirement of the Companies Law that external directors be elected by the general meeting under Section 239.

 

Text of New Article 42A

 

The following Article 42A will be added to the Articles of Association, as set out in Part D of Appendix D:

 

“42A. External Directors. (a) The powers of the Board of Directors and of the continuing Directors under Article 42 to appoint Directors, including to fill a vacancy and where the number of Directors in office is less than the minimum number provided for in Article 39, do not include the power to appoint an External Director. External Directors shall be elected only by the General Meeting in accordance with Section 239 of the Companies Law. (b) If the office of an External Director becomes vacant, the Board of Directors (or the continuing Directors) shall convene a General Meeting for the election of an External Director in accordance with the Companies Law.”

 

Approval Requirements under Israeli Law

 

The adoption of Article 42A is an amendment to the Articles of Association and requires the approval of shareholders by an Ordinary Majority. No director or shareholder has a personal interest in the proposal.

 

Proposed Resolution

 

It is proposed that the following resolution be adopted at the Meeting:

 

“RESOLVED, to approve the adoption of a new Article 42A of the Articles of Association, in the form set out in Part D of Appendix D to the Proxy Statement, confirming that the powers of the Board and of the continuing directors under Article 42 to appoint directors do not include the power to appoint external directors, who may be elected only by the General Meeting in accordance with Section 239 of the Companies Law, and providing that if the office of an external director becomes vacant the Board will convene a General Meeting to elect an external director in accordance with the Companies Law.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal. Abstentions and broker non-votes are not considered votes cast and will have no effect on the result.

 

Board Recommendation

 

The Board of Directors unanimously recommends a vote “FOR” the External Director Vacancies Proposal.

 

32

 

 

PROPOSAL 7

 

AUTHORITY TO CHANGE THE COMPANY’S NAME

(Item 7 on the Proxy Card; first session)

 

Background

 

The Company’s name, MBody AI Ltd., was adopted by shareholder resolution on October 17, 2025 in connection with the Business Combination. The Company wishes to preserve flexibility to respond to potential changes in the commercial, political and regulatory environment and in the terminology used to describe advanced artificial intelligence, including the term “super intelligence” (“SI”). The Company’s customers are large United States hospitality and gaming operators, and its growth plan depends on commercial, government and regulatory relationships in the United States and in other markets. The Board believes that the Company should be able to align its name with the terminology used by its customers, partners, investors and regulators if that terminology continues to shift, without the delay and cost of convening a further general meeting.

 

The Proposal

 

The Board asks shareholders to authorize it to change the Company’s name from “MBody AI Ltd.” to “MBody SI Ltd.”, or to such similar name as the Registrar of Companies approves, and to amend the Articles of Association accordingly, at such time within 24 months after the Meeting as the Board determines, or not at all. The Board will make that determination having regard to developments in terminology in the United States and global markets, the views of the Company’s customers, partners and investors, and the costs of the change. The authority does not change the Company’s ticker symbol, share capital, business, management or any right of shareholders. If the Board implements the change, the Company will announce it, file the amendment with the Israeli Registrar of Companies, and notify Nasdaq and the SEC. Shareholders will not need to exchange share certificates. If the Board does not implement the change within 24 months, the authority lapses and the Company’s name remains MBody AI Ltd.

 

Effect on the Articles of Association

 

Part A of Appendix D has two paragraphs. Paragraph 1 regularizes the Articles: the Articles on file with the Registrar of Companies continue to refer to the Company’s former name, Check-Cap Ltd., although shareholders approved the change of name to MBody AI Ltd. on October 17, 2025 and the Registrar of Companies registered the change with effect from August 27, 2026. Paragraph 1 does not itself change the Company’s name and takes effect upon the adoption of the resolution at the Meeting, whether or not the Board uses the authority. Paragraph 2 replaces the Company’s name wherever it appears in the Articles if the Board determines to change the name within 24 months after the Meeting. The Company will deliver the resolution to the Registrar of Companies within 14 days after its adoption under Section 21(b) of the Companies Law, and any change of name will take effect only upon its registration by the Registrar of Companies under Section 40 of the Companies Law.

 

Approval Requirements under Israeli Law

 

A change of the Company’s name is an amendment to the Articles of Association and requires the approval of shareholders by an Ordinary Majority. No director or shareholder has a personal interest in the proposal.

 

Proposed Resolution

 

It is proposed that the following resolution be adopted at the Meeting:

 

“RESOLVED, to authorize the Board of Directors, in its discretion and at any time within 24 months after the date of the Meeting, to change the name of the Company from “MBody AI Ltd.” to “MBody SI Ltd.”, or to such similar name as the Registrar of Companies may approve, and to approve the corresponding amendment of the Articles of Association of the Company, in the form set out in Part A of Appendix D to the Proxy Statement, effective upon the determination of the Board of Directors and the approval of the Registrar of Companies, all as described in the Proxy Statement.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal. Abstentions and broker non-votes are not considered votes cast and will have no effect on the result.

 

Board Recommendation

 

The Board of Directors unanimously recommends a vote “FOR” the Name Change Authority Proposal.

 

33

 

 

PROPOSAL 8

 

COMPENSATION POLICY

 

(Item 8 on the Proxy Card; second session)

 

Proposal 8 asks shareholders to approve the Company’s Compensation Policy, which reflects the Company’s business following the Business Combination, for a period of three years from the date of the Meeting. The amended and restated policy also amends the compensation caps and ratios. Proposal 8 is a single vote. It will be voted on at the second session of the Meeting, at 2:00 p.m. Eastern Time on the same day, after the Interval Approvals. See “Why the Meeting is held in two sessions on the same day” in the Notice.

 

Appendix A. Appendix A is the amended and restated Compensation Policy. The amendments to the policy approved by shareholders on December 18, 2023 are summarized below.

 

Approval Requirements under Israeli Law Applicable to Proposal 8

 

Under the Companies Law, a public company must adopt a compensation policy governing the terms of office and engagement of its office holders. The compensation policy must be recommended by the compensation committee, approved by the board of directors and approved by shareholders by a Special Majority under Section 267A of the Companies Law, and must be re-approved in that manner at least every three years. In adopting a compensation policy, the compensation committee and the board must consider the matters set out in Section 267B of, and Parts A and B of the First Schedule A to, the Companies Law, including the promotion of the company’s objectives, its business plan and long-term strategy; the creation of appropriate incentives for office holders taking into account the company’s risk management policy; the company’s size and the nature of its operations; and, with respect to variable compensation, the contribution of the office holder to the achievement of the company’s objectives and profits. The policy must address, among other things, the education, skills, expertise and achievements of office holders; the ratio between the cost of office holders’ compensation and the average and median cost of employment of the company’s other employees; the basis of variable components; the relationship between fixed and variable components; termination arrangements; and the ability to reduce variable compensation and to recover compensation paid on the basis of restated financial statements.

 

Board override. If shareholders do not approve a compensation policy by the required majority, the compensation committee and the board may nonetheless approve it under Section 267A(c) of the Companies Law, following further discussion and on the basis of detailed reasons, if they determine that its adoption is in the best interests of the company notwithstanding the shareholders’ vote. This applies to Proposal 8.

 

Our 2023 Compensation Policy was approved by shareholders on December 18, 2023. Under Section 267A of the Companies Law, it will cease to be in effect on December 18, 2026, three years after that date and four days before the Meeting.

 

The Board has approved the compensation matters described in Proposals 8 and 9 for submission to shareholders, on the terms described in this Proxy Statement. Because the Companies Law requires those matters to be approved first by a compensation committee that includes the external directors and then by the board, the Reconstituted Compensation Committee and then the Board will consider and, if they see fit, approve each of them as part of the Interval Approvals, after the external directors are elected at the first session and before the vote at the second session. If either of them changes any of those terms, the chairman of the Meeting will announce the change at the second session before the vote, and the Company will furnish a report on Form 6-K describing the change as soon as practicable. Each resolution under Proposals 5, 8 and 9 also asks shareholders to approve, to the extent required under the Companies Law, the approvals given by the Reconstituted Compensation Committee and the Board as part of the Interval Approvals.

 

34

 

 

Background and Reasons

 

The Board has reviewed the Compensation Policy in light of the Business Combination and has approved the Compensation Policy, for submission to the shareholders, for a period of three years from the date of the Meeting. The amendments update the policy to reflect the Company’s current business, governance and executive arrangements. The amendments, other than the changes to the caps and ratios described below, are:

 

  ● Business description (Section 4.1.4). The current policy describes the Company as a clinical-stage medical diagnostics company. The amended policy describes the Company’s current business: through its subsidiaries, the development and deployment of artificial intelligence and AI-driven robotics solutions, including the deployment, operation and management of fleets of autonomous robots for commercial customers in the hospitality, gaming and other sectors under long-term service agreements, supported by the Company’s MBody AI Orchestrator software platform, with operations principally in the United States and Canada.

 

●Directors engaged as executives (Section 7.1). The third paragraph of Section 7.1 is clarified so that a director who is also engaged as an executive is compensated under Section 6 only, with no stacking of Section 7 director fees for the same period, other than expense reimbursement, insurance, exculpation and indemnification.

 

●Bonus criteria (Section 6.2.4.1(b)). The current policy sets separate bonus criteria for the periods before and after the commencement of product sales, written for a clinical-stage company. The amended policy sets criteria for a commercial-stage operating company (including revenue, annual recurring revenue, gross margin, EBITDA, cash flow, robots deployed or under management, customer acquisition and retention, fleet utilization and service levels, safety, budget, capital raising and strategic transactions, product and technology milestones, and governance and compliance goals). The limit of 50% per criterion is retained, and the obsolete pre-sales clause is deleted.

 

●Equity plan references and exercise price (Sections 6.3.1 and 6.3.4). References to the Check-Cap Ltd. 2015 Equity Incentive Plan, which expired by its terms on June 23, 2025, are replaced with references to the 2026 Equity Incentive Plan described under Proposal 5 and other plans adopted from time to time. The minimum exercise price of options is changed from the average closing price over the 30 trading days preceding grant to the fair market value on the date of grant (the Nasdaq closing price), which is the standard required for incentive stock options under the U.S. Internal Revenue Code and for favorable tax treatment of options in Canada.

 

●Legal fees benefit (new Section 6.1.2(w1)). A new capped benefit permits the payment or advancement of reasonable legal fees and expenses incurred by an Executive in connection with a claim, dispute, investigation or proceeding arising from or relating to the Executive’s employment or service with the Company or its Affiliates, up to US$100,000 per Executive per calendar year inclusive of any gross-up. The Compensation Committee must approve each matter in advance and confirm that the matter is not a claim brought by the Executive against the Company or any Affiliate and does not conflict with the Company’s interests. To the extent a payment or advancement constitutes indemnification, it may be made only in accordance with Sections 258 to 264 of the Companies Law and the Company’s Articles of Association, and the Executive must repay any amount advanced to the extent required by law. No amount is payable under the benefit to the extent the same expenses are paid under an indemnification undertaking or the Company’s D&O insurance. This supports Section 2.7(c)(i) of the executive agreement described under Proposal 9(a). Any payment will be disclosed as required by applicable law.

 

●Mandatory employment law entitlements (new Section 6.1.3.3). Where mandatory law in the jurisdiction in which an Executive is employed entitles the Executive to notice, pay in lieu of notice, severance or other termination entitlements exceeding the policy caps, the Company may satisfy those legal entitlements without deviating from the policy.

 

35

 

 

●Parent guarantee (Section 2.15). Where an Office Holder is employed by a subsidiary, the Company may guarantee the subsidiary’s obligations under terms of office approved in accordance with the policy, limited to the monetary obligations expressly set out in those terms and within the policy limits. Such a guarantee forms part of the Terms of Office and Engagement of the Office Holder, is approved together with them in accordance with the Companies Law, and is not counted as an additional component for the purposes of the caps and ratios in Sections 6 and 7 of the policy. This supports the parent guarantee described under Proposal 9(a).

 

●Sign-on bonus (Section 6.2.4.3). The sign-on bonus, capped at 30% of first-year base salary, is available to a newly hired or newly appointed Executive, including an Executive first appointed as an Office Holder of the Company on the Company becoming the listed parent of its operating subsidiaries. The cap is unchanged.

 

●Tolerance (Section 6). The 10% tolerance is clarified to mean 10% of the applicable cap amount or ratio.

 

●External directors (Section 7.1). The amended policy refers to the External Director Regulations and provides that, with shareholder approval by the Section 239(b) majority, an external director may be paid cash and equity above the regulated amounts within the Section 7 director caps and with equity on terms no more favorable than other directors, as Regulation 8B permits. See Proposal 9(c).

 

●Clawback (Section 8). The recoupment provision is updated to refer to the Company’s clawback policy adopted under Rule 10D-1 under the Exchange Act and Nasdaq Listing Rule 5608.

 

●Conforming changes. Benefits available in the United States and Canada (including 401(k) and RRSP plans) are added to the benefits list in Section 6.1.2; references to U.S. and Canadian securities laws and Nasdaq rules are added; the cross-reference in Section 6.2.1 is corrected to “Sections 6.2.4.1(e) and 6.3”; the Company name is updated; and other typographical corrections are made.

 

The amendments to the compensation caps and ratios are described below under “Amendments to the Compensation Caps and Ratios.”

 

Compensation Committee and Board Considerations

 

In approving the amended and restated Compensation Policy for submission to shareholders, the Board considered the matters required under the Companies Law described above, the Company’s business plan and long-term strategy following the Business Combination, the compensation practices of comparable companies, the ratio between the cost of the Company’s office holders’ compensation and the average and median cost of employment of its other employees, and the need to attract and retain executives in the North American markets in which the Company operates. The Company did not engage an independent compensation consultant. The Board concluded that the amended and restated policy is consistent with the Company’s objectives and in the best interests of the Company and its shareholders. The Reconstituted Compensation Committee and the Board will consider the same matters as part of the Interval Approvals.

 

36

 

 

Amendments to the Compensation Caps and Ratios

 

The compensation caps and ratios in the current Compensation Policy were set in 2020 and carried into the policy approved on December 18, 2023 for a clinical-stage medical device company based in Israel with a small management team. Following the Business Combination, the Company is a commercial-stage operating company headquartered in North America with a larger and differently structured executive team. The Compensation Committee and the Board recommend that the caps and ratios be amended, as set out in Appendix A and summarized below. The figures are shown in brackets pending final determination by the Reconstituted Compensation Committee and the Board.

 

Provision

Current policy Proposed (Appendix A) Section
Annual base salary cap US$450,000 (CEO); US$330,000 (other Executives) US$500,000 for all Executives (single Executive band) 6.1.1.1
Annual bonus cap (% of base salary) 150% (CEO); 75% (other Executives) 150% for all Executives 6.2.4.1(e)
Variable compensation as % of total annual compensation Up to 85% (CEO); up to 75% (other Executives) Up to 90% for all Executives 6.2.1
Annual equity award cap (% of base salary) 400% (CEO); 200% (other Executives) 400% for all Executives 6.3.2
Termination and severance payments Up to 9 monthly base salaries (CEO); up to 3 monthly base salaries in the first three years and 9 thereafter (other Executives) Up to 12 monthly base salaries for all Executives, together with a pro-rated annual bonus for the year of termination based on actual performance, continuation of benefits for up to 12 months and continued vesting of equity awards for up to 12 months; the same limits on termination by reason of disability, less disability insurance benefits 6.1.3.2
Change of control payment One-time payment of up to 100% of annual cash compensation (base and target bonus) Unchanged at 100%, stated to be payable in lieu of the termination payment under Section 6.1.3.2, with benefit continuation and continued vesting still permitted 6.1.4
Director periodic fee cap (Board service) US$30,000 per year US$40,000 per year (committee fees of US$7,500, US$5,000 and US$2,500, the US$1,000 per-meeting fee, chair fees and the 400% director equity cap are unchanged) 7.1.1.1.1
Sign-on bonus; special bonus; notice 30% of first-year base; 3 monthly salaries; 3 months Unchanged 6.2.4.3; 6.2.4.2; 6.1.3.1

 

The principal change is to replace the separate caps for the Chief Executive Officer and for other Executives with a single band applicable to all Executives. The Board believes that a single band better reflects the structure of the Company’s executive team, in which the Chief Executive Officer, the Chief Financial Officer and other senior executives carry comparable responsibility for the Company’s growth, and avoids the need for further shareholder approvals as roles evolve. The amended caps remain ceilings, not targets: the actual terms of each Executive continue to be set individually by the Compensation Committee and the Board (and, where required, shareholders) within the Compensation Policy. At the proposed maxima, the variable components (bonus of 150%, equity of 400%, sign-on of 30% and special bonus of 25% of base salary) amount to approximately 86% of total compensation, within the proposed 90% ratio.

 

37

 

 

Consequences if Proposal 8 is not Approved

 

If Proposal 8 is not approved by shareholders, the Reconstituted Compensation Committee and the Board may approve the amended and restated policy under Section 267A(c) of the Companies Law as described above. If they do not, the Company will have no compensation policy in effect until shareholders approve one at a further general meeting, because the 2023 Compensation Policy will cease to be in effect on December 18, 2026, before the date of the Meeting. In that case, the terms of office of the Chief Executive Officer under Proposal 9(a), if approved by shareholders by the Special Majority under Section 272(c1) of the Companies Law, would take effect as approved terms, to the extent permitted by the Companies Law.

 

Proposed Resolution

 

“RESOLVED, to approve the amended and restated Compensation Policy for Executive Officers and Directors of the Company, including the amended compensation caps and ratios, in the form attached as Appendix A to the Proxy Statement, for a period of three years from the date of the Meeting, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to it, including the Interval Approvals.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal, provided that either (i) the majority voted in favor includes at least a majority of the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in the approval of the proposal, excluding abstentions, or (ii) the total number of votes cast against the proposal by such shareholders does not exceed two percent (2%) of the total voting rights in the Company. See “Controlling Shareholders and Personal Interests” in the Notice. By signing and returning the proxy card, or by voting online before or at the Meeting, you confirm that you are not a controlling shareholder and do not have a personal interest in the approval of this proposal, unless you have notified the Company otherwise as described in the Notice. Mr. McGee, as a controlling shareholder, and Mr. Fowler and each other director or officer whose terms of office are governed by the Compensation Policy, as persons having a personal interest, will be excluded from the second count on this proposal. If the proposal is not approved by shareholders, the Compensation Committee and the Board may approve it under Section 267A(c) of the Companies Law.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” the Compensation Policy Proposal.

 

38

 

 

PROPOSAL 9

 

OFFICE HOLDER COMPENSATION

 

(Items 9(a), 9(b), 9(c) and 9(d) on the Proxy Card; second session)

 

Proposal 9 consists of four separate votes: the terms of office and engagement of the Chief Executive Officer (Proposal 9(a)); the compensation of the non-employee directors other than the external directors and any controlling shareholder (Proposal 9(b)); the compensation of the external directors (Proposal 9(c)); and indemnification and exculpation undertakings for directors other than the Chief Executive Officer and any controlling shareholder (Proposal 9(d)). Each is a separate vote. Proposals 9(a), 9(b), 9(c) and 9(d) will be voted on at the second session of the Meeting, after the Interval Approvals.

 

Approval Requirements under Israeli Law Applicable to Proposal 9

 

Under Section 272(c1) of the Companies Law, the terms of office and engagement of a public company’s chief executive officer require the approval of the compensation committee, the board of directors and the shareholders by a Special Majority. In approving the terms, the compensation committee and the board must consider the matters set out in Section 267B of the Companies Law and the compensation policy, and must determine whether the terms conform to the policy. Where the terms do not conform to the policy, the committee and the board may approve them only in special circumstances, on the basis of detailed reasons and after considering the matters the policy must address. If shareholders do not approve the terms, the committee and the board may nonetheless approve them under Section 272(c1)(2), following further discussion and on the basis of detailed reasons. The terms of office and engagement of a director, including as to indemnification, exculpation and insurance, require the approval of the compensation committee, the board and the shareholders under Section 273; where the terms conform to the compensation policy, an Ordinary Majority applies.

 

Proposal 9(a): Terms of Office and Engagement of John Fowler as Chief Executive Officer (Item 9(a) on the Proxy Card)

 

Background

 

John Fowler has served as Chief Executive Officer of the Company since the closing of the Business Combination and as Chief Executive Officer of MBody AI Corp. since 2025. Mr. Fowler is also a director of the Company and a nominee under Proposal 3. Mr. Fowler beneficially owns approximately 4.4% of the Company’s outstanding Ordinary Shares, through Fowler Family Holdings Corp.

 

Mr. Fowler’s employment agreement with MBody AI Corp., the Company’s Nevada subsidiary (the “CEO Agreement”), was approved by the compensation committee and the board of directors of Check-Cap Ltd. before the closing of the Business Combination, with effect from August 17, 2026, subject to the approvals required under the Companies Law and the Compensation Policy. Shareholders are being asked to approve the terms of office and engagement summarized below, together with the guarantee by the Company of MBody AI Corp.’s payment obligations under the CEO Agreement and the indemnification and exculpation undertaking in the form attached as Appendix C and the amended and restated indemnification agreement between MBody AI Corp. and Mr. Fowler. No equity award to Mr. Fowler is proposed at this Meeting.

 

Since the closing of the Business Combination, Mr. Fowler has received compensation on the terms of the CEO Agreement, subject to the approvals described in this Proposal 9(a). If the required approvals are not obtained, his prior employment agreement with MBody AI Canada Corp. will govern, as the CEO Agreement provides. Following the election of the external directors at the first session, the Reconstituted Compensation Committee will consider Mr. Fowler’s terms, consider the matters required by Section 267B of the Companies Law and the Compensation Policy, determine whether the terms conform to the Policy and record its reasons, and approve and recommend the terms to the Board, as part of the Interval Approvals.

 

39

 

 

Principal Terms

 

The principal terms of the CEO Agreement are:

 

Term

Principal terms
Role and reporting Chief Executive Officer of the Company and of MBody AI Corp., employed by MBody AI Corp. (Nevada). Reports to the Board.
Effective date and term Effective August 17, 2026. Indefinite term.
Time commitment Substantially all of his business time.
Base salary US$375,000 per year.
Annual bonus Up to 150% of base salary (threshold 50%, target 100%), on measurable criteria set annually by the Compensation Committee under the Compensation Policy.
Sign-on bonus US$112,500, repayable pro rata on certain terminations in the first 12 months.
Equity Eligible to participate in the 2026 Equity Incentive Plan. No equity award is proposed at this Meeting; any grant to Mr. Fowler requires separate approval under Section 272(c1) of the Companies Law. Under the CEO Agreement, awards vest in full on a termination without cause or for good reason within 12 months after a change of control, and continue to vest for 12 months on a termination without cause or for good reason.
Termination On termination without cause or for good reason: 12 months’ base salary continuation, a pro-rata bonus, 12 months’ benefits continuation and 12 months’ continued vesting. On disability: 12 months’ base salary continuation, less disability benefits, and a pro-rata bonus. A release is required.
Change of control On termination without cause or for good reason within 12 months after a change of control: a lump sum of 100% of base salary plus target bonus, in lieu of salary continuation and the pro-rata bonus.
Notice 30 days by the Company; 12 months by the executive.
Benefits Customary executive benefits in accordance with the Compensation Policy, including health, insurance and security benefits, paid time off and reimbursement of business expenses.
Legal expenses benefit Payment or advancement of reasonable legal fees and expenses in proceedings arising from or relating to employment or service with the Company or its Affiliates, within the US$100,000 annual limit in Section 6.1.2(w1) of the Policy, subject to advance Compensation Committee approval and, to the extent the payment constitutes indemnification, to Sections 258 to 264 of the Companies Law.
Indemnification and insurance Indemnification and exculpation undertaking in the Appendix C form, approved under this Proposal 9(a); an amended and restated indemnification agreement with MBody AI Corp. covering service to MBody AI Corp. and its subsidiaries, with a separate limit of US$25,000,000, approved under this Proposal 9(a); and coverage under the Company’s D&O insurance.
Parent guarantee

Guarantee by the Company of the payment obligations of MBody AI Corp. under the CEO Agreement.

Clawback Compensation is subject to the Company’s clawback policy.

 

Conformity with the Compensation Policy. The proposed terms are within the caps of the Compensation Policy as proposed to be amended under Proposal 8.

 

40

 

 

Findings of the Compensation Committee and the Board

 

The principal terms of Mr. Fowler’s employment were approved by the compensation committee and the board of directors of Check-Cap Ltd. before the closing of the Business Combination. Separately, in approving Proposal 9(a) for submission to shareholders, the Board (with Mr. Fowler not participating) considered the matters required under Section 267B of the Companies Law and the Compensation Policy, including Mr. Fowler’s qualifications and experience, including as the founder and chief executive of a public company; his role in founding and leading MBody AI Corp. and in completing the Business Combination and the August 2026 offering; the compensation of chief executive officers at comparable companies; the ratio between the cost of the proposed terms and the average and median cost of employment of the Company’s other employees; the mix of fixed and variable components and the link between the variable components and the Company’s financing, acquisition and revenue performance; the termination arrangements and their relationship to Mr. Fowler’s tenure and expected contribution; and the clawback provisions. The Board concluded that the proposed terms are reasonable and in the best interests of the Company. The Reconstituted Compensation Committee and the Board will re-examine and record these findings as part of the Interval Approvals.

 

Findings in the alternative

 

Because Proposal 8 is voted at the same session as this Proposal 9(a), the Reconstituted Compensation Committee and the Board will record their findings in the alternative, as part of the Interval Approvals. If Proposal 8 is approved, they will record that the proposed terms conform to the Compensation Policy as amended. If it is not approved and the Compensation Policy is not approved under Section 267A(c), the Reconstituted Compensation Committee and the Board will record, under Section 267B of the Companies Law and Section 272(c1), detailed reasons for approving the terms in the absence of a compensation policy, including the severance term, the legal fees benefit, the parent guarantee and the sign-on bonus. Proposal 9(a) therefore stands whether or not Proposal 8 is approved.

 

Consequences if Proposal 9(a) is not Approved

 

If Proposal 9(a) is not approved, the Reconstituted Compensation Committee and the Board may, under Section 272(c1)(2) of the Companies Law and to the extent that the Companies Law permits for a Chief Executive Officer who is also a director, approve the terms notwithstanding the shareholders’ vote, following further discussion and on the basis of detailed reasons, and the Company would disclose that determination. If the terms are not approved by any of those routes, Mr. Fowler’s prior employment agreement with MBody AI Canada Corp. would continue to govern, as the CEO Agreement provides, and the Company may submit the terms, or revised terms, for approval at a later general meeting. The Company would determine the treatment of amounts paid under the CEO Agreement since the closing of the Business Combination in accordance with applicable law.

 

Proposed Resolution

 

“RESOLVED, to approve the terms of office and engagement of John Fowler as Chief Executive Officer of the Company, as described in the Proxy Statement, including the guarantee by the Company of the obligations of MBody AI Corp. to Mr. Fowler under his employment agreement, the indemnification and exculpation undertaking in the form attached as Appendix C to the Proxy Statement and the amended and restated indemnification agreement between MBody AI Corp. and Mr. Fowler, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to them, including the Interval Approvals.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal, provided that either (i) the majority voted in favor includes at least a majority of the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in the approval of the proposal, excluding abstentions, or (ii) the total number of votes cast against the proposal by such shareholders does not exceed two percent (2%) of the total voting rights in the Company. See “Controlling Shareholders and Personal Interests” in the Notice. By signing and returning the proxy card, or by voting online before or at the Meeting, you confirm that you are not a controlling shareholder and do not have a personal interest in the approval of this proposal, unless you have notified the Company otherwise as described in the Notice.

 

41

 

 

Mr. McGee, as a controlling shareholder, and Mr. Fowler, as the person whose terms are being approved, will be excluded from the second count on this proposal. If the proposal is not approved by shareholders, the Compensation Committee and the Board may approve the terms under Section 272(c1)(2) of the Companies Law as described above, to the extent that the Companies Law permits for a Chief Executive Officer who is also a director.

 

Board Recommendation

 

The Board of Directors (other than Mr. Fowler, who did not participate) recommends a vote “FOR” the CEO Compensation Proposal.

 

Proposal 9(b): Compensation of Non-Employee Directors (Item 9(b) on the Proxy Card)

 

Background

 

Section 7 of the Compensation Policy provides for the compensation of non-employee directors by way of annual fees for Board and committee service, per-meeting fees and annual equity awards within stated caps. Shareholders are being asked to approve the following compensation for each non-employee director of the Company other than the external directors (whose compensation is the subject of Proposal 9(c)) and any director who is a controlling shareholder of the Company, being, if the nominees under Proposal 3 are elected, David Lontini, and any such non-employee director appointed or elected in the future:

 

Component

Proposed Compensation Policy cap
Annual cash compensation US$40,000, payable quarterly in arrears, inclusive of Board and committee service (David Lontini) Section 7.1.1.1.1(i): Board fee US$30,000 (current) / US$40,000 (if Proposal 8 is approved), plus US$7,500 (Audit Committee) and US$5,000 (Compensation Committee) for a director serving on those committees
Annual committee fees None in addition to the annual cash compensation Section 7.1.1.1.1(ii) to (iv): US$7,500; US$5,000; US$2,500
Committee chair fees None Section 7.1.1.1.3: US$5,000; US$2,500
Per-meeting fee None Section 7.1.1.1.2: US$1,000
Annual equity award Grant date value of US$60,000 under the 2026 Equity Incentive Plan, granted on the date of each annual general meeting, vesting over three years in equal annual instalments, on the same terms as the awards to the external directors under Proposal 9(c); conditional on the approval of Proposal 5 Section 7.1.2: 400% of annual fees (Board and committee fees, excluding per-meeting fees); Section 6.3.3 via 7.1.2: vesting over a period of at least three years
Initial equity award None Section 7.1.2; 2026 Plan first-year director limit US$600,000
Expenses Reimbursement of reasonable expenses incurred in attending meetings and performing duties Section 7.1.1.2
Indemnification, exculpation and insurance Indemnification and exculpation undertaking in the Appendix C form (Proposal 9(d)); D&O insurance Sections 7.1.1.3 and 6.1.2(x) to (z)

 

42

 

 

If the nominees under Proposals 3 and 3A are elected, the directors who will receive the non-employee director compensation under Proposal 9(b) and the external director compensation under Proposal 9(c) will be David Lontini, Fiona George and Daniel Kokiw. Regan McGee and John Fowler will not receive any compensation for their service as directors under Proposals 9(b) or 9(c). The proposed compensation is identical to the compensation of the external directors under Proposal 9(c). It is within the caps of Section 7 of the Compensation Policy. The equity award will be made on the same terms (including vesting and exercise price, and with no vesting upon a change in control under the award agreement, subject to the 2026 Plan’s provisions for awards that are not assumed or substituted, described under “Proposal 5”) as the equity award to the external directors under Proposal 9(c), so that the external directors’ award is on terms no more favorable than those of the other directors. The proposed compensation was approved by the Board for submission to shareholders after considering the compensation of directors at comparable companies and the time commitment required of the Company’s directors. Mr. Lontini did not participate in the Board’s approval.

 

Because the Company has a controlling shareholder, the exemption in Regulation 5D of the Reliefs Regulations from the requirement of Section 118A of the Companies Law that the members of the compensation committee who are not external directors be compensated in accordance with the External Director Regulations is not available to the Company, including following the amendment of the Reliefs Regulations in March 2024. Mr. Lontini will serve on the Compensation Committee, and his compensation will therefore be identical in all respects to the compensation of the external directors. Accordingly, the cash and equity components of Mr. Lontini’s compensation may not be reallocated, and if Proposal 9(c) is not approved, Mr. Lontini will receive, for as long as he serves on the Compensation Committee, the same compensation as the external directors, being the annual and per-meeting compensation prescribed by the External Director Regulations and reimbursement of expenses.

 

Proposed Resolution

 

“RESOLVED, to approve the compensation of the non-employee directors of the Company, other than the external directors and any director who is a controlling shareholder of the Company, as described in the Proxy Statement, with the equity component subject to and conditional upon the approval of Proposal 5, provided that, for as long as such a director serves on the Compensation Committee, his or her compensation shall be identical to the compensation of the external directors and, if Proposal 9(c) is not approved, shall be the annual and per-meeting compensation prescribed by the External Director Regulations, together with reimbursement of expenses, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to it, including the Interval Approvals.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal, provided that either (i) the majority voted in favor includes at least a majority of the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in the approval of the proposal, excluding abstentions, or (ii) the total number of votes cast against the proposal by such shareholders does not exceed two percent (2%) of the total voting rights in the Company. The proposed compensation conforms to the terms of the Compensation Policy, but because the current Compensation Policy will cease to be in effect before the Meeting, the Company is submitting this proposal for approval by a Special Majority, whether or not Proposal 8 is approved. See “Controlling Shareholders and Personal Interests” in the Notice. By signing and returning the proxy card, or by voting online before or at the Meeting, you confirm that you are not a controlling shareholder and do not have a personal interest in the approval of this proposal, unless you have notified the Company otherwise as described in the Notice. Mr. McGee, as a controlling shareholder, Mr. Lontini, as the director whose compensation is being approved, and the estate of the late Scott Walters, of which Ms. George is the executor, will be excluded from the second count on this proposal. Abstentions and broker non-votes are not considered votes cast and will have no effect on the result.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” the Director Compensation Proposal.

 

43

 

 

Proposal 9(c): Compensation of the External Directors (Item 9(c) on the Proxy Card)

 

Background

 

Under the External Director Regulations, an external director is entitled to annual and per-meeting compensation within the amounts prescribed by those regulations for a company of the Company’s size, and to reimbursement of expenses. Under Regulation 5(f) of the Reliefs Regulations, because U.S. law imposes additional duties on the Company’s external directors as independent directors, the maximum amounts are increased to base amounts of NIS 133,770 per year and NIS 4,020 per meeting. These amounts are adjusted on February 1 of each year for changes in the Israeli consumer price index since October 2015. The current maximum amounts reflect the adjustment made on February 1, 2026, and the amounts will next be adjusted on February 1, 2027.

 

Basis for the proposed compensation. The external directors may be paid annual cash compensation up to the maximum permitted by law. The proposed annual cash compensation of US$40,000 is within that maximum. The proposed annual equity award is compensation in securities under Regulation 8B of the External Director Regulations. Regulation 8B permits a company to grant securities to an external director in addition to cash compensation, provided that the securities are granted under a compensation plan that also includes all of the other directors of the Company and additional office holders, and applies to the securities the rules for “relative compensation” in Regulation 8A. For this purpose, “other directors” do not include a controlling shareholder or a director who holds another position with the Company, so Mr. McGee and Mr. Fowler are not other directors. Under those rules: (i) the external directors’ compensation may not exceed the average compensation of the other directors, and the equity award to each external director is identical to the equity award to Mr. Lontini under Proposal 9(b); (ii) each external director receives the same compensation; (iii) at least two other directors must be serving when the compensation is determined, and at the time of the Interval Approvals and the vote at the second session, Mr. Lontini, Kai Sorensen, Ghaleb El Masri and Anurag Sharma will all be serving as other directors; and (iv) because the compensation exceeds 50% of the maximum amount, it requires shareholder approval by the Section 239(b) Special Majority. When the terms of Messrs. Sorensen, El Masri and Sharma end at the conclusion of the Meeting, only one other director will be serving. Regulation 8A provides that if that condition ceases to be met during an external director’s term because of a change in the composition of the board, and the compensation is a fixed amount, the company continues to pay the compensation it paid before the change. The Company intends to rely on that provision, as the equity award is a fixed annual grant date value. There can be no assurance that a court or regulatory authority would agree with that approach. The Board believes that compensation at the prescribed amounts does not allow the Company to attract and retain qualified independent directors in the North American market in which the Company operates and recruits its directors.

 

Proposed compensation. The Board has approved, for submission to shareholders, the following compensation for each external director, in lieu of the annual and per-meeting fees prescribed by the External Director Regulations:

 

Component

Proposed Compensation Policy cap
Annual cash compensation US$40,000, payable quarterly in arrears Section 7.1.1.1.1: Board fee US$30,000 (current policy) / US$40,000 (if Proposal 8 is approved), plus US$7,500 (Audit Committee) and US$5,000 (Compensation Committee): US$42,500 (current) / US$52,500 (proposed) for an external director serving on both committees
Annual equity award Grant date value of US$60,000 under the 2026 Equity Incentive Plan, granted on the date of each annual general meeting, vesting over three years in equal annual instalments, on the same terms as the awards to the other non-employee directors under Proposal 9(b); conditional on the approval of Proposal 5. Section 7.1.2: 400% of the annual fee (US$170,000 on US$42,500); Section 6.3.3 via 7.1.2: vesting over a period of at least three years
Per-meeting fees None Section 7.1.1.1.2: up to US$1,000 per meeting
Expenses Reimbursement of reasonable expenses Section 7.1.1.2
Indemnification, exculpation and insurance Indemnification and exculpation undertaking in the Appendix C form (Proposal 9(d)); D&O insurance on the same terms as other directors Sections 7.1.1.3 and 6.1.2(x) to (z)

 

44

 

 

The proposed compensation exceeds the amounts prescribed by the External Director Regulations. It does not exceed the amounts permitted for directors under the Compensation Policy: the cash compensation of US$40,000 is within the periodic fee cap for a director serving on the Audit Committee and the Compensation Committee under Section 7.1.1.1.1 of the Compensation Policy as currently in effect (US$42,500) and as proposed to be amended under Proposal 8 (US$52,500), and the equity award of US$60,000 is within the limit of 400% of annual fees under Section 7.1.2. The equity award will be made on terms (including vesting and exercise price, and with no vesting upon a change in control under the award agreement, subject to the 2026 Plan’s provisions for awards that are not assumed or substituted, described under “Proposal 5”) no more favorable than those of the equity awards to the Company’s other non-employee directors described under Proposal 9(b). The cash and equity amounts for the other non-employee directors under Proposal 9(b) are the same as those of the external directors; see Proposal 9(b).

 

Approval Requirements under Israeli Law

 

Under the External Director Regulations, the approval of external director compensation above the prescribed amounts requires the same Special Majority that applies to the election of an external director under Section 239(b) of the Companies Law. The second count is made among shareholders who are not controlling shareholders and who do not have a personal interest in the matter arising from a relationship with a controlling shareholder. Accordingly, Mr. McGee’s Ordinary Shares will be excluded from the second count on Item 9(c). There is no Board override. The Reconstituted Compensation Committee and the Board will approve the compensation as part of the Interval Approvals, after the external directors are elected at the first session, and shareholders will vote on Item 9(c) at the second session. Section 278 of the Companies Law provides that a director with a personal interest in a matter may participate in the discussion and vote at the audit committee or the board of directors if a majority of the members of that body have a personal interest in it. Section 278 does not refer to the compensation committee. Other Israeli companies have applied the same exception to the compensation committee, and the Reconstituted Compensation Committee, a majority of whose members (Ms. George and Mr. Kokiw) have a personal interest in this proposal, intends to do so. There can be no assurance that a court would accept that approach. Ms. George and Mr. Kokiw will not participate in the Board’s approval unless a majority of the directors of the Company has a personal interest in it. In any event, the compensation also requires the approval of the shareholders.

 

If Proposal 9(c) is not approved, or if Proposal 9(b) is not approved, each external director will be entitled to the annual and per-meeting compensation prescribed by the External Director Regulations and to reimbursement of expenses, and will not receive the equity award. Proposal 9(c) is conditional upon the approval of Proposal 9(b) because, under Regulation 8A of the External Director Regulations, the external directors’ compensation may not exceed the average compensation of the other directors. For the same reason, if Proposal 5 is not approved, the external directors will not receive the equity award under Proposal 9(c), because the other non-employee directors will not receive the equity award under Proposal 9(b). In that case, Mr. Lontini will receive the same compensation as the external directors for as long as he serves on the Compensation Committee, as described under Proposal 9(b).

 

Proposed Resolution

 

“RESOLVED, subject to and conditional upon the approval of Proposal 9(b), to approve, in accordance with Regulation 5(f) of the Companies Regulations (Reliefs for Companies with Securities Listed on an Exchange Outside of Israel), 5760-2000, and Regulations 8A and 8B of the Companies Regulations (Rules Regarding Compensation and Expenses of External Directors), 5760-2000, the compensation of the external directors of the Company, consisting of annual cash compensation of US$40,000 and an annual equity award with a grant date value of US$60,000, conditional upon the approval of Proposal 5, together with reimbursement of expenses, with the equity award identical to and on the same terms as the equity awards to the other directors of the Company, all as described in the Proxy Statement.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal, provided that either (i) the majority voted in favor includes at least a majority of the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in the approval of the proposal arising from a relationship with the controlling shareholder, excluding abstentions, or (ii) the total number of votes cast against the proposal by such shareholders does not exceed two percent (2%) of the total voting rights in the Company. See “Controlling Shareholders and Personal Interests” in the Notice. By signing and returning the proxy card, or by voting online before or at the Meeting, you confirm that you are not a controlling shareholder and do not have a personal interest in the approval of this proposal, unless you have notified the Company otherwise as described in the Notice.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” the External Director Compensation Proposal.

 

45

 

 

Proposal 9(d): Indemnification and Exculpation Undertakings for Directors (Item 9(d) on the Proxy Card)

 

Background

 

The Companies Law and our Articles of Association permit the Company, subject to the approvals required under the Companies Law, to exculpate its office holders in advance from liability for breach of the duty of care (other than in connection with a distribution), to undertake in advance to indemnify them for certain liabilities and expenses, and to insure them against certain liabilities. Articles 65 to 68 of our Articles of Association authorize the Company to do so to the fullest extent permitted by law. Indemnification and exculpation are components of the terms of office and engagement of office holders under the Compensation Policy (Sections 6.1.2(x) and 7.1.1.3).

 

The Board has approved, for submission to shareholders, the grant to each of the Company’s directors other than the Chief Executive Officer and any director who is a controlling shareholder of the Company, including the directors and external directors elected at the Meeting and any director appointed or elected in the future, of an indemnification and exculpation undertaking in the form attached as Appendix C (the “Indemnification Undertaking”). No Indemnification Undertaking to Mr. McGee, who is a controlling shareholder, is proposed at this Meeting. Mr. Fowler’s Indemnification Undertaking, in the same form, is included in Proposal 9(a). The Indemnification Undertaking is identical in form to the undertaking approved by the Compensation Committee and the Board for the Company’s executive officers who are not directors. The Indemnification Undertaking replaces the indemnification agreements previously granted by Check-Cap Ltd. to its directors, which capped Company-funded indemnification at US$5,000,000. Those agreements will continue to apply to acts performed during the prior service of a director under them, including the indemnification of Mr. Kokiw and Mr. Lontini in connection with the derivative proceeding described under “Proposal 3A.”

 

Summary of the Indemnification Undertaking

 

Under the Indemnification Undertaking, the Company undertakes to indemnify each director, to the fullest extent permitted by the Companies Law, for (i) monetary liability imposed in favor of a third party by judgment, settlement or arbitral award; (ii) reasonable litigation expenses, including legal fees, incurred in proceedings brought by or on behalf of the Company or a third party, or in criminal proceedings in which the director is acquitted or that do not require proof of criminal intent; (iii) reasonable litigation expenses incurred in connection with investigations or proceedings by an authority that conclude without an indictment or monetary liability in lieu of criminal proceedings; and (iv) payments to injured parties and expenses in connection with administrative enforcement proceedings under the Israeli Securities Law, in each case in respect of acts performed in the director’s capacity as an office holder of the Company or its subsidiaries.

 

Foreseeable events and limit. The indemnification under clause (i) is limited to events that the Board has determined are foreseeable in light of the Company’s actual activities, as listed in the Schedule to the Indemnification Undertaking, and to an aggregate amount, for all persons indemnified by the Company for such liabilities, equal to the greater of US$25,000,000 and 25% of the Company’s consolidated shareholders’ equity according to its most recent consolidated financial statements available before the date of payment (the “Limit”). The Schedule lists 30 categories of events, including events relating to the Company’s artificial intelligence and robotics products, the operation of autonomous machines near persons, batteries, equipment authorization, customs and tariffs, privacy and biometric data, registration statements, restatements, Nasdaq listing matters, the Business Combination, regulatory investigations and any redomestication of the Company. The Board has determined, under Section 260(b) of the Companies Law, that the events listed in the Schedule are foreseeable in light of the Company’s actual activities and that the Limit is reasonable in the circumstances, having regard to the nature and scale of the Company’s activities, the risks to which office holders are exposed and the limits of the Company’s D&O insurance. The Reconstituted Compensation Committee and the Board will record those determinations, with respect to the Limit and the Schedule in the form attached as Appendix C, as part of the Interval Approvals. The Limit is in addition to, and is not reduced by, amounts paid under the Company’s D&O insurance or by a subsidiary under its own indemnity. The Limit does not apply to the expense categories in clauses (ii) to (iv), to expenses in connection with informal inquiries, subpoenas and internal investigations, to the advancement of expenses or to the insurance covenant. If claims exceed the Limit, the remaining Limit is allocated among the indemnified persons pro rata. The Company will notify the director of any payment or commitment that reduces the Limit and, if the remaining Limit is insufficient, will propose to its authorized organs an increase of the Limit or retroactive indemnification, as the Companies Law permits.

 

Advancement. The Company will advance litigation expenses as they are incurred, within 20 days after a substantiated request, and at the director’s election will pay counsel directly, against the director’s undertaking to repay amounts to which he or she is ultimately found not entitled.

 

Entitlement. A director who submits a substantiated request is presumed to be entitled to indemnification or an advance; only a court or independent counsel may determine otherwise, and if no determination is made within 60 days the entitlement is deemed established, in each case subject to the exclusions and the Limit.

 

Insurance covenant. The Company undertakes to maintain D&O insurance covering the director, on terms no less favorable than those applying to any other office holder, during his or her service and for 6 years thereafter, including run-off cover on a change of control and Side A difference-in-conditions cover with a prior-acts retroactive date no later than September 9, 2025, to provide a copy of the policy on request and to give not less than 30 days’ prior notice of cancellation, non-renewal or material reduction of cover and prompt notice of any exhaustion or material erosion of limits. Indemnification under the Indemnification Undertaking is in addition to insurance, and the Company will not require the director to claim under or exhaust any insurance policy before the Company performs.

 

Group co-ordination. Where a director or officer is also party to an indemnification agreement with MBody AI Corp. or MBody AI Canada Corp., the indemnity of the company in whose service the relevant act occurred is primary. The director or officer may claim under any of them first and is not required to exhaust another indemnity or insurance before the Company performs. The director or officer may not recover more than once for the same liability.

 

Exculpation and exclusions. The Indemnification Undertaking also exculpates each director in advance from liability to the Company for damages caused by a breach of the duty of care, to the extent permitted by the Companies Law, other than in connection with a distribution. It does not apply to a breach of the duty of loyalty (other than a good-faith breach with reasonable grounds to believe the act would not harm the Company), an intentional or reckless breach of the duty of care, an act intended to derive an unlawful personal benefit, or a fine or penalty imposed on the director.

 

46

 

 

The Company also maintains directors’ and officers’ liability insurance covering its directors and officers, with an aggregate limit of US$22,500,000, which was approved by the Current Compensation Committee and the Board and, as described under “The Board of Directors and Corporate Governance - Committees of the Board,” will be ratified by the Reconstituted Compensation Committee following the election of the external directors.

 

Proposed Resolution

 

“RESOLVED, to approve the grant of indemnification and exculpation undertakings to the directors of the Company, in the form attached as Appendix C to the Proxy Statement, to each director of the Company serving from time to time, including each director and external director elected at the Meeting, other than the Chief Executive Officer, whose undertaking is approved under Proposal 9(a), and any director who is a controlling shareholder of the Company, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to them, including the Interval Approvals.”

 

Vote Required

 

The affirmative vote of the holders of a majority of the Ordinary Shares represented at the Meeting, in person or by proxy, and entitled to vote and voting on the matter, is required to approve this proposal, provided that either (i) the majority voted in favor includes at least a majority of the votes cast by shareholders who are not controlling shareholders and who do not have a personal interest in the approval of the proposal, excluding abstentions, or (ii) the total number of votes cast against the proposal by such shareholders does not exceed two percent (2%) of the total voting rights in the Company. The Indemnification Undertaking conforms to the terms of the Compensation Policy and is in the same form for all directors, but because the current Compensation Policy will cease to be in effect before the Meeting, the Company is submitting this proposal for approval by a Special Majority, whether or not Proposal 8 is approved. See “Controlling Shareholders and Personal Interests” in the Notice. By signing and returning the proxy card, or by voting online before or at the Meeting, you confirm that you are not a controlling shareholder and do not have a personal interest in the approval of this proposal, unless you have notified the Company otherwise as described in the Notice. Mr. McGee, as a controlling shareholder, and Mr. Lontini, Ms. George (including the Ordinary Shares held by the estate of the late Scott Walters, of which she is the executor and beneficiary) and Mr. Kokiw, as the directors who are to receive the Indemnification Undertaking, will be excluded from the second count on this proposal. Abstentions and broker non-votes are not considered votes cast and will have no effect on the result.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” the Indemnification Proposal.

 

47

 

 

REVIEW AND DISCUSSION OF FINANCIAL STATEMENTS

 

In accordance with Section 60(b) of the Companies Law, the Board is presenting to shareholders, for review and discussion at the Meeting, the Company’s audited consolidated financial statements and the report of the Board for the year ended December 31, 2025. This item does not involve a shareholder vote.

 

The Company’s audited consolidated financial statements for the year ended December 31, 2025, which form part of the Company’s Annual Report on Form 20-F for that year filed with the SEC on April 27, 2026 under the Company’s former name, Check-Cap Ltd. (the 2025 Annual Report), are available on the SEC’s website at www.sec.gov and on the Company’s website at ir.mbody.ai. Shareholders may receive a hard copy of the Form 20-F containing the audited financial statements free of charge upon request. Neither the audited financial statements nor the Form 20-F forms part of the proxy solicitation material.

 

SHAREHOLDER PROPOSALS

 

Any shareholder who intends to present a proposal at the Meeting must satisfy the requirements of the Companies Law and the regulations thereunder. Under Section 66(b) of the Companies Law, as modified by the Reliefs Regulations, only shareholders who severally or jointly hold at least one percent (1%) of the outstanding voting rights (or, for a proposal to nominate or remove a director, at least five percent (5%)) are entitled to request that the Board include a proposal on the agenda of a general meeting, provided that the proposal is appropriate for consideration by shareholders at such meeting, by submitting the proposal within seven days of publication of the Company’s notice of the meeting. Accordingly, a qualifying shareholder may request to include a proposal on the agenda of the Meeting by submitting the proposal in writing to the Company at 7111 Syntex Drive, 3rd Floor, Mississauga, Ontario, Canada, Attention: Chief Financial Officer, or by email at ir@mbody.ai, so that it is received no later than November 24, 2026, together with the documentation and information required under Israeli law. If the Board determines that a shareholder proposal is duly and timely received and is appropriate under applicable Israeli law for inclusion on the agenda, the Company will publish a revised agenda for the Meeting no later than December 1, 2026 by furnishing a Report on Form 6-K to the SEC and, if required, will adjust the date of the Meeting to provide the notice period required under the Companies Law.

 

WHERE YOU CAN FIND ADDITIONAL INFORMATION

 

The Company is subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers and fulfils these requirements by filing or furnishing reports with the SEC. The Company’s SEC filings are available to the public on the SEC’s website at www.sec.gov and on the Company’s website at ir.mbody.ai. Information on the Company’s website is not incorporated by reference into this Proxy Statement.

 

As a foreign private issuer, the Company is exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements. The circulation of this Proxy Statement should not be taken as an admission that the Company is subject to those proxy rules.

 

YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN THIS PROXY STATEMENT. WE HAVE NOT AUTHORIZED ANYONE TO GIVE ANY INFORMATION DIFFERENT FROM THE INFORMATION CONTAINED IN THIS PROXY STATEMENT. THIS PROXY STATEMENT IS DATED NOVEMBER 17, 2026. YOU SHOULD NOT ASSUME THAT THE INFORMATION CONTAINED IN THIS PROXY STATEMENT IS ACCURATE AS OF ANY LATER DATE, AND THE FURNISHING OF THIS PROXY STATEMENT TO SHAREHOLDERS SHALL NOT CREATE ANY IMPLICATION TO THE CONTRARY.

 

OTHER MATTERS

 

Management knows of no other business to be transacted at the Meeting. If any other matters are properly presented to the Meeting, the persons named in the enclosed form of proxy will vote upon such matters in accordance with their best judgment, to the extent permitted by applicable law.

 

By Order of the Board of Directors,

 

Regan McGee

 

Chairman of the Board of Directors

 

November 17, 2026

 

48

 

 

APPENDICES AND SCHEDULES

 

Appendix

Contents
Appendix A

Amended and Restated Compensation Policy for Executive Officers and Directors [Proposal 8]

Appendix B MBody AI Ltd. 2026 Equity Incentive Plan, with Israeli, United States and Canadian appendices [Proposal 5]
Appendix C Form of Indemnification and Exculpation Undertaking, with Schedule of foreseeable events [Proposals 9(a) and 9(d)]
Appendix D

Amendments to the Articles of Association (Schedule of Amendments): Part A (regularization; and the change of name if the Board exercises the authority under Proposal 7) [Proposal 7]; Part B (no par value) [Proposal 1]; Part C (authorized share capital) [Proposal 2]; Part D (new Article 42A) [Proposal 6]; Part E (effectiveness and filing)

 

49

 

 

Appendix A: Amended and Restated Compensation Policy (Proposal 8)

 

MBODY AI LTD.

 

COMPENSATION POLICY FOR EXECUTIVE OFFICERS AND DIRECTORS

 

1. PURPOSE

 

This Compensation Policy (the “Policy”) constitutes the Compensation Policy (as such term is defined in the Companies Law) of MBody AI Ltd. (formerly Check-Cap Ltd.) (the “Company”) with respect to the determination of Terms of Office and Engagement of Office Holders (as such term is defined in the Companies Law), if and to the extent such determination is required by the Companies Law be made pursuant to the Compensation Policy.

 

2. DEFINITIONS; CONSTRUCTION

 

2.1. “Affiliate” of any Person, shall mean any other Person that, directly or indirectly through one or more intermediaries, is controlled by such Person, and the term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.

 

2.2. “Applicable Law” shall mean any applicable law, rule, regulation, statute, extension order, judgment, order or decree of any federal, state or local governmental, regulatory or adjudicative authority or agency, of any jurisdiction, and the rules and regulations of any stock exchange or trading or quotation system on which the securities of the Company are then traded, listed or quoted.

 

2.3. “Board” means the Board of Directors of the Company.

 

2.4. “CEO” means the Chief Executive Officer of the Company.

 

2.5. “Committee” means the Compensation Committee of the Board, within the meaning of the Companies Law.

 

2.6. “Companies Law” means the Israeli Companies Law, 5759-1999 together with the regulations promulgated thereunder, all as amended from time to time.

 

2.7. “Director” means any member of the Board of Directors of the Company.

 

2.8. “Executive” means any Office Holder who does not serve solely as a director.

 

2.9. “External Director” means as set forth in the Companies Law.

 

2.10. “Office Holders” means as set forth in the Companies Law, regardless of whether such Office Holder is employed by the Company or an Affiliate thereof.

 

2.11. “Person” means (whether or not a capitalized term) any individual, corporation, partnership, limited liability company, firm, joint venture, association, joint-stock company, trust, estate, unincorporated organization or other entity.

 

2.12. “Terms of Office and Engagement” means as defined in the Companies Law.

 

A-1

 

 

2.13. Terms not otherwise defined herein shall have the meaning ascribed to them in the Companies Law, unless the context dictates otherwise. To the extent any provision herein conflicts with the conditions of any Applicable Law, the provisions of the Applicable Law shall prevail over this Policy and the Board is empowered hereunder to interpret and enforce such prevailing provisions. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”. References to any law or regulation, rule or ordinance, including any section or other part thereof, shall refer to that as amended from time to time and shall include any successor law. The use of captions and titles in this Policy is for the convenience of reference only and shall not affect the meaning of any provision of this Plan.

 

2.14. Nothing in this Policy shall confer upon any person, including, any Office Holder, any rights, entitlements, benefits or remedies whatsoever, including any right or entitlement to any compensation, remuneration or benefits of any kind or nature or to interfere with or limit in any way the right and authority of the Company or any its Affiliates to determine any compensation, remuneration or benefits or to terminate the service or employment of any Office Holder. The Terms of Office and Engagement of an Office Holder shall only be as set in an agreement between such Office Holder and the Company or its Affiliates or in a written undertaking of the Company or its Affiliates or in a resolution of the relevant organ of the Company or such Affiliate setting forth the Terms of Office and Engagement and their applicability to the relevant Office Holder, and, in each case, as prescribed by Applicable Law. No representation or warranty is made by the Company in adopting this Policy, and no custom or practice shall be inferred from this Policy or the implementation thereof, which is specific and applied on a case-by-case basis.

 

2.15. To the extent that an Office Holder’s engagement or service is effected pursuant to an agreement between the Company or any Affiliate thereof, on the one hand, and an Affiliate of the Office Holder, on the other hand, then this Policy shall apply, mutatis mutandis, to the same extent as if the service or engagement would have been made pursuant to an agreement with the Office Holder personally. To the extent that an Office Holder’s engagement or service (including, a Director in his capacity as such or in other capacities) is not through employment relations with the Company or any Affiliate thereof then this Policy shall apply, mutatis mutandis. Where an Office Holder is employed or engaged by an Affiliate, the Company may guarantee the obligations of that Affiliate under the Terms of Office and Engagement approved in accordance with this Policy, limited to the monetary obligations expressly set out in those Terms of Office and Engagement and within the limits of this Policy; such a guarantee forms part of the Terms of Office and Engagement of the Office Holder, is approved together with them in accordance with the Companies Law, and is not counted as an additional component for the purposes of the caps and ratios in Sections 6 and 7.

 

2.16. This Policy shall not apply, and shall have no effect with respect to or derogate from, any Terms of Office and Engagement of any Office Holder which are in effect prior to the date of adoption of this Policy.

 

2.17. To the extent that after the date on which this Policy is approved in accordance with the Companies Law relief is granted as to the mandatory or minimum requirements prescribed by Applicable Law to be included in a Compensation Policy as of the date hereof, or any limitation contained in this Policy is more stringent than that required by Applicable Law, than such relief or less stringent limitation shall be deemed incorporated by reference into this Policy notwithstanding anything else to the contrary, unless otherwise determined by the Board.

 

A-2

 

 

3. ADMINISTRATION

 

3.1. To the extent permitted under the Companies Law, this Policy shall be administered by the Board, unless and to the extent an action necessary for the administration of this Policy is required under the Companies Law to be taken by the Committee (and in any such event, all references herein to the Board shall be construed as references to the Committee).

 

3.2. Subject to the terms and conditions of this Policy and any mandatory provisions of Applicable Law, and in addition to the Board’s powers provided elsewhere in this Policy and by the Companies Law, the Board shall have full authority in its discretion, from time to time and at any time, to determine any of the following:

 

(a) to interpret the Policy;

 

(b) prescribe, amend and rescind rules and regulations relating to and for carrying out the Policy, as it may deem appropriate; and

 

(c) any other matter which is necessary or desirable for, or incidental to, the administration of the Policy and any determination made pursuant thereto.

 

4. GENERAL CONSIDERATIONS

 

4.1. This Policy is made, and the Terms of Office and Engagement determined pursuant hereto shall be determined, on the basis of various considerations, including those listed below.

 

4.1.1. The Compensation Policy was designed, among other things, to ensure the Company’s ability to recruit and retain the highly talented management personnel that have appropriate qualifications is one of the key elements to the Company. The Company believes that in order to attract and retain competent and skilled Office Holders that would support the efforts to create shareholder value, the levels of Terms of Office and Engagement should generally be within a range of between average and above average levels in comparable companies. In certain circumstances, in order to attract unique talents that are considered by the Company as such, the Terms of Office and Engagement may exceed the above levels.

 

4.1.2. Promoting the Company’s objectives, its business plan and its long-term strategy. The Company believes that attracting and retaining Office Holders that have appropriate qualifications is one of the key elements to the Company’s success. In order to attract and retain Office Holders that possess skills, experience, professional capabilities and motivation that would support the Company’s efforts to increase shareholder value, the Terms of Office and Engagement under which such Office Holders are retained should be competitive, should reflect the anticipated contribution of such Office Holders to the Company and its business, should reflect the scope of authority and responsibilities of the Office Holder and should create adequate incentives for such Office Holders to dedicate their full attention, skills and efforts to the success and growth of the Company.

 

4.1.3. Creating appropriate incentives to the Company’s Office Holders, considering, among other factors, the Company’s risk management policy. In this respect, the Company will strive to create balanced compensation arrangements under which an Office Holder will be motivated to contribute to the achievement of corporate targets by creating a link between performance and compensation. On the other hand, attention will be given to the need to allocate an appropriate portion to compensation that is not based on performance with a view to maintaining caution as to the tolerance of risk management. In addition, the Company believes that the Terms of Office and Engagement should reflect a balance between short-term and long-term achievements, between personal performance of an Office Holder and performance of the Company or specific divisions or regions of the Company, between past performance and future performance and taking into account various other considerations that are appropriate in each individual case. Moreover, the Company believes that the Terms of Office and Engagement of each Office Holder are both a reflection of the Company’s general policies and the individual circumstances relating to the retention of such Office Holder, and therefore, there may be variations between the Terms of Office and Engagement of different Office Holders.

 

A-3

 

 

4.1.4. The size of the Company and the nature of its operations. The Company, through its subsidiaries, deploys, operates and manages fleets of autonomous cleaning robots for commercial customers in the hospitality, gaming and other sectors under long-term service agreements, supported by its proprietary MBody AI Orchestrator software platform, with operations principally in the United States and Canada. In addition, the Company operates in an environment and markets that are dynamic and are continuously in flux offering multiple and different challenges. Accordingly, in connection with the determination of the Terms of Office and Engagement of each Office Holder, appropriate attention should be given to the particular circumstances and challenges of such Office Holder.

 

4.1.5. The Terms of Office and Engagement of an Office Holder should generally be determined after consideration is given to the terms offered to comparable Office Holders in comparable companies, to the extent such information is readily available, with a view to the Company’s ability to offer competitive terms and retain competent and capable Office Holders.

 

4.2. The Terms of Office and Engagement of an Office Holder may include a combination of various components, such as: salary and auxiliary payments and benefits, bonuses, equity or equity-linked awards, expense reimbursement, insurance, exculpation and indemnification, and compensation and benefits mandated by Applicable Law. In each instance, the appropriate components should be considered, and not necessarily all of the above mentioned components need be included.

 

5. SPECIFIC CONSIDERATIONS IN THE DETERMINATION OF TERMS OF OFFICE AND ENGAGEMENT

 

With a view to achieving the general purpose and intent of the considerations as set forth in Section 4, the Terms of Office and Engagement of an Office Holder shall be predominantly based on the following considerations:

 

5.1. The education, qualification, skills, expertise, professional experience, accomplishments, references, reputation and achievements of the Office Holder;

 

5.2. If applicable, the experience, references, reviews, achievements and sustained performance of the Office Holder overtime with the Company and its Affiliates;

 

5.3. The seniority, tenure and duration of employment with or service to the Company or its Affiliates;

 

5.4. The job function, organizational level, position and areas of and scope of responsibility and authority of the Office Holder;

 

5.5. The obligations, responsibilities, roles and objectives imposed on such Office Holder under Applicable Law;

 

5.6. The need to retain Office Holders who have relevant skills, know-how or unique expertise;

 

5.7. Prior Terms of Office and Engagement with the Company and its Affiliates or previous employers;

 

5.8. The then current and prospective condition of the Company’s business, affairs, budget, operations, activities, liabilities, financial results, plans and strategy;

 

5.9. Geographical location and region of activity, and the then common employment or compensation practices in the industry and/or the relevant geographical location, region of activity or jurisdiction;

 

A-4

 

 

5.10. The terms of compensation of other groups of employees of the Company and its Affiliates that are determined to be relevant;

 

5.11. The employment or compensation practices of comparable companies. The extent to which reference to comparable companies shall be required, as well as the parameters for determination of the identity of the companies which are comparable, shall be examined in each instance. Such parameters may include: the field of operation or industry, public or privately held companies, size, local or global operations, business condition, numbers of years of operations and jurisdiction of incorporation or of the executive headquarters;

 

5.12. Intra-organizational implications, including impact on other relevant employees of the Company and its Affiliates;

 

5.13. The ratio between the cost of the Terms of Office and Engagement of the Office Holder and the total cost of salary (as such term is defined in the Companies Law) of other employees of the Company, and specifically the average and median total cost of salary (as such term is defined in the Companies Law) of other employees of the Company (including, for purposes of this section, those engaged through manpower companies), and the effect of such differences on the employment environment in the Company;

 

5.14. If the Terms of Office and Engagement include variable components, inclusion of provisions reducing variable components, and setting a limit on the exercise value of an equity variable component, all at the Board’s discretion;

 

5.15. If the Terms of Office and Engagement include termination benefits, the period of employment or service of the Office Holder, the Office Holder’s Terms of Office and Engagement during such period, the performance of the Company (or the applicable Affiliate or division) during such period, the Office Holder’s contribution towards the Company’s achievement of its goals and maximizing its profits, and the circumstances of termination;

 

5.16. If the Terms of Office and Engagement include equity or equity-linked components, the value thereof and the anticipated incentive associated with such components;

 

5.17. Any requirements prescribed by the Companies Law, U.S. and Canadian securities laws and Nasdaq rules, and any other Applicable Law, from time to time;

 

5.18. General goals and objectives of the Company (or if applicable, the relevant Affiliate or division) and incentivizing the Office Holder to reach and achieve these goals;

 

5.19. The specific goals or targets defined for the Executive or for which such Executive is recruited or retained and incentivizing the Office Holder to reach and achieve these goals; and

 

5.20. Such other considerations as are deemed relevant or applicable in the circumstances.

 

The relevancy and applicability of the foregoing considerations shall be weighed in each particular instance, taking into account that the Company may, in the future, operate in various jurisdictions, each of which may differ significantly in the norms of its employment practices.

 

The determination shall be made on the basis of all or part of the foregoing considerations and the weight of any particular consideration shall be as determined in the particular instance and based on the specific circumstances.

 

The Company may, but shall not be required to, obtain advice from advisors and professionals for the purpose of assessing and determining the above considerations as the Company deems necessary, including, for the purpose of gathering relevant data, market research, labor practices and economic/cost analysis.

 

A-5

 

 

6. COMPONENTS OF TERMS OF OFFICE AND ENGAGEMENT OF AN EXECUTIVE

 

The Terms of Office and Engagement of an Executive may include a combination of all or any part of the following components. In each instance, consideration shall be given as to which components are appropriate and their respective weight. Any deviation of up to 10% of the applicable ratio or cap amount set forth in this Policy shall not be deemed as a deviation from this Policy.

 

6.1. Fixed Compensation

 

6.1.1. Base Salary

 

6.1.1.1. The base salary of an Executive shall be determined during the course of negotiations for his employment in the Company, conducted by the person who will directly supervise him (for the CEO, the Chairman of the Board, and for the other Executives, the CEO). The base salary will be determined personally for each Executive and shall express the skills of the candidate (including, among other things, his education, expertise, professional experience), his achievements, suitability with the intended position job requirements and the conditions in the relevant market for similar positions in similar companies, on the recruitment date. The annual gross base salary (i.e., excluding any benefits and entitlements) of an Executive shall not exceed US$500,000. The Executives’ salary may be linked to any relevant index.

 

6.1.1.2. In order to retain Executives, the Executives’ base salary shall be reviewed annually, taking into consideration the challenges of the given year and the following year, the complexity of the Executives’ roles, their scope and importance to the Company’s performance, all based upon the general considerations specified above.

 

6.1.2. Additional Benefits and Terms:

 

The Terms of Office and Engagement of an Executive may include the following additional benefits and terms:

 

(a) Pension

 

(b) Further education fund

 

(c) Severance pay

 

(d) Managers insurance

 

(e) Medical insurance (including vision and dental) and life insurance, including with respect to immediate family members

 

(f) 401(k), registered retirement savings plan (RRSP) or similar retirement plan, including employer matching contributions

 

(g) Disability insurance

 

(h) Periodic medical examination

 

(i) Leased car or company car (as well as bearing the cost of related expenses or reimbursement thereof), or the value of the use thereof, or transportation allowance

 

(j) Telecommunication and electronic devices and communication expenses, including (without limitation) cellular telephone and other devices, personal computer/laptop, Internet, or the value of the use thereof

 

(k) Paid vacation and the number of vacation days that may be accrued, including, if applicable, the redemption thereof

 

A-6

 

 

(l) Sick days

 

(m) Holiday and special occasion gifts

 

(n) Recuperation pay

 

(o) Expense reimbursement (including domestic and international travel expenses and per diem payments)

 

(p) Payments or participation in relocation and related costs and expenses

 

(q) Clothing allowance

 

(r) Loans or advances (subject to Applicable Law)

 

(s) Professional or academic courses or studies

 

(t) Newspaper or online subscriptions

 

(u) Professional literature

 

(v) Professional membership dues or subscription fees

 

(w) Professional advice or analysis (such as pension, insurance and tax)

 

(w1) Payment or advancement of reasonable legal fees and expenses incurred by the Executive in connection with any claim, dispute, investigation or proceeding arising from or relating to the Executive’s employment or service with the Company or its Affiliates, in an amount not exceeding US$100,000 per Executive per calendar year (inclusive of any gross-up), provided that (i) each matter is approved in advance by the Committee, which shall confirm that the matter is not a claim brought by the Executive against the Company or any Affiliate and does not conflict with the interests of the Company; (ii) to the extent any such payment or advancement constitutes indemnification of the Executive by the Company, it shall be made only in accordance with, and subject to the limitations of, Sections 258 to 264 of the Companies Law and the Company’s Articles of Association, and the Executive shall repay any amount advanced to the extent required by Applicable Law; and (iii) no amount shall be paid under this paragraph to the extent the same expenses are paid under any indemnification undertaking or D&O Insurance

 

(x) Exculpation and indemnification

 

(y) General directors’ and officers’ liability insurance (“D&O Insurance”) covering persons serving at present or in the future, from time to time, as directors and officers of the Company and its subsidiaries (including those who also serve as officers, directors or employees of a controlling shareholder), including extensions, renewals or replacement thereof.

 

Subject to Applicable Law, the acquisition, extension, renewal or replacement of D&O Insurance may be approved solely by the Committee provided that (i) the maximum aggregate limit of liability pursuant to the D&O Insurance (including Side “A” coverage) shall be not more than US$50 million for each D&O Insurance period; and (ii) the Committee shall have determined that the D&O Insurance is on market terms and shall not have a material impact on the Company’s profitability, assets or liabilities.

 

(z) D&O Insurance with respect to specific events, such as public offerings (including by the extension of an existing D&O Insurance policy), or with respect to periods to time following which the then existing insurance coverage ceases to apply, such as “run-off” coverage in connection with a change in control. Subject to Applicable Law, the acquisition of such D&O Insurance may be approved solely by the Committee provided that the conditions set forth in paragraph (y) above have been met.

 

A-7

 

 

(aa) Non-solicitation and/or non-compete undertakings for a period of time after termination, and payment in consideration for such undertaking not exceeding the total amount of compensation (including benefits) that would have been payable to the Executive had he or she continued to be employed during the non-solicitation or non-compete period

 

(bb) Other benefits generally provided to Company employees (or any applicable Affiliate or division)

 

(cc) Other benefits or entitlements mandated by Applicable Law

 

(dd) Other benefits and entitlements that are part of compensation practices in the industry, relevant geographical location, region of activity or jurisdiction

 

Any of the above benefits may include gross up of taxes and mandatory payments required to be made by Applicable Law.

 

6.1.3. Termination Conditions

 

6.1.3.1. Advance Notice. Advance notice of termination, not exceeding the higher of the period required by Applicable Law or three (3) months.

 

6.1.3.2. Termination and Severance Payments

 

The Terms of Office and Engagement of an Executive may include the following termination payment (in addition to any mandatory severance payments under Applicable Law) in an amount that shall not exceed:

 

●For an Executive: up to twelve (12) monthly (gross) base salaries, together with (i) a pro-rated annual bonus for the year of termination based on actual performance, (ii) continuation of the benefits under Section 6.1.2 for up to twelve (12) months, and (iii) continued vesting of equity awards for up to twelve (12) months following the termination date in accordance with Section 6.3.7. The same limits apply to payments on termination by reason of disability, less any disability insurance benefits payable in respect of the same period.

 

When determining termination and severance payments, the Compensation Committee and Board shall take into consideration the Office Holder’s term of employment, the Office Holder’s compensation during employment with the Company, the Company’s performance during such period, the contribution of the Office Holder to achieving the Company’s goals and the circumstances of termination.

 

6.1.3.3. Mandatory Employment Law Entitlements. To the extent an Executive is employed or engaged in a jurisdiction where mandatory provisions of Applicable Law, including mandatory statutory entitlements or common-law principles applicable to the termination of employment, entitle the Executive to notice periods, pay in lieu of notice, severance or other termination entitlements that exceed the caps set forth in this Section 6.1.3, the Company may satisfy such legally mandated entitlements, and such payments shall not be deemed a deviation from this Policy.

 

6.1.4. Change-of-Control. The Terms of Office and Engagement of an Executive may include a one-time payment of up to 100% of the Executive’s annual cash compensation (i.e., annual (gross) base salary and target annual bonus) in connection with a Transaction, as defined in the Equity Plan (as such term is defined below), subject to such other terms and conditions as the Committee and Board may determine. Such payment may be made in lieu of the termination payment under Section 6.1.3.2, in which case the continuation of benefits and vesting permitted by that Section may continue to apply.

 

A-8

 

 

6.2. Variable Compensation

 

6.2.1. The Company believes that the Terms of Office and Engagement should reflect a balance between short- term and long-term achievements, between personal performance of an Office Holder and performance of the Company or specific divisions or regions of the Company, between past performance and future performance and taking into account various other considerations that are appropriate in each individual case. Therefore, the Company believes that annual variable compensation (including, without limitation, plan-based annual bonuses and the value of equity, as set forth in Sections 6.2.4.1(e) and 6.3 hereof, special bonuses and sign-on bonus) may constitute up to 90% of the overall (combined fixed and variable) annual compensation of an Executive.

 

6.2.2. Variable compensation (cash and equity-based) may be subject to measurable and/or non-measurable criteria, provided that, subject to Section 6.2.1, (i) with respect to the CEO and any other Office Holder who is not subordinate to the CEO, only a non-material portion of the aggregate variable compensation may be based on non-measurable criteria (unless the aggregate variable compensation does not exceed three monthly salaries per year, in which case all of the variable compensation may be based on non-measurable criteria), while taking into account the contribution to the Company of such Office Holder; and (ii) with respect to any Office Holder who is subordinate to the CEO, up to 100% of the annual variable compensation awarded to such Office Holder may be based on non-measurable criteria, without limitation.

 

6.2.3. Subject to Applicable Law, the following shall be authorized to determine the measurable criteria in the case of variable compensation (cash and equity-based) that is based on measurable criteria and to determine and approve if and to what extent the measurable criteria have been achieved, provided that the criteria is consistent with this Policy:

 

Office Holder   Authorized Body
Office Holder other than the CEO and Director   CEO
CEO   Committee and Board
Director   Shareholders

 

Notwithstanding the foregoing, with respect to a Director, the Committee and Board may determine the measurable criteria provided that one of the following conditions apply:

 

(1) All of the following conditions apply: (i) the determination must be consistent with this Policy; (ii) the award must be based only on measurable criteria; (iii) the potential award is up to three monthly salaries; and (iv) the measurable criteria are approved in advance by the Committee and Board.

 

(2) All of the following conditions apply: (i) the determination must be consistent with this Policy; (ii) the Office Holder is serving in an operational position in addition to serving as a Director; and (iii) at the time of the approval, no Directors who are receiving from the Company criteria-based compensation (in their capacity as a Director or other Office Holder) shall participate in the approvals.

 

6.2.4. Bonuses. Bonuses may include plan-based annual bonuses and other bonuses:

 

6.2.4.1. Annual Bonus

 

(a) With respect to each year, an Executive Management Bonus Plan (the “Bonus Plan”) may be prepared for each Executive, containing any or all of the criteria described in clause (b) below, subject to Sections 6.2.1 and 6.2.2. The Bonus Plan may, but shall not be required to, be set out in individual agreements with the applicable Executives. To the extent applicable, the Bonus Plan may be revisited during the annual period, including in order to account for significant changes in the Company’s business or operations or material changes in the market(s) in which the Company operates during such year.

 

A-9

 

 

(b) The criteria for the Bonus Plan will be categorized in three types, as follows:

 

●Company Performance Criteria: Overall Company performance criteria (may be determined on a Company-wide or divisional basis), which are based on the following actual financial (whether GAAP or non-GAAP) and operational results, with the following weights assigned to such measures:

 

(i) Financial and operational measures, which may include: revenues, annual recurring revenue, gross margin, operating profit, EBITDA or adjusted EBITDA, cash flow and cash balance; the number of robots deployed, contracted or under management; customer acquisition, retention and expansion; fleet utilization, uptime and service-level performance; safety and quality objectives; meeting the Company’s budget; success in raising capital and completing strategic transactions; product and technology milestones, including the development of the Company’s software platform; execution of projects; and compliance with corporate governance, legal and regulatory goals. Each such criterion may constitute up to 50% of the total Company performance criteria and the total individual performance criteria, as applicable.

 

●Individual Performance Criteria: Quantitative individual performance criteria, which are based on the achievement of specific pre-defined goals determined for each individual Executive, in accordance with his or her position. The individual performance criteria and weights of such criteria shall be in accordance with clause (i) above.

 

●Managerial Appraisal: Qualitative individual performance criteria, which may be based on specific pre- defined competencies and behaviors for each individual Executive. The evaluation of the performance of the CEO shall be performed by the Board and the evaluation of the performance of other Executives shall be performed by the CEO, considering the contribution of the Executive to the Company and its Affiliates and other considerations such as (without limitation) the need to retain an Executive with skills, know-how or unique expertise; the responsibilities imposed on an Executive; changes that occurred in the responsibilities imposed on an Executive during the year; performance satisfaction, including assessing the degree of involvement of an Executive and devotion of efforts in the performance of the Executive’s duties; assessment of an Executive’s ability to work in coordination and cooperation with other employees; and Executive’s contribution to an appropriate control environment and ethical environment.

 

The following will be considered when determining the allocation of the above criteria, which may differ from one Executive to another: (i) emphasizing the high level of accountability to overall Company performance and financial results expected of each Executive; (ii) creating a personal link between each Executive’s compensation and the achievement of the corporate goals; and (iii) driving individuals to a high-performance culture.

 

(c) The criteria and the method of measuring the criteria underlying the bonuses may differ from period to period and from one Executive to another.

 

(d) The Bonus Plan may, but shall not be required to, include a minimum percentage of achievement of the performance criteria(s) for a given year that shall be required in order to pay any annual cash bonus to any Executive under the Bonus Plan for such calendar year, less than which threshold(s) will prevent any Executive from qualifying for an annual cash bonus in such calendar year. In such event, once the minimum threshold(s) are achieved, the formula for calculating the annual cash bonus payout at the end of the year for an Executive may result in a partial bonus payout in the event that an Executive achieves less than 100% of his or her performance criteria.

 

A-10

 

 

(e) The maximum bonus amount per year under the Bonus Plan that an Executive will be entitled to receive for any given calendar year may not exceed 150% of the annual (gross) base salary of that Executive.

 

(f) The authorized body shall be entitled to reduce or cancel an Executive’s annual bonus at his or its discretion.

 

(g) An Executive whose employment shall commence during a bonus year will be entitled to a pro-rated bonus, provided that the Executive has been employed for at least six months during the bonus year; provided, however, that under special circumstances, the authorized body may determine that an Executive whose employment commenced more than six month into the bonus year shall be entitled to a pro-rated bonus. An Executive whose employment terminated during a bonus year (including upon a change of control event) will be entitled to a pro-rated bonus for that year, other than if the employment was terminated for Cause (as such term shall be defined in the Executive’s individual agreement and in the absence thereof, as defined in the Equity Plan), in which case an Executive shall not be entitled to an annual bonus.

 

6.2.4.2. Special Bonuses

 

(a) The Terms of Office and Engagement of an Executive may include other bonuses (cash bonus or equity award) payable under special and exceptional circumstances (“Special Bonuses”). Special Bonuses shall be based on the achievement by the Company (or the applicable Affiliate or division) or the Executive of specific goals or the occurrence of specific events (such as, without limitation, execution of projects not within the scope of the annual work plan, exceptional and extraordinary efforts to execute a project within the scope of the annual work plan and exceptional contribution to the Company’s success and promotion of its goals).

 

(b) The Special Bonus payable to an Executive may be up to three (3) times the monthly gross base salary (in addition to any annual bonus or Sign-on Bonus (as defined below) (if any)).

 

6.2.4.3. Sign-on Bonus

 

(a) The Terms of Office and Engagement of a newly hired or newly appointed Executive (including an Executive first appointed as an Office Holder of the Company following the Company becoming the listed parent of its operating subsidiaries) may include a signing bonus (the “Sign-on Bonus”). Sign-on Bonuses shall be determined taking into consideration market considerations and the specific circumstances of the Executive.

 

(b) The Sign-on Bonus payable to such an Executive may be up to 30% of such Executive’s annual base salary for the first year of employment or appointment (in addition to any annual bonus or Special Bonus (if any)).

 

6.3. Equity-Based Compensation

 

6.3.1. Equity awards will be made in the manner prescribed by the Company’s 2026 Equity Incentive Plan (including its Israeli, United States and Canadian appendices), as amended, and under such other equity plans for employees, directors and service providers of the Company or its Affiliates that the Company may adopt from time to time (the “Equity Plans”). These may include: options to purchase shares of the Company, share appreciation rights, restricted share units, restricted share awards, performance based awards and any other type of equity compensation that is based on the Company’s securities and may be granted under applicable tax regimes.

 

A-11

 

 

6.3.2. The maximum value of all equity awards, in the aggregate, that are granted to a particular Executive on an annual basis shall not exceed 400% of the annual base salary of that Executive. The maximum value of all equity awards shall be determined as of the date(s) of grant, other than cash-settled equity awards, which shall be determined as of the date(s) of payment. To determine the maximum annual value of an equity award as of the grant date, the aggregate fair value of the equity award is measured at the grant date in accordance with the accounting treatment in the financial statements and is spread over the vesting period according to generally accepted accounting principles.

 

6.3.3. Equity awards will be subject to an overall vesting period or reverse-vesting, as applicable (being measured by the last vesting date from the date of commencement of vesting) of no less than three (3) years (including periodic vesting dates during such period), with a minimum period of one (1) year prior to the vesting of the first tranche of equity awards granted to Executives. Such minimum vesting or holding period is an appropriate incentive, on a long- term basis. As set forth in the Equity Plans, the Equity Plan administrator shall also have the authority to determine the specific vesting schedule, including partial or full acceleration of vesting of equity awards in certain events, including termination events or change in control, as the Equity Plan administrator deems appropriate, as well as other adjustments, modifications and changes to the terms of the equity awards (which adjustments, modifications and adjustments may be made either at the time of approval of the award or at any time thereafter), as permitted under the terms of the Equity Plans and subject to Applicable Law. The maximum term of any equity award (prior to its expiration) shall be ten (10) years from the date of grant.

 

6.3.4. With respect to an equity award under the Equity Plan that includes an exercise price – the exercise price shall not be lower than the fair market value of an ordinary share of the Company on the date of grant, being the closing price of the Company’s ordinary shares on the Nasdaq Stock Market on the date of grant (or, if no closing price is reported on that date, on the last trading day preceding the date of grant), or such other measure of fair market value as is required for the award to qualify for the intended tax treatment under the Applicable Law of the jurisdiction in which the Executive is taxed.

 

6.3.5. In the event that equity awards granted to groups of employees of the Company and/or its Affiliates are subject to a re-pricing or other amendment or adjustment of terms that is applied to the entire group of such employees, then such re-pricing or other amendment or adjustment may be applied also to Executives that constitute part of the same group, subject to obtaining all approvals required under Applicable Law.

 

6.3.6. The Board and/or the Committee may amend other terms of an Executive’s grant(s) to the extent provided in the applicable Equity Plan and subject to Applicable Law.

 

6.3.7. The Company may approve to accelerate the vesting and/or continue the vesting and/or the exercise eligibility of an Executive’s equity awards after termination of such Office Holder’s service or engagement, in accordance with the provisions of the Equity Plans.

 

6.4. Subject to Applicable Law, a non-material amendment to the terms of office and engagement of an Office Holder who is subordinate to the CEO (as compared to those approved by the Committee) shall not require the approval of the Committee, provided that such amendment was approved by the CEO and the amended engagement terms are consistent with this Policy.

 

A-12

 

 

7. COMPONENTS OF TERMS OF OFFICE AND ENGAGEMENT OF A DIRECTOR

 

7.1. Director Compensation

 

The Terms of Office and Engagement of a Director (including an External Director, if any is serving on the Board) may include a combination of all or any part of the following components. In each instance, a consideration shall be made as to which components are appropriate and their respective weight.

 

The Terms of Office and Engagement of an External Director shall be subject to and determined in accordance with the Companies Law and the Companies Regulations (Rules Regarding Compensation and Expenses of External Directors), 5760-2000 (the “External Director Regulations”). Subject to the approval of the shareholders of the Company by the majority required under Section 239(b) of the Companies Law, an External Director may be paid cash compensation and granted equity awards in amounts exceeding those prescribed by the External Director Regulations, provided that such compensation does not exceed the caps applicable to Directors under this Section 7 and that any equity award is on terms no more favourable than those of equity awards to the other Directors, as permitted by Regulation 8B of the External Director Regulations.

 

Except as set forth in this Section 7, Directors shall not be entitled to any compensation, unless they are employed or engaged in an additional position at the Company or an Affiliate, in which case their compensation in that capacity shall be determined in accordance with Section 6 of this Policy and they shall not be entitled to compensation under this Section 7 in respect of the same period of service, other than reimbursement of expenses and the insurance, exculpation and indemnification described in Section 7.1.1.3.

 

7.1.1. Fees and benefits

 

7.1.1.1. Fees

 

7.1.1.1.1. Periodic Fees. Fees payable with respect to a period of service on the Board and/or any committee thereof, typically an annual fee. The terms of the periodic fees may refer to circumstance and the effect of partial service throughout the relevant period of the fee entitlement. The periodic fees shall not exceed an amount reflecting an annual fee of (i) US$40,000 for service on the Board; (ii) US$7,500 for service on the Audit Committee of the Board; (iii) US$5,000 for service on the Committee; and (iv) US$2,500 for service on any other committee of the Board.

 

7.1.1.1.2. Per Meeting Fees. A fee payable for each meeting of the Board and/or any committee thereof, whether participation was in person, through a telephone or through a written consent. The per meeting fee (the “Per Meeting Fee”) shall not exceed US$1,000. Different Per Meeting Fees may be determined for participation in person, through a telephone call or through a written consent.

 

7.1.1.1.3. Chairman Fee. A fee may be payable to the chairman of the Board (who is not an Active Chairman, which is determined in accordance with Section 7.2) and/or any committee of the Board (in addition to the periodic fees and/or per meeting fee) in an amount that shall not exceed an annual fee of (i) US$10,000 for service as Chairman of the Board; (ii) US$5,000 for service as Chairman of the Audit Committee of the Board; and (iii) US$2,500 for service as Chairman of any other committee of the Board.

 

7.1.1.2. Reimbursement of expenses, including travel, stay and lodging;

 

7.1.1.3. Insurance (as set forth in clauses (y) and (z) of Section 6.1.2), exculpation and indemnification;

 

7.1.1.4. Other compensation, benefits or entitlements mandated by Applicable Law; and

 

7.1.1.5. Other benefits and entitlements that are part of directors’ compensation practices in the industry, relevant geographical location, region of activity or jurisdiction.

 

A-13

 

 

7.1.2. Equity Awards

 

The provisions of Section 6.3 shall apply to awards of equity grants to Directors, except that (i) equity awards to Directors shall not be required to have a minimum period of one year prior to the vesting of the first tranche; and (ii) the maximum value of all equity awards, in the aggregate, that are granted to a particular Director on an annual basis shall not exceed 400% of the annual fee (including for service on the Board and any committee thereof and for service as a Chairman of the Board and any committee thereof, but excluding any Per Meeting Fees) of that Director.

 

7.2. Compensation of an Active Chairman of the Board

 

An “Active Chairman” means a Chairman of the Board who has been declared as such in view of increased involvement in the Company’s activities and increased time investment in the performance of such position compared to other members of the Board.

 

In the event that the Chairman of the Board is an Active Chairman, then his or her compensation in such capacity may be up to two (2) times each of the cash and equity and other compensation and benefits to which the other Directors are entitled in their capacity as Directors pursuant to Section 7.1 above.

 

The compensation of an Active Chairman shall express, among other things, the scope of involvement in the Company’s activities and the time invested by the Active Chairman in the performance of such position.

 

8. RECOUPMENT

 

The Terms of Office and Engagement of an Office Holder shall include provisions that require an Office Holder to repay to the Company amounts paid to such Office Holder as part of the Terms of Office and Engagement, if they were paid on the basis of figures that later transpire to be incorrect and were restated in the Company’s financial statements, and shall be subject to the Company’s clawback policy adopted in accordance with Rule 10D-1 under the U.S. Securities Exchange Act of 1934 and Nasdaq Listing Rule 5608, as in effect from time to time. The Compensation Committee shall be entitled to determine the amounts and conditions of such repayment, which may include terms under which (i) repayment will be made either on a pre-tax basis or an after-tax basis, unless and to the extent the Office Holder was able to recoup tax payments made with respect to the amounts to be repaid, (ii) no repayment obligation shall arise after the lapse of a period of time to be set forth in the Terms of Office and Engagement of an Office Holder, being no less than three years from the date on which the original payments was due to be made, (iii) the period of time of no more than 12 months over which the repayment payments to the Company shall be made and the ability to make the repayment in installments or (to the extent permitted under Applicable Law) as a set-off against cash compensation paid by the Company to the Executive during such period , (iv) no repayment obligation shall arise in the event that the reason or basis for the restatement was due to changes in the Applicable Law, including generally acceptable accounting principles or financial reporting standards; and (v) such other provisions as determined in each case, subject to Applicable Law. Nothing in this Section 8 shall derogate from or limit any other or similar provisions imposed on an Office Holder by Applicable Law, including, securities laws.

 

9. EFFECTIVENESS; TERM

 

9.1. The Policy shall take effect upon its approval in accordance with the Companies Law.

 

9.2. The term of this Policy shall not be limited in time, except that it will terminate at the earlier of (i) such time that the Policy is no longer in effect under the Companies Law, or (ii) such time that the Policy is terminated by the Board, to the extent that the Board has the power under the Companies Law to terminate the Policy, or (iii) such time that the determination of Terms of Office and Engagement of Office Holders is not required to be made pursuant to a Compensation Policy under the Companies Law, including, without limitation, in the event that the Company ceases to be a Public Company (as defined in the Companies Law), in which case this Policy shall have no effect with respect to Terms of Office and Engagement of Office Holders with respect to the period after the Company ceases to be a Public Company.

 

A-14

 

 

10. NON-EXCLUSIVITY OF THIS POLICY

 

10.1. Neither the adoption of this Policy nor the submission of this Policy to shareholders of the Company for approval (to the extent required under the Companies Law), shall be construed as creating any limitations on the power or authority of the Board or the Committee to adopt such other or additional incentive or other compensation arrangements of whatever nature as they may deem necessary or desirable or preclude or limit the continuation of any other policy, practice or arrangement for the payment of compensation or fringe benefits to employees generally, or to any class or group of employees, which the Company or any Affiliate now has lawfully put into effect, including, without limitation, any retirement, pension, savings and stock purchase plan, insurance, death and disability benefits and executive short-term or long-term incentive plans.

 

10.2. The Terms of Office and Engagement of an Office Holder may contain such other terms and conditions not inconsistent with this Policy (to the extent required by the Companies Law).

 

11. GOVERNING LAW

 

This Policy shall be governed by the laws of the State of Israel, excluding its conflict of law rules, except with respect to matters that are subject to tax or labor laws in any specific jurisdiction, which shall be governed by the respective laws of such jurisdiction. Certain definitions, which refer to laws other than the laws of such jurisdiction, shall be construed in accordance with such other laws.

 

12. SEVERABILITY

 

If any provision of this Policy shall be determined to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other jurisdiction. In addition, if any particular provision contained in this Policy shall for any reason be held to be excessively broad as to duration, geographic scope, activity or subject, it shall be construed by limiting and reducing such provision as to such characteristic so that the provision is enforceable to fullest extent compatible with the Applicable Law as it shall then appear.

 

Approved by the Company’s Board of Directors: [●], 2026. Approved by the shareholders of the Company: [●], 2026.

 

A-15

 

 

APPENDIX B

 

MBODY AI LTD.

 

2026 EQUITY INCENTIVE PLAN

 

1. Purpose

 

The purpose of this 2026 Equity Incentive Plan (the “Plan”) is to attract, retain and motivate employees, directors and consultants of MBody AI Ltd. (the “Company”) and its Subsidiaries, to provide them with incentives to promote the long-term success of the Company, and to align their interests with those of the Company’s shareholders, by providing for the grant of Options, Share Appreciation Rights, Restricted Shares, Restricted Share Units, Performance Awards and Other Share-Based Awards. Awards to Participants who are subject to tax in Israel, the United States or Canada are also governed by Appendix I, Appendix II or Appendix III, respectively, which form part of the Plan.

 

2. Definitions

 

As used in the Plan, the following terms have the meanings set out below. Additional defined terms applicable to particular jurisdictions appear in the Appendices.

 

“Administrator” means the Board or the Committee, as the body administering the Plan in accordance with Section 4.

 

“Affiliate” means any entity that, directly or indirectly, controls, is controlled by or is under common control with the Company, and, for the purposes of Appendix I, any “employing company” within the meaning of Section 102 of the Ordinance.

 

“Applicable Law” means the laws, rules and regulations applicable to the Plan and Awards, including the Companies Law, the Ordinance, the Code, the Income Tax Act (Canada), the securities laws of Israel, the United States, Canada and any other relevant jurisdiction, and the rules of any stock exchange on which the Shares are listed.

 

“Appendix” means each of Appendix I (Israel), Appendix II (United States) and Appendix III (Canada), and any other appendix or sub-plan adopted by the Administrator under Section 4.3.

 

“Award” means an Option, Share Appreciation Right, Restricted Share, Restricted Share Unit, Performance Award or Other Share-Based Award granted under the Plan.

 

“Award Agreement” means the written or electronic agreement or notice between the Company and a Participant setting out the terms of an Award, which is subject to the Plan and the applicable Appendix.

 

“Board” means the Board of Directors of the Company.

 

“Cause” means unless otherwise defined in the Participant’s Award Agreement or employment or service agreement, any of the following: (i) the Participant’s theft, fraud, embezzlement or dishonesty in connection with the Company or an Affiliate; (ii) the Participant’s material breach of a confidentiality, non-competition, non-solicitation or intellectual property obligation to the Company or an Affiliate; (iii) the Participant’s conviction of, or plea of guilty or no contest to, a felony or indictable offense or any crime involving moral turpitude; (iv) the Participant’s willful failure to perform his or her material duties after written notice and a reasonable opportunity to cure; (v) the Participant’s willful misconduct or gross negligence causing material harm to the Company or an Affiliate; or (vi) any other circumstance that constitutes cause for termination of employment under Applicable Law or under which the Company or the relevant Affiliate is entitled to terminate the Participant’s employment without notice or severance under Applicable Law. The determination of Cause shall be made by the Administrator in good faith.

 

B-1

 

 

“Change in Control” means the occurrence of any of the following: (i) a merger, consolidation, amalgamation or similar transaction involving the Company, unless the holders of the Company’s voting shares immediately before the transaction hold more than 50% of the voting power of the surviving or resulting entity (or its parent) immediately after the transaction in substantially the same proportions; or (ii) a sale, lease or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than to an entity of which the Company’s shareholders hold more than 50% of the voting power in substantially the same proportions. A Change in Control shall not include a transaction effected solely to change the jurisdiction of incorporation of the Company or to create a holding company owned in substantially the same proportions by the Company’s shareholders, an issuance of securities by the Company in a financing transaction, or an internal reorganization in which the ultimate beneficial ownership of the Company and its Subsidiaries does not change. Where a Participant’s Award Agreement, or an employment or service agreement of the Participant approved in accordance with the Companies Law, defines “Change in Control” or “Change of Control” differently, that definition applies to that Participant’s Awards. Where required to avoid adverse tax consequences under Section 409A of the Code, “Change in Control” shall be interpreted in accordance with Appendix II.

 

“Code” means the U.S. Internal Revenue Code of 1986, as amended, and the regulations under it.

 

“Committee” means the Compensation Committee of the Board, or another committee of the Board designated by the Board to administer the Plan, in each case constituted in compliance with the Companies Law and Applicable Law.

 

“Companies Law” means the Israeli Companies Law, 5759-1999, as amended, and the regulations under it.

 

“Compensation Policy” means the compensation policy of the Company for its office holders, as in effect from time to time under the Companies Law.

 

“Consultant” means any natural person, or any entity wholly owned by a natural person, engaged by the Company or a Subsidiary to render bona fide consulting or advisory services, other than services in connection with the offer or sale of securities in a capital-raising transaction or that directly or indirectly promote or maintain a market for the Company’s securities.

 

“Director” means a member of the Board or of the board of directors of a Subsidiary.

 

“Disability” means unless otherwise defined in the Award Agreement, the Participant’s inability, by reason of physical or mental illness or injury, to perform the essential functions of his or her position for a period of 180 consecutive days or 180 days in any 365-day period, as determined by the Administrator in good faith on the basis of medical evidence, or as otherwise defined under Applicable Law where a different definition is required.

 

“Effective Date” means the date on which the Plan was adopted by the Board, being [●], 2026.

 

“Employee” means any person employed by the Company or a Subsidiary, including an officer or Director who is so employed. A Participant shall not cease to be an Employee by reason of an approved leave of absence or a transfer between the Company and any Subsidiary or between Subsidiaries.

 

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.

 

B-2

 

 

“Exercise Price” means the price per Share payable on exercise of an Option, or the base price of a Share Appreciation Right.

 

“Fair Market Value” means as of any date, (i) if the Shares are listed on the Nasdaq Stock Market or another established stock exchange, the closing sale price of a Share on that exchange on that date or, if no sale is reported on that date, on the last preceding date on which a sale was reported; or (ii) if the Shares are not so listed, the value determined in good faith by the Administrator by a reasonable valuation method consistent with Applicable Law, including, for U.S. taxpayers, Section 409A of the Code. An Appendix may specify a different measure of fair market value where required for the intended tax treatment of an Award in that jurisdiction.

 

“Grant Date” means the date on which the Administrator completes the corporate action constituting the grant of an Award or such later date specified by the Administrator, provided that no Award to an office holder of the Company shall be effective before all approvals required under the Companies Law have been obtained.

 

“Non-Employee Director” means a member of the Board who is not an Employee.

 

“Option” means a right to purchase Shares at the Exercise Price granted under Section 6, including, for U.S. taxpayers, an Incentive Stock Option or a Non-Qualified Stock Option as defined in Appendix II, and, for Israeli taxpayers, a Section 102 Award or Section 3(i) Award as defined in Appendix I.

 

“Ordinance” means the Israeli Income Tax Ordinance (New Version), 5721-1961, as amended, and the rules and regulations under it.

 

“Other Share-Based Award” means an Award granted under Section 10.2.

 

“Participant” means an Employee, Director or Consultant who has been granted an Award.

 

“Performance Award” means an Award granted under Section 10.1 whose vesting, exercisability or settlement is subject to the achievement of performance goals.

 

“Restricted Share” means a Share granted under Section 8 that is subject to forfeiture and transfer restrictions.

 

“Restricted Share Unit” or “RSU” means a right granted under Section 9 to receive one Share, or its cash equivalent, on the vesting or settlement date.

 

“Service” means a Participant’s employment or engagement with the Company or a Subsidiary as an Employee, Director or Consultant. A change in the capacity in which a Participant provides Service, or a transfer between the Company and a Subsidiary, shall not be a termination of Service, subject to the Appendices.

 

“Share” means an Ordinary Share of the Company, as adjusted under Section 14.

 

“Share Appreciation Right” or “SAR” means a right granted under Section 7 to receive the excess of the Fair Market Value of a Share on the exercise date over the Exercise Price, in Shares or cash.

 

“Subsidiary” means any entity in which the Company holds, directly or indirectly, more than 50% of the voting power or economic interest, and, for the purposes of Incentive Stock Options, a “subsidiary corporation” within the meaning of Section 424(f) of the Code.

 

“Successor Company” means the surviving, resulting or acquiring entity in a Change in Control, or any parent or Affiliate of it, as determined by the Administrator.

 

B-3

 

 

“Ten Percent Shareholder” means a person who, at the Grant Date, owns (within the meaning of Section 424(d) of the Code) shares possessing more than 10% of the total combined voting power of all classes of shares of the Company or any parent or Subsidiary.

 

“Trustee” means a trustee appointed by the Company or an Affiliate and approved by the Israel Tax Authority in accordance with Section 102 of the Ordinance, or any other trustee appointed by the Administrator to hold Awards or Shares on behalf of Participants.

 

3. Shares Subject to the Plan

 

3.1. Reserve. Subject to adjustment under Section 14, the maximum aggregate number of Shares that may be issued under the Plan is 1,841,517 Shares (the “Share Reserve”). Shares issued under the Plan may be authorized but unissued Shares or Shares held in treasury, to the extent permitted by Applicable Law. The Share Reserve is a fixed number. It shall not increase automatically or by action of the Board alone, and any increase requires the approval of the Company’s shareholders under Section 18.2.

 

3.2. ISO limit. Subject to adjustment under Section 14, the maximum aggregate number of Shares that may be issued on exercise of Incentive Stock Options (as defined in Appendix II) is 1,841,517 Shares.

 

3.3. Share counting. Shares subject to an Award that expires, is forfeited, is cancelled or terminates without the issuance of Shares, or is settled in cash, shall again be available for Awards. The following Shares shall not be added back to the Share Reserve: (i) Shares tendered or withheld to pay the Exercise Price of an Option or SAR; (ii) Shares tendered or withheld to satisfy tax withholding on any Award; (iii) Shares subject to a SAR that are not issued on its net settlement; and (iv) Shares repurchased by the Company with the proceeds of Option exercises.

 

3.4. Substitute Awards. Awards granted in assumption of, or in substitution for, awards previously granted by an entity acquired by the Company or a Subsidiary or with which the Company or a Subsidiary combines (“Substitute Awards”) shall not reduce the Share Reserve, and Shares subject to Substitute Awards shall not be added back to the Share Reserve on their forfeiture or expiry, in each case to the extent permitted by Applicable Law and the rules of the Nasdaq Stock Market.

 

4. Administration

 

4.1. Administrator. The Plan shall be administered by the Committee, or by the Board to the extent the Board so determines or the Committee is not constituted. Any action required under the Companies Law to be taken by the compensation committee, the board or the shareholders of the Company shall be taken by that body, and references in the Plan to the Administrator shall be read accordingly.

 

4.2. Powers. Subject to the Plan, the Appendices, the Company’s Compensation Policy and Applicable Law, the Administrator has full authority to: (i) select the Employees, Directors and Consultants to whom Awards are granted; (ii) determine the type, number, Grant Date, Exercise Price, vesting, exercisability, performance goals, settlement, expiry and other terms of each Award; (iii) approve forms of Award Agreement; (iv) determine Fair Market Value; (v) interpret and construe the Plan, the Appendices and Award Agreements, and correct any defect or reconcile any inconsistency in them; (vi) adopt, amend and rescind rules and procedures for the administration of the Plan; (vii) accelerate vesting or exercisability, extend the post-termination exercise period, or waive conditions of an Award, subject to Sections 11 and 15; (viii) make the elections and filings contemplated by the Appendices, including the election of the type of Section 102 Award; (ix) determine whether, to what extent and under what circumstances Awards may be settled in cash, Shares or other property; and (x) make all other determinations necessary or advisable for the administration of the Plan. The Administrator’s determinations are final and binding on all persons.

 

B-4

 

 

4.3. Appendices and sub-plans. The Administrator may adopt appendices, sub-plans, rules or procedures applicable to Participants in particular jurisdictions to comply with or obtain favorable treatment under local tax, securities, exchange control or labor laws, which may modify the terms of the Plan as applied to those Participants but may not increase the Share Reserve or otherwise conflict with Section 18.2.

 

4.4. Delegation. To the extent permitted by Applicable Law, the Administrator may delegate to one or more officers of the Company the authority to grant Awards to Employees and Consultants who are not office holders of the Company within the meaning of the Companies Law, subject to limits set by the Administrator.

 

4.5. Limitation of liability; indemnification. No member of the Board or the Committee, and no officer to whom authority is delegated, shall, subject to applicable law, be liable for any action or determination made in good faith with respect to the Plan or any Award. Any indemnification of such a person is governed exclusively by the Company’s Articles of Association, the indemnification undertaking (if any) approved for that person under the Companies Law, and applicable law.

 

5. Eligibility; Limits

 

5.1. Eligible persons. Awards may be granted to Employees, Directors and Consultants of the Company and its Subsidiaries, and to persons to whom an offer of employment or engagement has been extended, provided that the Award shall not become effective before the commencement of Service. Incentive Stock Options may be granted only to Employees of the Company or a Subsidiary that is a “subsidiary corporation” under Section 424(f) of the Code.

 

5.2. Companies Law approvals. The Plan does not itself grant any Award to any person. Any Award to a Director, to the chief executive officer of the Company, to a controlling shareholder of the Company or a relative of a controlling shareholder, or to any other person whose terms of office and engagement require approval under the Companies Law, shall be subject to, and shall not be effective until, all approvals required under the Companies Law and the Company’s Compensation Policy have been obtained.

 

5.3. Non-Employee Director limit. The aggregate grant date fair value (computed in accordance with applicable financial accounting rules) of Awards granted to any Non-Employee Director in respect of his or her service as a Director during any calendar year, together with any cash fees paid to the Non-Employee Director in respect of that service for that year, shall not exceed US$400,000 (US$600,000 in the calendar year in which the Non-Employee Director first joins the Board). Awards to Non-Employee Directors shall in addition comply with the Company’s Compensation Policy, and Awards to external directors within the meaning of the Companies Law shall comply with the Companies Regulations (Rules Regarding Compensation and Expenses of External Directors), 5760-2000.

 

6. Options

 

6.1. Grant. The Administrator may grant Options on such terms as it determines, subject to the Plan and the applicable Appendix. Each Option shall be designated in the Award Agreement as an Incentive Stock Option, a Non-Qualified Stock Option, a Section 102 Award, a Section 3(i) Award or an Option under Appendix III, as applicable; an Option not so designated shall be a Non-Qualified Stock Option or the equivalent under the applicable Appendix.

 

6.2. Exercise Price. The Exercise Price of an Option shall be determined by the Administrator and shall not be less than 100% of the Fair Market Value of a Share on the Grant Date (110% in the case of an Incentive Stock Option granted to a Ten Percent Shareholder), except for Substitute Awards granted in a manner consistent with Section 424(a) of the Code and Section 409A of the Code, where applicable.

 

B-5

 

 

6.3. Term. No Option shall be exercisable after the tenth anniversary of its Grant Date (the fifth anniversary in the case of an Incentive Stock Option granted to a Ten Percent Shareholder), or such shorter term as the Award Agreement provides.

 

6.4. Vesting and exercisability. Options shall vest and become exercisable at such times and subject to such conditions as the Administrator determines, subject to Section 11. Unless the Administrator determines otherwise, vesting shall be suspended during any unpaid leave of absence, to the extent permitted by Applicable Law.

 

6.5. Exercise; payment. An Option shall be exercised by notice to the Company (or its designated agent or the Trustee) in the form prescribed by the Administrator, accompanied by payment of the Exercise Price and any required tax withholding. Payment may be made, as the Administrator permits, (i) in cash or by check or wire transfer; (ii) by delivery or attestation of previously owned Shares having a Fair Market Value equal to the Exercise Price; (iii) by a “cashless exercise” through a broker acceptable to the Company; (iv) by “net exercise,” under which the Company withholds from the Shares otherwise issuable a number of Shares having a Fair Market Value equal to the Exercise Price; or (v) by any combination of the foregoing or other method permitted by Applicable Law. No fractional Shares shall be issued.

 

6.6. Rights as a shareholder. A Participant shall have no rights as a shareholder in respect of Shares subject to an Option until the Shares are issued and registered in the Participant’s name (or the Trustee’s name), and no adjustment shall be made for dividends or other rights for which the record date precedes the date of issuance, except as provided in Section 14.

 

7. Share Appreciation Rights

 

7.1. The Administrator may grant SARs, alone or in tandem with an Option, on such terms as it determines. On exercise, the Participant shall receive, in Shares, cash or a combination as the Administrator determines, an amount equal to the excess of the Fair Market Value of a Share on the exercise date over the Exercise Price, multiplied by the number of Shares in respect of which the SAR is exercised. The Exercise Price of a SAR shall not be less than 100% of the Fair Market Value of a Share on the Grant Date, and no SAR shall be exercisable after the tenth anniversary of its Grant Date. Sections 6.4 to 6.6 apply to SARs mutatis mutandis.

 

8. Restricted Shares

 

8.1. The Administrator may grant Restricted Shares for such consideration (if any, and not less than the minimum required by Applicable Law), subject to such vesting conditions and restrictions on transfer and for such restricted period, as it determines, subject to Section 11. Restricted Shares shall be evidenced by book entry or certificates held by the Company or the Trustee until the restrictions lapse, and the Participant shall deliver such share powers or instruments of transfer as the Administrator requires.

 

8.2. A Participant holding Restricted Shares shall have the right to vote them. Dividends and distributions on Restricted Shares shall be subject to Section 12.

 

8.3. Unless the Award Agreement or the Administrator provides otherwise, Restricted Shares that have not vested on the Participant’s termination of Service shall be forfeited (or, if purchased, repurchased by the Company at the lower of cost and Fair Market Value, to the extent permitted by Applicable Law).

 

B-6

 

 

9. Restricted Share Units

 

9.1. The Administrator may grant RSUs, each representing the right to receive one Share (or, if the Administrator so determines, cash equal to the Fair Market Value of one Share) on the vesting or settlement date, subject to such conditions as it determines and to Section 11. RSUs shall be settled within the period specified in the Award Agreement and, in any event, within the period required by the applicable Appendix to obtain the intended tax treatment. A Participant shall have no rights as a shareholder in respect of RSUs until Shares are issued in settlement. Unless the Award Agreement or the Administrator provides otherwise, RSUs that have not vested on the Participant’s termination of Service shall be forfeited.

 

10. Performance Awards and Other Share-Based Awards

 

10.1. Performance Awards. The Administrator may grant Awards whose grant, vesting, exercisability or settlement depends on the achievement of one or more performance goals over a performance period determined by the Administrator. Performance goals may be based on any measure of Company, Subsidiary, business unit or individual performance the Administrator selects, including, for example, revenues, annual recurring revenue, gross margin, operating profit, EBITDA or adjusted EBITDA, cash flow, robots deployed or under management, customer acquisition, retention and expansion, fleet utilization and service-level performance, safety and quality measures, share price, total shareholder return, strategic transactions and product milestones, and may be absolute or relative, and may be adjusted by the Administrator for extraordinary, unusual or non-recurring items in a manner consistent with the Company’s Compensation Policy. The Administrator shall determine whether and to what extent performance goals have been achieved and may reduce (but not, for a Participant who is an office holder, increase) the amount payable.

 

10.2. Other Share-Based Awards. The Administrator may grant other Awards that are denominated in, valued by reference to or otherwise based on Shares, including deferred share units and fully vested Shares in lieu of cash compensation otherwise payable, on such terms as it determines, subject to Section 11.

 

11. Minimum Vesting

 

Awards shall vest over a period of not less than one year from the Grant Date, provided that (i) up to 5% of the Share Reserve may be granted as Awards without regard to this minimum; (ii) the Administrator may provide for earlier vesting on a Participant’s death, Disability or retirement, or in connection with a Change in Control under Section 14; (iii) Awards to Non-Employee Directors granted on the date of an annual general meeting may vest on the earlier of the first anniversary of the Grant Date and the date of the next annual general meeting, provided at least 50 weeks have elapsed; and (iv) Substitute Awards are not subject to this Section 11.

 

12. Dividends and Dividend Equivalents

 

No dividends or dividend equivalents shall be paid on Options or SARs. Dividends on unvested Restricted Shares and dividend equivalents credited on unvested RSUs, Performance Awards or Other Share-Based Awards shall be accumulated (in cash or additional units, as the Administrator determines) and paid only if and when, and to the extent that, the underlying Award vests, and shall be forfeited if the underlying Award is forfeited. Dividends and dividend equivalents on Awards held by a Trustee shall be subject to the applicable Appendix.

 

B-7

 

 

13. Termination of Service

 

13.1. Unless the Award Agreement or the Administrator provides otherwise, and subject to Section 13.4 and the Appendices: (i) on a termination of Service for Cause, all Awards, whether or not vested, shall be forfeited immediately; (ii) on a termination of Service by reason of death or Disability, all unvested Awards that are subject only to time-based vesting shall vest in full on the date of termination, each unvested Performance Award shall vest pro rata based on actual performance, measured at the end of the performance period (or, if the Administrator so determines, at the date of termination) and prorated for the portion of the performance period elapsed before termination, and vested Options and SARs shall remain exercisable for 12 months after termination (but not beyond their term); and (iii) on any other termination of Service, vested Options and SARs shall remain exercisable for 3 months after termination (but not beyond their term), and unvested Awards shall be forfeited. Except as provided in Section 13.4 or the Award Agreement, Awards do not continue to vest after termination of Service. Awards that have vested shall not be forfeited other than on a termination of Service for Cause or under Section 17. If the exercise of an Option or SAR during a post-termination period is prevented by Applicable Law or a Company trading policy, the period shall be extended until 30 days after the restriction lapses, but not beyond the term of the Award.

 

13.2. For the purposes of the Plan, a Participant’s Service terminates on the date the Participant ceases actively to provide Service, as determined by the Administrator, without regard to any period of notice, pay in lieu of notice or severance, whether under contract, statute or common law, except to the extent Applicable Law requires otherwise (including, for Participants employed in Canada, as provided in Appendix III).

 

13.3. The Administrator may, in its discretion, extend the post-termination exercise period of an Option or SAR (but not beyond its term), accelerate vesting on or after termination of Service, or provide for continued vesting, in each case subject to Section 11, the Company’s Compensation Policy and Applicable Law.

 

13.4. Approved agreement terms. Where a Participant’s employment or service agreement, approved in accordance with the Companies Law, provides for (i) the continued vesting of Awards for a period after termination of Service, (ii) the acceleration of vesting on death, Disability, a termination of Service without Cause or for good reason (as defined in that agreement), or in connection with a Change in Control, (iii) the pro-rata vesting of Performance Awards, or (iv) a post-termination exercise period longer than that in Section 13.1, the Award Agreement shall give effect to those terms, and Sections 13.1 and 14 shall be read accordingly. Where an Award continues to vest after termination of Service: (a) the Participant shall be treated as remaining in Service for vesting purposes only, for the period the agreement provides; (b) a Performance Award shall vest pro rata based on actual performance as provided in Section 13.1(ii); and (c) vested Options and SARs shall remain exercisable for 3 months after the last vesting date in that period (or such longer period as the Award Agreement provides), but not beyond their term. Nothing in this Section 13.4 permits vesting earlier than Section 11 allows, other than within the exceptions in Section 11.

 

14. Adjustments; Change in Control; Dissolution

 

14.1. Capital adjustments. In the event of a share split, reverse share split, share dividend, bonus issue, recapitalization, reclassification, combination, exchange of shares, spin-off, extraordinary cash dividend or other change in the Company’s capital structure affecting the Shares without receipt of consideration by the Company, the Administrator shall equitably adjust the number and kind of Shares subject to the Share Reserve and the limits in Sections 3.2 and 5.3, the number and kind of Shares subject to outstanding Awards, the Exercise Price of outstanding Options and SARs, and any performance goals, so as to prevent enlargement or dilution of rights, in a manner consistent with Section 424 and Section 409A of the Code where applicable. The conversion of convertible securities and the issuance of Shares for consideration shall not require an adjustment.

 

B-8

 

 

14.2. Change in Control: assumption or substitution. In the event of a Change in Control, unless the Administrator determines otherwise, each outstanding Award shall be assumed, or an equivalent award substituted, by the Successor Company. An Award shall be considered assumed or substituted if, following the Change in Control, it confers the right to receive, for each Share subject to the Award immediately before the Change in Control, the consideration (whether shares, cash or other property) received by holders of Shares in the Change in Control (or, if holders were offered a choice, the type of consideration chosen by the holders of a majority of the Shares, or solely shares of the Successor Company of equivalent fair market value as determined by the Administrator), with vesting and other terms no less favorable to the Participant than those in effect immediately before the Change in Control, and with performance goals deemed achieved at the greater of target and actual performance through the Change in Control and converted to time-based vesting for the balance of the performance period.

 

14.3. Agreements govern. No Participant shall be entitled to the vesting or acceleration of an Award by reason of or in connection with a Change in Control, except to the extent the Participant’s Award Agreement, or an employment or service agreement, so provides. In the event of any conflict between this Section 14 and such an agreement regarding the effect of a Change in Control on the Participant’s Awards, the agreement shall prevail.

 

14.4. Awards not assumed. If an Award is not assumed or substituted in a Change in Control, the Administrator may, without the Participant’s consent, take any one or more of the following actions: (i) provide that the Award shall vest in full (with performance goals deemed achieved as in Section 14.2) and, in the case of an Option or SAR, be exercisable for a period before the Change in Control determined by the Administrator, and terminate on the Change in Control to the extent not exercised; (ii) cancel the Award in exchange for a payment, in cash, shares of the Successor Company or other property, equal to the value of the vested portion of the Award (and, if the Administrator so determines, the unvested portion) as determined by the Administrator, which in the case of an Option or SAR shall be the excess, if any, of the per-Share consideration in the Change in Control over the Exercise Price (and may be zero if the Exercise Price equals or exceeds that consideration), and which may be paid on the same schedule and subject to the same escrows, holdbacks, earn-outs and other contingencies as apply to holders of Shares; or (iii) any combination of the foregoing. The Administrator need not treat all Awards or all Participants alike.

 

14.5. Dissolution or liquidation. In the event of the proposed dissolution or liquidation of the Company, the Administrator shall notify Participants and each Award shall terminate immediately before the consummation of the dissolution or liquidation, unless the Administrator provides for earlier exercise or vesting.

 

14.6. Binding effect; agreements. The Administrator’s determinations under this Section 14 are final and binding. The Administrator may require, as a condition of the treatment of an Award under this Section 14, that a Participant execute such agreements, releases and instruments as the Company or the Successor Company reasonably requires, consistent with those required of holders of Shares. No action under this Section 14 shall be treated as an amendment of a Participant’s rights or give rise to any liability to the Company, its Affiliates or their officers, directors and agents, and the Administrator’s powers shall not be limited by any adverse tax consequence to a Participant.

 

15. No Repricing

 

Except for adjustments under Section 14.1, the Administrator shall not, without the prior approval of the Company’s shareholders, (i) reduce the Exercise Price of an outstanding Option or SAR; (ii) cancel an outstanding Option or SAR in exchange for an Option or SAR with a lower Exercise Price or for another Award; (iii) cancel an outstanding Option or SAR whose Exercise Price exceeds the Fair Market Value of a Share in exchange for cash or other property; or (iv) take any other action that is treated as a repricing under the rules of the Nasdaq Stock Market or applicable financial accounting rules.

 

B-9

 

 

16. Transferability

 

Awards may not be sold, pledged, assigned, hypothecated, transferred or otherwise disposed of other than by will or the laws of descent and distribution, and may be exercised during the Participant’s lifetime only by the Participant (or the Participant’s legal representative in the case of Disability), except that the Administrator may permit the transfer of Awards other than Incentive Stock Options and Section 102 Awards to a Participant’s family member or a trust or entity for the benefit of family members, for no consideration, subject to Applicable Law. Awards and Shares held by a Trustee are subject to the transfer restrictions of the applicable Appendix.

 

17. Clawback; Market Stand-Off; Conditions on Issuance; Taxes

 

17.1. Clawback. All Awards, and any Shares, cash or other property delivered under them, are subject to the Company’s clawback policy adopted in accordance with Rule 10D-1 under the Exchange Act and Nasdaq Listing Rule 5608, to the recoupment provisions of the Company’s Compensation Policy, to any other clawback or recoupment policy of the Company in effect from time to time, and to any recoupment required by Applicable Law, and each Participant agrees to repay or forfeit amounts as required under any of them.

 

17.2. Market stand-off. In connection with an underwritten public offering of the Company’s securities, a Participant shall not, without the consent of the Company or the managing underwriter, sell, transfer or otherwise dispose of any Shares acquired under the Plan for such period, not exceeding 180 days after the offering (plus any extension required by the underwriters’ customary terms), as the Company or the underwriter requests, and shall execute any lock-up agreement so requested.

 

17.3. Conditions on issuance. Shares shall not be issued under an Award unless the issuance complies with Applicable Law, and the Company may require the Participant to make such representations and agree to such restrictions and legends as the Company considers necessary. The Company shall have no obligation to register the Shares under the U.S. Securities Act of 1933 or the securities laws of any other jurisdiction, and shall have no liability for any failure to issue Shares where the necessary authority cannot be obtained.

 

17.4. Withholding; tax liability. All tax consequences of Awards, and of the issuance, holding, sale or other disposition of Shares under them, are the sole responsibility of the Participant. The Company, its Affiliates and the Trustee may withhold from any payment or delivery under the Plan, or from any other amount owed to the Participant, any taxes, social security contributions and other amounts required to be withheld under Applicable Law, and may require payment of such amounts as a condition of the exercise, vesting, settlement or release of an Award. The Administrator may permit withholding to be satisfied by the delivery or withholding of Shares having a Fair Market Value not exceeding the maximum statutory withholding rate. Each Participant shall indemnify the Company, its Affiliates and the Trustee against any liability for taxes, interest or penalties arising from the Participant’s Awards.

 

17.5. Data. By accepting an Award, a Participant consents to the collection, use, processing and transfer of personal data by the Company, its Affiliates, the Trustee and their service providers, in Israel, the United States, Canada and elsewhere, for the purposes of administering the Plan, subject to Applicable Law.

 

B-10

 

 

18. Amendment and Termination

 

18.1. The Board may amend, suspend or terminate the Plan or any Appendix at any time. The Administrator may amend any Award, provided that no amendment of the Plan or an Award shall, without the Participant’s consent, materially impair the Participant’s rights under an outstanding Award, except as provided in Sections 14 and 17 and except for amendments required to comply with Applicable Law or to avoid adverse tax consequences under Section 409A of the Code.

 

18.2. The following amendments require the approval of the Company’s shareholders, in addition to the Board: (i) an increase in the Share Reserve or the ISO limit, other than under Section 14.1; (ii) an expansion of the class of persons eligible to receive Awards; (iii) an extension of the term of the Plan; (iv) any action prohibited by Section 15 without shareholder approval; (v) an amendment to this Section 18.2; and (vi) any other amendment for which shareholder approval is required by Applicable Law or the rules of the Nasdaq Stock Market, including, in respect of Incentive Stock Options, Section 422 of the Code.

 

19. Term; Effective Date; Shareholder Approval

 

19.1. The Plan is effective on the Effective Date. Unless earlier terminated by the Board, no Award shall be granted under the Plan after the tenth anniversary of the Effective Date, but Awards granted before that date shall continue in accordance with their terms.

 

19.2. The Plan has been adopted by the Board subject to approval by the Company’s shareholders within 12 months before or after the Effective Date for the purposes of Section 422 of the Code and the rules of the Nasdaq Stock Market, to the extent applicable. Until such approval is obtained, no Incentive Stock Option may be exercised. If the shareholders do not approve the Plan within that period, Options designated as Incentive Stock Options shall be treated as Non-Qualified Stock Options, and the Plan shall otherwise remain in effect. Shareholder approval of the Plan does not constitute approval of any Award to an office holder of the Company that requires separate approval under the Companies Law.

 

19.3. Prior plan. The Check-Cap Ltd. 2015 Equity Incentive Plan (including its United States Sub-Plan), adopted by the Board on June 23, 2015 and approved by the shareholders on August 13, 2015, expired by its terms on June 23, 2025. No awards shall be granted under it. The Plan is a new plan and not an amendment or restatement of the 2015 plan.

 

20. General Provisions

 

20.1. No right to Service or Awards. Nothing in the Plan or any Award confers any right to continue in Service or interferes with the right of the Company or a Subsidiary to terminate a Participant’s Service at any time. No person has any claim to be granted an Award, and there is no obligation of uniform treatment of Participants.

 

20.2. No effect on other benefits. Awards shall not be taken into account in computing any benefit under any pension, severance, retirement or other benefit plan or under Applicable Law (including for the purposes of severance pay under Israeli law and reasonable notice under Canadian law), except as expressly provided in that plan or required by Applicable Law.

 

20.3. Unfunded plan. The Plan is unfunded. Participants have no rights greater than those of unsecured general creditors of the Company in respect of Awards.

 

20.4. Governing law; jurisdiction. The Plan and all Awards shall be governed by the laws of the State of Israel, without regard to conflict of laws principles, except that the Appendices shall be interpreted in accordance with the tax laws of the relevant jurisdiction to the extent necessary to obtain the intended tax treatment. The competent courts of Tel Aviv-Jaffa, Israel shall have exclusive jurisdiction over any dispute arising from the Plan, subject to any mandatory forum under the Applicable Law of a Participant’s jurisdiction of employment.

 

B-11

 

 

20.5. Severability; construction. If any provision of the Plan or an Award is held invalid or unenforceable, the remaining provisions shall continue in effect and the invalid provision shall be construed so as to give effect to its intent to the fullest extent permitted by law. Headings are for convenience only. In the event of a conflict between the Plan and an Award Agreement, the Plan prevails unless the Award Agreement expressly provides otherwise; in the event of a conflict between the Plan and an Appendix in respect of a Participant to whom that Appendix applies, the Appendix prevails.

 

20.6. Notices. Notices under the Plan shall be in writing and delivered in person, by courier, by registered mail or by electronic means to the Company at its principal executive offices (attention: Chief Financial Officer) and to the Participant at the address in the Company’s records, and shall be deemed received on delivery or, if sent by registered mail, seven days after dispatch.

 

20.7. Section 350 and 351. Participants shall not be deemed a class of shareholders or creditors of the Company for the purposes of Sections 350 and 351 of the Companies Law or any successor provisions.

 

20.8. Equal rights; Articles. Shares issued under the Plan shall have the same rights as the other Ordinary Shares of the Company under the Company’s Articles of Association, subject to the Plan, the applicable Appendix and the Award Agreement. Any amendment of the Articles of Association that modifies the rights attaching to the Ordinary Shares, including any re-designation of the Ordinary Shares as shares without par value, shall apply equally to Awards and to Shares issued under the Plan, and the Plan shall continue to apply with the modifications that amendment requires. The grant of an Award or the issuance of Shares does not entitle a Participant to compensation on any change in the Company’s capital, except as provided in Section 14.

 

Adopted by the Board of Directors on [●], 2026. Approved by the shareholders on [●], 2026.

 

B-12

 

 

APPENDIX I

 

ISRAELI APPENDIX TO THE MBODY AI LTD. 2026 EQUITY INCENTIVE PLAN

 

1. General

 

1.1. This Appendix I applies to Awards granted to Participants who are residents of the State of Israel or who are deemed residents of Israel for tax purposes (“Israeli Participants”). It forms part of the Plan and shall be read together with it. In the event of a conflict between this Appendix I and the Plan in respect of an Israeli Participant, this Appendix I prevails. Capitalized terms not defined in this Appendix I have the meanings given in the Plan.

 

1.2. Awards under this Appendix I are intended to qualify, as applicable, as Awards under Section 102 of the Ordinance (“Section 102 Awards”) or Section 3(i) of the Ordinance (“Section 3(i) Awards”), and shall be subject to the Ordinance, the Income Tax Rules (Tax Benefits in Share Issuance to Employees), 5763-2003 (the “Rules”), and any ruling, approval or guidance of the Israel Tax Authority (“ITA”) applicable to the Plan or the Award.

 

2. Additional definitions

 

“Controlling Shareholder” means a “controlling shareholder” within the meaning of Section 32(9) of the Ordinance.

 

“Eligible 102 Participant” means an Israeli Participant who is an Employee or an office holder (nose misra) of the Company or an Affiliate, other than a Controlling Shareholder (before or as a result of the grant).

 

“Election” means the Company’s election under Section 102(g) of the Ordinance of the tax track (the Capital Gains Track or the Ordinary Income Track) applicable to Trustee 102 Awards.

 

“Capital Gains Track” means the tax track under Section 102(b)(2) and (b)(3) of the Ordinance.

 

“Ordinary Income Track” means the tax track under Section 102(b)(1) of the Ordinance.

 

“Holding Period” means the period during which a Trustee 102 Award, and the Shares and other rights derived from it, must be held by the Trustee in order to qualify for the tax treatment of the applicable track, being, at the date of adoption of the Plan, 24 months from the Grant Date for the Capital Gains Track and 12 months for the Ordinary Income Track, or such other period as the Ordinance provides.

 

“Non-Trustee 102 Award” means a Section 102 Award granted under Section 102(c) of the Ordinance that is not held by a Trustee.

 

“Trustee 102 Award” means a Section 102 Award granted under Section 102(b) of the Ordinance and held by the Trustee for the benefit of the Participant.

 

3. Types of Awards; eligibility

 

3.1. Eligible 102 Participants may be granted Section 102 Awards only (Trustee 102 Awards or Non-Trustee 102 Awards, as designated by the Company). Israeli Participants who are Consultants, Controlling Shareholders or otherwise not Eligible 102 Participants may be granted Section 3(i) Awards only. The Administrator may determine otherwise where permitted by Applicable Law.

 

B-13

 

 

3.2. The Company shall designate each Section 102 Award as a Trustee 102 Award or a Non-Trustee 102 Award, and each Trustee 102 Award as being under the Capital Gains Track or the Ordinary Income Track in accordance with the Election. Once an Election is made, all Trustee 102 Awards shall be granted under the elected track until the Election is changed in accordance with Section 102(g) of the Ordinance, which may not occur before the end of the year following the year in which the first grant under the Election was made. The Election does not prevent the grant of Non-Trustee 102 Awards or Section 3(i) Awards.

 

3.3. Section 102 Awards, and any other Awards under this Appendix I, may be Options, RSUs, Restricted Shares or other Awards permitted under Section 102 and the Plan.

 

4. Trustee 102 Awards

 

4.1. Trustee 102 Awards may be granted only after the Plan and the Trustee have been submitted to the ITA for approval in accordance with Section 102, and not earlier than 30 days after such submission (or such shorter period as the ITA permits). If within 90 days of submission the ITA notifies the Company that it does not approve the Plan or the Trustee, Awards intended as Trustee 102 Awards shall be treated as Non-Trustee 102 Awards unless the ITA determines otherwise.

 

4.2. Trustee 102 Awards, and all Shares issued on their exercise or vesting and all rights derived from them (including bonus shares and dividends), shall be issued to or controlled by the Trustee and held in trust for the Participant for at least the Holding Period. The Participant shall not sell, release from trust or otherwise dispose of a Trustee 102 Award or the Shares or rights derived from it before the end of the Holding Period. A disposition before the end of the Holding Period shall be subject to the tax consequences under Section 102, which shall be borne solely by the Participant.

 

4.3. The Trustee shall not release any Award or Share before the Participant has paid the Exercise Price (if any) and all taxes due, and shall act in accordance with the trust agreement between the Company and the Trustee, the Ordinance, the Rules and any ITA approval. The Participant shall sign any documents required by the Company or the Trustee, including an undertaking to be bound by the trust agreement and to release the Trustee from liability for actions taken in good faith.

 

4.4. Any Share split, bonus share or other right issued in respect of Shares held by the Trustee shall be issued to the Trustee and held subject to the same Holding Period. Dividends on Shares held by the Trustee shall be paid to the Trustee and released to the Participant, net of tax, in accordance with Section 102.

 

4.5. Restricted Shares and RSUs granted as Trustee 102 Awards shall be subject to this Section 4 mutatis mutandis, and Shares issued on the vesting of RSUs shall be issued to the Trustee.

 

5. Non-Trustee 102 Awards and Section 3(i) Awards

 

5.1. Non-Trustee 102 Awards and Section 3(i) Awards may be issued directly to the Participant or, if the Administrator determines, to a trustee or supervising trustee, in which case Section 4 shall apply mutatis mutandis to the extent relevant.

 

5.2. A Participant who receives a Non-Trustee 102 Award shall, on termination of Service, provide the Company or the relevant Affiliate with a guarantee or security satisfactory to it to cover any future tax liability arising from the Award, as required by Section 102(c)(2) of the Ordinance.

 

B-14

 

 

6. Fair market value for Section 102

 

Solely for the purpose of determining the tax liability under Section 102(b)(3) of the Ordinance in respect of a Trustee 102 Award under the Capital Gains Track, if the Shares are listed on a stock exchange on the Grant Date, the fair market value of a Share on the Grant Date shall be the average closing price of the Shares on the 30 trading days preceding the Grant Date, and, if the Shares are first listed within 90 days after the Grant Date, the average closing price on the 30 trading days following the listing, in each case as the Ordinance provides. This Section 6 does not affect the determination of the Exercise Price under Section 6.2 of the Plan.

 

7. Integration; tax

 

7.1. The provisions of Section 102, the Rules and any ITA approval or ruling applicable to the Plan are incorporated into this Appendix I and into each Award Agreement for a Section 102 Award, and prevail over any inconsistent provision of the Plan or the Award Agreement. Any provision of Section 102 or the Rules that is necessary to obtain or preserve the intended tax treatment and is not expressly set out in this Appendix I shall be deemed included.

 

7.2. All taxes, including income tax, capital gains tax, national insurance and health tax, arising from the grant, vesting, exercise, sale or release of an Award or Share, or from any other event under the Plan, shall be borne solely by the Participant. The Company, its Affiliates and the Trustee may withhold taxes as required by Applicable Law, including under Rule 7(b) of the Rules, and shall not be required to release any Share or make any payment until all such taxes have been paid or arrangements satisfactory to them have been made. The Participant shall indemnify the Company, its Affiliates and the Trustee against any tax liability, interest or penalty arising from the Participant’s Awards.

 

7.3. Any Award granted to an Israeli Participant who is an office holder or a Controlling Shareholder shall be subject to the approvals required under the Companies Law and the Company’s Compensation Policy.

 

B-15

 

 

APPENDIX II

 

UNITED STATES APPENDIX TO THE MBODY AI LTD. 2026 EQUITY INCENTIVE PLAN

 

1. General

 

1.1. This Appendix II applies to Awards granted to Participants who are citizens or residents of the United States or who are otherwise subject to U.S. federal income tax in respect of an Award (“U.S. Participants”). It forms part of the Plan and shall be read together with it. In the event of a conflict between this Appendix II and the Plan in respect of a U.S. Participant, this Appendix II prevails. Capitalized terms not defined in this Appendix II have the meanings given in the Plan.

 

1.2. This Appendix II is intended to enable the grant of Options that qualify as incentive stock options under Section 422 of the Code (“Incentive Stock Options” or “ISOs”) and Options that do not so qualify (“Non-Qualified Stock Options”), and to ensure that Awards to U.S. Participants are exempt from or comply with Section 409A of the Code.

 

2. Incentive Stock Options

 

2.1. ISOs may be granted only to Employees of the Company or of a Subsidiary that is a “subsidiary corporation” of the Company within the meaning of Section 424(f) of the Code. An Option granted to a U.S. Participant shall be a Non-Qualified Stock Option unless the Award Agreement expressly designates it as an ISO.

 

2.2. The Exercise Price of an ISO shall not be less than 100% of the Fair Market Value of a Share on the Grant Date, or 110% in the case of a Ten Percent Shareholder. The term of an ISO shall not exceed ten years from the Grant Date, or five years in the case of a Ten Percent Shareholder.

 

2.3. To the extent the aggregate Fair Market Value (determined at the Grant Date) of Shares with respect to which ISOs are exercisable for the first time by a U.S. Participant during any calendar year, under all plans of the Company and its parent and subsidiary corporations, exceeds US$100,000, the excess Options (taken in the order granted) shall be treated as Non-Qualified Stock Options.

 

2.4. An ISO shall be exercisable after termination of employment only to the extent, and within the period, permitted by Section 422 of the Code: three months after termination other than for death or Disability (as defined in Section 22(e)(3) of the Code), and twelve months after termination for such Disability. An ISO exercised after those periods shall be treated as a Non-Qualified Stock Option. An approved leave of absence exceeding three months shall be treated as a termination of employment for ISO purposes on the ninety-first day unless re-employment is guaranteed by statute or contract.

 

2.5. A U.S. Participant who disposes of Shares acquired on exercise of an ISO within two years after the Grant Date or one year after the exercise date shall notify the Company in writing within 30 days of the disposition and of the amount realized.

 

2.6. ISOs are not transferable other than by will or the laws of descent and distribution and are exercisable during the Participant’s lifetime only by the Participant. Any adjustment of an ISO under Section 14 of the Plan shall be made in a manner that does not constitute a “modification” under Section 424(h) of the Code unless the Administrator determines otherwise. No Award shall be treated as an ISO if it fails to satisfy the requirements of Section 422 of the Code, and to that extent it shall be a Non-Qualified Stock Option. Neither the Company nor any Director, officer or Affiliate shall have any liability to a Participant if an Option intended to be an ISO does not qualify as such.

 

B-16

 

 

2.7. ISOs may not be granted after the tenth anniversary of the earlier of the Effective Date and the date of shareholder approval of the Plan. The ISO limit in Section 3.2 of the Plan applies.

 

3. Section 409A

 

3.1. Awards to U.S. Participants are intended to be exempt from, or to comply with, Section 409A of the Code, and the Plan and Award Agreements shall be interpreted accordingly. Options and SARs granted to U.S. Participants shall have an Exercise Price not less than Fair Market Value on the Grant Date, determined in a manner consistent with Section 409A, and shall not include any feature for the deferral of compensation other than the deferral of recognition of income until exercise.

 

3.2. RSUs and other Awards that constitute “nonqualified deferred compensation” under Section 409A shall be settled at a time and in a form that complies with Section 409A. If a U.S. Participant is a “specified employee” within the meaning of Section 409A on the date of a “separation from service,” any payment under an Award that is subject to Section 409A and payable on account of the separation from service shall be delayed until the first business day after the six-month anniversary of the separation (or, if earlier, death), to the extent required by Section 409A. A termination of Service shall be a “separation from service” for the purposes of any Award subject to Section 409A. Each installment payment under an Award is a separate payment for the purposes of Section 409A. “Change in Control” shall, for any Award subject to Section 409A whose payment is triggered by it, mean an event that is also a “change in control event” under Treasury Regulation Section 1.409A-3(i)(5).

 

3.3. The Administrator may amend the Plan or any Award, without the Participant’s consent, to the extent necessary to avoid adverse tax consequences under Section 409A. Neither the Company nor any Affiliate makes any representation that Awards are exempt from or comply with Section 409A, and neither shall have any liability to a Participant for any tax, interest or penalty under Section 409A.

 

4. Other U.S. provisions

 

4.1. Section 83(b). A U.S. Participant who receives Restricted Shares may make an election under Section 83(b) of the Code within 30 days after the Grant Date and shall provide a copy of the election to the Company.

 

4.2. Rule 16b-3. Awards to Participants subject to Section 16 of the Exchange Act are intended to satisfy the requirements of Rule 16b-3 under the Exchange Act, and the Administrator may impose such conditions as are necessary to that end.

 

4.3. Securities law. Shares issued to U.S. Participants shall be registered on Form S-8 or issued in reliance on an exemption from registration, and shall be subject to such legends and restrictions as the Company considers necessary. The Company may condition the exercise or settlement of an Award on the effectiveness of a registration statement or the availability of an exemption.

 

4.4. Withholding. The Company or the employing Subsidiary shall withhold federal, state and local taxes and FICA as required by law, and may satisfy withholding by withholding Shares as provided in Section 17.4 of the Plan.

 

4.5. Shareholder approval; amendment. The Administrator may amend this Appendix II without shareholder approval except to the extent shareholder approval is required by Section 422 of the Code, the rules of the Nasdaq Stock Market or Section 18.2 of the Plan.

 

B-17

 

 

APPENDIX III

 

CANADIAN APPENDIX TO THE MBODY AI LTD. 2026 EQUITY INCENTIVE PLAN

 

1. General

 

1.1. This Appendix III applies to Awards granted to Participants who are residents of Canada for the purposes of the Income Tax Act (Canada) (the “Tax Act”) or who are employed in Canada or otherwise subject to Canadian income tax in respect of an Award (“Canadian Participants”). It forms part of the Plan and shall be read together with it. In the event of a conflict between this Appendix III and the Plan in respect of a Canadian Participant, this Appendix III prevails. Capitalized terms not defined in this Appendix III have the meanings given in the Plan.

 

2. Options

 

2.1. The Exercise Price of an Option granted to a Canadian Participant shall not be less than the Fair Market Value of a Share on the Grant Date, determined in a manner consistent with paragraph 110(1)(d) of the Tax Act, and Options shall be granted only in respect of Shares that are “prescribed shares” for the purposes of that paragraph, so that the Participant may be eligible for the deduction under paragraph 110(1)(d) where its conditions are met. The Company makes no representation that the deduction will be available.

 

2.2. Options granted to Canadian Participants shall be settled in Shares on exercise. The Company shall not settle an Option in cash without the Participant’s consent, and, where the Participant elects a cash settlement offered by the Company, the Company or the employing Subsidiary may make the election under subsection 110(1.1) of the Tax Act so that the Participant remains eligible for the deduction under paragraph 110(1)(d). The Administrator shall administer any net exercise or cashless exercise in a manner that does not cause the Option to fail to qualify for paragraph 110(1)(d).

 

3. Restricted Share Units and Performance Awards

 

3.1. RSUs and Performance Awards granted to Canadian Participants are intended to be exempt from the “salary deferral arrangement” rules in the Tax Act by reason of paragraph (k) of the definition of that term in subsection 248(1) of the Tax Act. Accordingly, notwithstanding any other provision of the Plan, each RSU or Performance Award granted to a Canadian Participant shall be settled, in Shares or cash, no later than December 31 of the third calendar year following the calendar year in which the services to which the Award relates were rendered, and the Award Agreement shall specify the year of service to which the Award relates. Any RSU or Performance Award that would otherwise be settled after that date shall be settled on or before it.

 

3.2. RSUs granted to Canadian Participants in respect of services rendered in a prior year (including in lieu of a bonus) shall be structured to comply with Section 3.1, and the Administrator may decline to grant, or may modify, any Award that would not so comply.

 

3.3. Where RSUs are settled in newly issued Shares for no cash consideration, the Company intends the arrangement to be an agreement to issue securities to which Section 7 of the Tax Act applies, and Shares shall be issued from treasury in settlement unless the Administrator determines otherwise.

 

3.4. No Canadian Participant shall be permitted to elect to defer the settlement of an RSU or Performance Award beyond the period in Section 3.1.

 

B-18

 

 

4. Termination of Service

 

4.1. For a Canadian Participant, the date of termination of Service shall be the last day on which the Participant actively provides Service to the Company or a Subsidiary, and shall not be extended by any period of reasonable notice, pay in lieu of notice or severance under contract or common law, except to the extent that applicable employment standards legislation requires a minimum notice period to be treated as continued employment, in which case the termination date shall be the last day of that minimum statutory notice period. A Canadian Participant shall not be entitled to damages or compensation in respect of the loss of any Award, or of any right to vest in or exercise an Award, that results from the termination of Service, except as required by applicable employment standards legislation.

 

5. Securities law

 

5.1. Awards to Canadian Participants, and Shares issued under them, are made in reliance on the exemption from the prospectus requirement in section 2.24 of National Instrument 45-106 Prospectus Exemptions (or any successor provision) for distributions to employees, executive officers, directors and consultants, and participation in the Plan by a Canadian Participant shall be voluntary. Any resale of Shares by a Canadian Participant shall be made through the facilities of the Nasdaq Stock Market or otherwise in compliance with applicable Canadian securities laws, including National Instrument 45-102 Resale of Securities.

 

6. Withholding; currency

 

6.1. The Company or the employing Subsidiary shall withhold and remit income tax, Canada Pension Plan and Employment Insurance amounts and any other amounts required under the Tax Act and provincial legislation in respect of Awards, and may satisfy withholding by the sale of Shares on the Participant’s behalf or the withholding of Shares as provided in Section 17.4 of the Plan, or by requiring payment from the Participant.

 

6.2. Amounts denominated in U.S. dollars shall be converted to Canadian dollars for tax purposes at the rate required by the Tax Act, and the Company shall have no liability for exchange rate fluctuations.

 

7. Other

 

7.1. Where a Canadian Participant is employed in the Province of Quebec, the Participant acknowledges that he or she has requested that the Plan, the Award Agreement and all related documents be drawn up in English.

 

7.2. The Administrator may amend this Appendix III without shareholder approval except as required by Section 18.2 of the Plan or Applicable Law.

 

7.3. Chargeback. Where an Award is granted to a Canadian Participant employed by a Subsidiary, the Company and that Subsidiary may enter into a reimbursement or chargeback agreement under which the Subsidiary bears the cost of the Award, and the Company may require the Subsidiary to make any withholding, remittance or reporting required of the employer under the Tax Act. Nothing in such an agreement confers any right on a Participant.

 

B-19

 

 

Appendix C

 

Form of Indemnification and Exculpation Undertaking

 

MBody AI Ltd. (the “Company”)

 

Date: [__________]

 

To: [Name of Office Holder], Israeli ID / Passport No. [__________] (the “Office Holder”)

 

(A)Sections 258 to 264 of the Israeli Companies Law, 5759-1999 (the “Companies Law”) and Articles 65 to 68 of the Company’s Articles of Association (the “Articles”) permit the Company, subject to the approvals required under the Companies Law, to exculpate its Office Holders in advance from liability for breach of the duty of care, to undertake in advance to indemnify them and to insure their liability.

 

(B)The Compensation Committee and the Board of Directors of the Company (the “Board”) have approved, and the general meeting of shareholders has approved on [__], 2026, the grant of this Undertaking to the Office Holder, and the Board has made the determinations set out in Section 3.2.

 

(C)The Company wishes to induce the Office Holder to serve, and to continue to serve, as an Office Holder of the Company.

 

Accordingly, the Company undertakes to the Office Holder as follows:

 

1.Definitions

 

1.1“Office Holder” has the meaning given in Section 1 of the Companies Law and includes the Office Holder in his or her capacity as an office holder of a Subsidiary or of another entity in which he or she serves at the Company’s request (a “Group Company”), and, to the fullest extent permitted by law and the Articles, in any other capacity in which he or she acts for or at the request of the Company or a Group Company, including as an employee, consultant, agent or authorized signatory.

 

1.2“Subsidiary” means any company controlled, directly or indirectly, by the Company, including MBody AI Corp. and MBody AI Canada Corp.

 

1.3“Securities Law” means the Israeli Securities Law, 5728-1968, and “Administrative Proceeding” means a proceeding under Chapters H3, H4 or I1 of the Securities Law.

 

1.4“Expenses” means reasonable litigation expenses, including attorneys’ fees, expert fees, court costs and other costs reasonably incurred in connection with a proceeding, investigation or Administrative Proceeding.

 

1.5“Event” means any act or omission of the Office Holder in his or her capacity as an Office Holder of the Company, including service at a Group Company, whether before or after the date of this Undertaking, and includes any act or omission of the Office Holder in any office or capacity at MBody AI Corp. or MBody AI Canada Corp., including before the date on which that company became a Subsidiary and, for MBody AI Corp., from September 9, 2025. For any act or omission before that company became a Subsidiary, the Company’s obligations apply only to the extent permitted by the Companies Law and the Articles, are subject to Sections 3 and 5, and are secondary to the indemnity of that company, and Section 7.2 does not apply to them.

 

C-1

 

 

2.Undertaking to Indemnify

 

2.1Subject to the Companies Law and this Undertaking, the Company undertakes to indemnify the Office Holder for any liability or expense imposed on or incurred by him or her in respect of an Event, as follows:

 

(a)a monetary liability imposed on him or her in favor of another person by a judgment, including a settlement or an arbitrator’s award approved by a court, provided that the Event is one of the events listed in the Schedule (Foreseeable Events);

 

(b)reasonable Expenses incurred as a result of an investigation or proceeding conducted against him or her by an authority authorized to conduct an investigation or proceeding, that ended without the filing of an indictment against him or her and without the imposition of a monetary liability in lieu of criminal proceedings, or that ended without the filing of an indictment but with the imposition of a monetary liability in lieu of criminal proceedings for an offense that does not require proof of criminal intent, or in connection with a monetary sanction;

 

(c)reasonable Expenses incurred by him or her or charged to him or her by a court, in a proceeding filed against him or her by the Company, on its behalf or by another person, or in a criminal indictment in which he or she is acquitted, or in a criminal indictment in which he or she is convicted of an offense that does not require proof of criminal intent;

 

(d)a payment to a party injured by a violation, as described in Section 52ND(a)(1)(a) of the Securities Law, and Expenses incurred in connection with an Administrative Proceeding, including reasonable litigation expenses and attorneys’ fees; and

 

(e)any other liability or expense for which an Office Holder may be indemnified under the Companies Law, the Securities Law or any other law, as in effect from time to time, to the extent permitted by the Articles.

 

2.2To the fullest extent permitted by the Companies Law, Expenses under Sections 2.1(b), 2.1(c) and 2.1(d) include Expenses incurred by the Office Holder in connection with: (i) any informal or preliminary inquiry, examination or investigation by a governmental, regulatory or self-regulatory authority, including the U.S. Securities and Exchange Commission, Nasdaq, the Israel Securities Authority and the Ontario Securities Commission; (ii) any subpoena, civil investigative demand, document preservation notice or request for information or testimony; (iii) any notice that an enforcement recommendation is under consideration; and (iv) any internal investigation described in Section 2.3; in each case whether or not the Office Holder is named as a respondent and whether or not a formal proceeding has begun.

 

C-2

 

 

2.3If the Company, a Group Company or a committee of the board of directors of either begins an internal investigation, review or inquiry in which the Office Holder is a subject or is to be interviewed, the Company will, to the fullest extent permitted by the Companies Law: (i) notify the Office Holder in writing before the first interview, and identify the subject matter and the persons who conduct it; (ii) pay for independent counsel of the Office Holder’s choice from that time, whether or not a formal proceeding has begun; (iii) permit that counsel to attend any interview of the Office Holder; and (iv) give the Office Holder not less than ten (10) business days’ written notice before it waives privilege over any communication made by the Office Holder to counsel for the Company or in the investigation. The Company will advance these Expenses under Section 4.

 

2.4If the Office Holder is entitled to indemnification for part, but not all, of a liability or expense, the Company will indemnify the Office Holder for that part.

 

2.5To the extent that a payment under Section 2.2 or 2.3 is not indemnification permitted under Section 260 of the Companies Law, including Expenses incurred by the Office Holder as a witness and not as a person against whom an investigation or proceeding is conducted, the Company will make that payment as a reimbursement of expenses that forms part of the Office Holder’s terms of office, as approved under the Companies Law and subject to the Company’s compensation policy, and Sections 4.2 and 5 apply to it as if it were indemnification.

 

3.Foreseeable Events and Limit

 

3.1The undertaking under Section 2.1(a) is limited to the events listed in the Schedule and to an aggregate amount, for all persons indemnified by the Company under undertakings in this form or otherwise for such liabilities, equal to the greater of (i) US$25,000,000 and (ii) 25% of the Company’s shareholders’ equity, on a consolidated basis, according to the Company’s most recent consolidated financial statements available before the date of payment (the “Limit”).

 

3.2The Board has determined that the events listed in the Schedule are foreseeable in light of the Company’s actual activities at the time of the grant of this Undertaking, and that the Limit is reasonable in the circumstances, having regard to the nature and scale of the Company’s activities, the risks to which Office Holders are exposed and the limits of the Company’s directors’ and officers’ liability insurance, as required under Section 260(b) of the Companies Law.

 

3.3The Limit is in addition to, and is not reduced by, amounts paid under any insurance policy or by a Subsidiary under its own indemnity. The Limit does not apply to the liabilities and expenses under Sections 2.1(b) to 2.1(e) (to the extent permitted by law), to Expenses under Sections 2.2 and 2.3, to the advancement of Expenses under Section 4 or to the insurance covenant under Section 6.

 

3.4If the aggregate amounts claimed by indemnified persons under Section 2.1(a) exceed the remaining Limit, the remaining Limit will be allocated among them pro rata to the amounts for which each is entitled to indemnification, determined at the time of payment.

 

3.5The Company will notify the Office Holder in writing, within ten (10) business days, of any payment, commitment, security or guarantee that reduces the Limit. The notice will state the amount and the balance that remains. The Company will also confirm the balance that remains each year and on the Office Holder’s request.

 

C-3

 

 

3.6The Company will not agree with any other indemnified person to an allocation, priority or ranking of the Limit that departs from Section 3.4. If the balance that remains is, or is likely to be, less than the Office Holder’s claim, the Company will promptly and in good faith put to its authorized organs a proposal to increase the Limit.

 

3.7If indemnification in advance is not available for a liability or expense, including because the event is not listed in the Schedule or because the Limit is reached, the Company will promptly and in good faith put to its authorized organs a proposal to indemnify the Office Holder retroactively, as the Companies Law and the Articles permit, and will notify the Office Holder in writing of the outcome.

 

4.Advancement of Expenses

 

4.1The Company will advance Expenses as they are incurred, within 20 days after receipt of a written request accompanied by reasonable supporting documentation, and, at the Office Holder’s election, will pay counsel directly.

 

4.2The Office Holder undertakes to repay any amount advanced to which he or she is ultimately determined not to be entitled under this Undertaking or the Companies Law, without linkage or interest except as required by law.

 

4.3As part of the advancement of Expenses, the Company will provide any security or guarantee that the Office Holder is required to post under an interim decision of a court or arbitrator, including to replace a lien on the Office Holder’s assets. The Company will not require the Office Holder to pledge, encumber or exhaust his or her own assets first. A security or guarantee given for a liability under Section 2.1(a) is subject to the Schedule, counts against the Limit while it is outstanding, and stops counting when it is released without being applied.

 

5.Exclusions

 

5.1The Company will not indemnify, exculpate or insure the Office Holder for any of the following:

 

(a)a breach of the duty of loyalty, except, with respect to indemnification and insurance, to the extent that the Office Holder acted in good faith and had reasonable grounds to assume that the act would not harm the Company;

 

(b)a breach of the duty of care committed intentionally or recklessly, other than a breach committed solely negligently;

 

(c)an act committed with the intent to derive an unlawful personal benefit; or

 

(d)a fine, monetary sanction, civil fine or ransom imposed on the Office Holder, or a payment under Section 52ND(a)(1)(a) of the Securities Law or an expense in an Administrative Proceeding, except as permitted under Section 2.1(d).

 

C-4

 

 

6.Insurance

 

6.1The Company undertakes to maintain directors’ and officers’ liability insurance covering the Office Holder, on terms no less favorable than those that apply to any other office holder of the Company, throughout his or her service and for six (6) years thereafter, including run-off cover in the event of a change of control of the Company, on terms consistent with the Company’s compensation policy in effect from time to time.

 

6.2The Company will provide the Office Holder with a copy of the policy each year on request and will give the Office Holder not less than thirty (30) days’ prior written notice of any cancellation, non-renewal or material reduction of cover, and prompt written notice of any exhaustion or material erosion of limits.

 

6.3Indemnification under this Undertaking is in addition to insurance. The Company will not require the Office Holder to claim under, pursue or exhaust any insurance policy before the Company performs this Undertaking. To the extent the Company pays an amount that an insurer is liable to pay, the Company will be subrogated to the Office Holder’s rights against that insurer, except under Side A cover in favor of the Office Holder.

 

6.4The insurance will include Side A difference-in-conditions cover that responds directly to the Office Holder where the Company does not or cannot indemnify, and will have a prior-acts retroactive date no later than September 9, 2025.

 

6.5The Company will notify each relevant insurer of any claim, and of any circumstance that may give rise to a claim, in the manner and within the time that the policy requires. The Company will not, by act or omission, prejudice the cover available to the Office Holder. The Office Holder may give notice directly to an insurer, and the Company will provide the policy details and reasonable assistance for that purpose.

 

7.Group Co-ordination

 

7.1Where the Office Holder is also party to an indemnification agreement with MBody AI Corp., MBody AI Canada Corp. or another Group Company, the indemnity of the company in whose service the relevant Event occurred is primary.

 

7.2The Office Holder may claim under any of those indemnities first and is not required to exhaust another indemnity or any insurance before the Company performs this Undertaking but may not recover more than once for the same liability or expense. To the extent the Company pays an amount for which another Group Company is primarily liable, the Company will be subrogated to the Office Holder’s rights against that Group Company.

 

8.Exculpation

 

8.1Subject to the Companies Law, the Company exculpates the Office Holder in advance from any liability to the Company for damage caused by a breach of his or her duty of care toward the Company, other than a breach of the duty of care in connection with a distribution (as defined in the Companies Law) and other than as set out in Section 5.

 

C-5

 

 

9.Procedure

 

9.1The Office Holder will notify the Company promptly in writing of any legal proceeding that may give rise to indemnification and will provide the Company with all documents reasonably requested. Failure to notify will not release the Company except to the extent the Company is materially prejudiced.

 

9.2The Company may assume the defense with counsel reasonably acceptable to the Office Holder, unless there is a conflict of interest between them. The Company will not settle a proceeding in a manner that imposes liability on the Office Holder that is not fully indemnified, or that involves an admission of liability, without his or her consent, which he or she may withhold in his or her absolute discretion. The Company will give the Office Holder the proposed terms of any settlement not less than five (5) business days before it agrees to them. The Office Holder will not settle a proceeding for which indemnification is sought without the Company’s consent, not to be unreasonably withheld.

 

10.Entitlement and Enforcement

 

10.1The Company will pay any amount due under Section 2 within thirty (30) days after it receives a written request with reasonable supporting documentation. Section 4 governs the time for advances.

 

10.2When the Office Holder submits a written request for indemnification or for an advance, with reasonable supporting documentation, the Office Holder is presumed to be entitled to it. The Company carries the burden to prove otherwise. A failure by the Company to make a determination, or a determination by the Company that the Office Holder did not meet a standard of conduct, is not a defense to a claim by the Office Holder and creates no presumption against the Office Holder.

 

10.3Only the following may determine that the Office Holder is not entitled to indemnification or to an advance: (i) a court of competent jurisdiction; or (ii) independent legal counsel of recognized standing that neither the Company nor the Office Holder has retained in the preceding five (5) years. The Company and the Office Holder will select that counsel by agreement. If they do not agree within ten (10) days, the chairman of the Israel Bar Association will select that counsel. That counsel will give a written, reasoned opinion at the Company’s expense. If no determination is made within sixty (60) days after the Office Holder’s written request, the Office Holder’s entitlement is deemed established to the fullest extent permitted by law, and the Company will pay the amount requested within seven (7) days thereafter. Nothing in this Section 10 requires or permits the Company to pay an amount excluded under Section 5 or in excess of the Limit, and any amount paid under this Section 10 remains subject to Section 4.2.

 

10.4If the Company does not pay an amount due under this Undertaking on time, the Office Holder may bring proceedings to enforce this Undertaking. To the extent permitted by the Companies Law, the Company will indemnify the Office Holder for all reasonable Expenses of those proceedings if the Office Holder prevails in whole or in part.

 

C-6

 

 

10.5An amount that the Company does not pay when due bears interest and linkage differentials, as defined in the Adjudication of Interest and Linkage Law, 5721-1961, from the due date until payment.

 

11.General

 

11.1This Undertaking will be construed in accordance with the Companies Law. If any applicable law is amended to permit broader indemnification, exculpation or insurance, this Undertaking will be read to include it to the extent permitted by the Articles and approved as required by the Companies Law.

 

11.2The Company’s obligations continue after the Office Holder ceases to serve, irrespective of the manner in which he or she ceases to serve, including resignation, removal, expiry of term or termination for any reason, with respect to Events occurring during his or her service and bind the Company’s successors. The Company will require any successor, whether by merger, consolidation, reorganization, domestication, conversion, continuance, transfer of all or substantially all of its assets or otherwise, to assume this Undertaking expressly and in writing, on terms no less favorable to the Office Holder, at or before the effective time of that transaction. If the successor is not subject to the Companies Law, the successor will give its undertaking to the fullest extent permitted by the law of its jurisdiction. To the fullest extent permitted by the Companies Law, this Undertaking benefits the Office Holder’s estate, heirs, executors, administrators and personal representatives, and the Office Holder’s spouse or domestic partner where a claim is made against that person because of his or her relationship to the Office Holder. The death, incapacity or insolvency of the Office Holder does not end or impair the Company’s obligations.

 

11.3This Undertaking does not limit any other right of the Office Holder to indemnification or insurance. It replaces any prior indemnification agreement or undertaking between the Company (formerly Check-Cap Ltd.) and the Office Holder with respect to Events occurring after its date, without derogating from rights under any prior agreement in respect of earlier Events.

 

11.4This Undertaking is governed by the laws of the State of Israel, and the competent courts in Tel Aviv-Jaffa have jurisdiction over any dispute arising from it; that jurisdiction is exclusive for proceedings brought by the Company and non-exclusive for proceedings brought by the Office Holder.

 

11.5The Company may not amend or revoke this Undertaking to the detriment of the Office Holder without his or her written consent, except with respect to Events occurring after notice of the amendment or revocation, and subject to the approvals required by law.

 

11.6Each provision of this Undertaking is separate. If a provision is held invalid or unenforceable, the other provisions remain in effect. If a provision is held to exceed what the Companies Law permits, it will be read to give it the fullest effect that the Companies Law permits.

 

C-7

 

 

11.7A release, waiver or settlement that the Office Holder gives to the Company or a Group Company, in connection with the end of his or her employment or office or with any dispute, does not affect the Office Holder’s rights under this Undertaking unless it refers expressly to this Undertaking. A general release is deemed to exclude those rights.

 

MBody AI Ltd.  
     
By:        
Name:  [Name]  
Title: [Title]  
Date:    
     
Acknowledged and agreed:  
     
By:    
Name: [Name of Office Holder]  
Title:    
Date:    

 

C-8

 

 

Schedule: Foreseeable Events

 

The following events are the events that the Board has determined to be foreseeable in light of the Company’s actual activities for purposes of Section 2.1(a):

 

1.Offering, issuance, sale or purchase of securities of the Company, including public offerings, private placements, at-the-market programs, warrants and equity awards, and any disclosure, prospectus, registration statement or offering document relating to them.

 

2.Reporting and disclosure obligations under the Israeli Securities Law, the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, Nasdaq rules and other applicable securities laws, including periodic and current reports and proxy materials.

 

3.Mergers, acquisitions, business combinations, reorganizations, dispositions and joint ventures, including the business combination with MBody AI Corp. completed on August 26, 2026, and any change in control of the Company.

 

4.Decisions regarding distributions, dividends, share repurchases and capital structure.

 

5.Approval of financial statements, accounting policies and internal controls, and tax matters, including tax reporting and withholding.

 

6.Employment matters, including hiring, termination, compensation, benefits, labor relations, discrimination and harassment claims.

 

7.Research, development, regulatory approvals, product liability, product recalls and clinical or field trials, and compliance with health, safety and consumer protection laws.

 

8.Intellectual property, including infringement, licensing, ownership and protection of intellectual property rights.

 

9.Privacy, data protection, cybersecurity and information technology systems, including artificial intelligence products and the processing of personal data.

 

10.Contracts and transactions with customers, suppliers, distributors, lenders and other third parties, including transactions with controlling shareholders and office holders.

 

11.Competition and antitrust law, anti-bribery and anti-corruption laws, export controls and sanctions.

 

12.Environmental matters.

 

13.Financing transactions, including loans, credit facilities, guarantees and security interests.

 

14.Insolvency, liquidation, creditor arrangements and related proceedings.

 

15.Actions taken in connection with litigation, arbitration and regulatory investigations, including derivative and class actions.

 

16.Research, development, training, validation, testing, deployment, marketing, sale, licensing, leasing, servicing or use of software, artificial intelligence or machine learning systems, robots and any product or service that incorporates them, including claims that relate to their performance, safety, accuracy or bias.

 

C-9

 

 

17.Operation of autonomous or semi-autonomous machines near persons, including claims for personal injury, bodily injury or damage to property, and occupational or workplace safety proceedings.

 

18.Storage, charging, transportation, disposal or failure of batteries or energy-storage components, including hazardous-materials transport rules, fire and building codes, recalls and field actions.

 

19.Importation, exportation, distribution, deployment or operation of any robot, device, product or component, including equipment authorization, certification, registration, labelling or spectrum compliance under the rules of the U.S. Federal Communications Commission, Innovation, Science and Economic Development Canada or any other communications regulator, and restrictions that relate to equipment or vendors on a covered or restricted list.

 

20.Customs, tariff, duty or import matters, including classification, valuation, country of origin, duty rates, trade-remedy tariffs, antidumping and countervailing duties, forced-labor import prohibitions, importer-of-record obligations, customs audits, detentions, seizures and penalty proceedings.

 

21.Reviews, restrictions or proceedings by a governmental authority that concern connected equipment, software or components of foreign origin or foreign-affiliated vendors, including supply-chain reviews and procurement or deployment restrictions, and related obligations of the Company to customers.

 

22.Collection, recording, processing, storage, transmission or retention of images, video, audio, biometric information, geolocation data, facility maps or telemetry at or from customer or third-party premises, and surveillance, wiretap, biometric-privacy, employee-monitoring or consumer-privacy laws.

 

23.Advertising, marketing or performance claims about a product or service, and claims by or for employees or labor organizations of a customer or third party that arise from the deployment of automation at their facilities.

 

24.Preparation, filing, effectiveness or amendment of a registration statement or prospectus filed with the U.S. Securities and Exchange Commission or another securities authority, including on Form F-1, F-3, F-4 or S-8, and liability under Sections 11, 12 or 15 of the U.S. Securities Act of 1933.

 

25.Restatement, correction, revision, withdrawal or reissuance of the Company’s financial statements, and proceedings under Section 304 of the Sarbanes-Oxley Act of 2002 or Rule 10D-1 under the U.S. Securities Exchange Act of 1934, other than any repayment, forfeiture or recovery of compensation, which the Company will not indemnify.

 

26.Compliance with the continued listing requirements of Nasdaq or another securities exchange, including deficiency notices, hearings, appeals, reverse or forward share splits, suspension and delisting.

 

27.Negotiation, approval, financing, disclosure, completion and integration of the business combination with MBody AI Corp. and of any transaction between or among the Company, MBody AI Corp., MBody AI Canada Corp. or their securityholders, and claims that such a transaction was approved, disclosed or valued improperly.

 

C-10

 

 

28.Inquiries, examinations, investigations or proceedings, formal or informal, by the U.S. Securities and Exchange Commission, the Israel Securities Authority, the Ontario Securities Commission, Nasdaq, the Public Company Accounting Oversight Board, FINRA, a tax authority or another governmental, regulatory or self-regulatory authority, and internal investigations by or for the Company, a Group Company or a board committee.

 

29.Redomestication, domestication, conversion, continuance or change of jurisdiction of the Company or a Group Company, and related shareholder approval, disclosure, tax, accounting or regulatory matters.

 

30.Any of the above events in connection with service at a Group Company.

 

C-11

 

 

APPENDIX D

 

AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF MBODY AI LTD. (FORMERLY CHECK-CAP LTD.)

 

SCHEDULE OF AMENDMENTS

 

This Appendix D sets out the amendments to the Articles of Association of the Company (the “Articles”) proposed for approval at the Annual General Meeting of Shareholders of the Company to be held on December 22, 2026 (the “Meeting”). Each Part is the subject of a separate resolution, as described in Part E. References to Articles are to the Articles as in effect on the date of the Proxy Statement. Capitalized terms used and not otherwise defined in this Appendix D have the meanings given to them in the Articles.

 

PART A - COMPANY NAME [Proposal 7]

 

1.Regularization. The Articles continue to refer to the Company’s former name, Check-Cap Ltd., which was changed to MBody AI Ltd. by a resolution of the shareholders adopted on October 17, 2025, and the Articles on file with the Registrar of Companies were not amended at that time, although the Registrar of Companies registered the change of name with effect from August 27, 2026. With effect from the adoption of the resolution approving this Part A, the Articles are amended as follows:

 

(a)the heading of the Articles, “ARTICLES OF ASSOCIATION OF CHECK-CAP LTD.”, is replaced with “ARTICLES OF ASSOCIATION OF MBODY AI LTD.”;

 

(b)in Article 1(a), the definition of “Company” is replaced with the following: “”Company” shall mean MBody AI Ltd. אמבודי איי אי בע”מ.”; and

 

(c)in the form of proxy in Article 34(a), “CHECK-CAP LTD.” is replaced with “MBODY AI LTD.”.

 

2.

Change of Name. If the Board of Directors determines, at any time within 24 months after the date of the Meeting, to change the name of the Company, then, with effect from the registration of the change of name by the Registrar of Companies in accordance with Section 40 of the Companies Law, each reference in the Articles to “MBody AI Ltd.” or “MBODY AI LTD.” shall be replaced with “MBody SI Ltd.” or “MBODY SI LTD.”, respectively, and the reference in Article 1(a) to “אמבודי איי אי בע”מ” shall be replaced with “אמבודי אס אי בע”מ”, or in each case with such similar name as the Registrar of Companies approves. If the Board of Directors does not so determine within that period, this paragraph 2 shall lapse and the Articles shall continue to bear the name of the Company as amended by paragraph 1.

 

D-1

 

 

PART B - RE-DESIGNATION OF THE ORDINARY SHARES AS SHARES OF NO PAR VALUE [Proposal 1]

 

With effect from the adoption of the resolution approving this Part B, the entire authorized share capital of the Company, issued and unissued, consisting of 18,000,000 Ordinary Shares of nominal value NIS 48.00 each, is re-designated as 18,000,000 Ordinary Shares of no par value, and the Articles are amended as follows:

 

1.Article 2 is replaced in its entirety with the following: “2. The Company is a limited liability company, and each Shareholder’s obligations to the Company shall therefore be limited to the payment of the amount, if any, that remains unpaid on the issue price of the shares held by such Shareholder in accordance with the terms of issuance of such shares, subject to the provisions of the Companies Law. No Shareholder shall be liable to the Company for any amount in respect of the nominal value that applied to any share before the re-designation of the Company’s shares as shares of no par value, to the extent that such nominal value exceeded the price at which such share was issued.”

 

2.Article 6(a) is replaced with the following: “(a) The share capital of the Company shall consist of 18,000,000 Ordinary Shares of no par value (referred to in this Article 6 as the “Shares” and elsewhere throughout these Articles as “shares”).”

 

3.In Article 6(b)(ii), “according to the proportionate nominal value of the Shares held thereby” is replaced with “pro rata to the number of Shares held thereby”, and in Article 6(b)(iii), “in accordance with the proportionate nominal value of the Shares held thereby” is replaced with “pro rata to the number of Shares held thereby”.

 

4.In Article 7(a), the second sentence is replaced with the following: “Any such increase shall be of such number of shares, which shall be shares of no par value unless such resolution provides otherwise, and such shares shall confer such rights and preferences, and shall be subject to such restrictions, as such resolution shall provide.”

 

5.Article 9(a)(i) and (ii) are replaced with the following: “(i) consolidate all or any part of its issued or unissued authorized share capital into a smaller number of shares; (ii) divide or sub-divide its shares (issued or unissued), or any of them, into a larger number of shares (subject, however, to the provisions of the Companies Law), and the resolution whereby any share is divided may determine that, as among the holders of the shares resulting from such subdivision, one or more of the shares may, in contrast to others, have any such preferred or deferred rights or rights of redemption or other special rights, or be subject to any such restrictions, as the Company may attach to unissued or new shares;”

 

D-2

 

 

6.Article 9(b)(i) is replaced with the following: “(i) determine, as to the holders of shares so consolidated, which issued shares shall be consolidated into each share;”

 

7.Article 9(b)(v) is replaced with the following: “(v) to the extent permitted by applicable law, cause the fractional shares of the Shareholders entitled thereto to be aggregated and sold, by the Company’s transfer agent or by any other person designated by the Board of Directors, to any person, whether or not a Shareholder, on any securities exchange on which the shares are then listed or otherwise, and cause the net proceeds of such sale to be distributed among such Shareholders pro rata to their respective fractional entitlements, or cause the transfer of fractional shares by certain Shareholders to other Shareholders or to any other person so as most expediently to preclude or remove any fractional shareholdings, and cause the transferees of such fractional shares to pay the transferors thereof the fair value thereof, and the Board of Directors is hereby authorized to act, and to authorize the Company’s transfer agent to act, as agent for the holders, transferors and transferees of any such fractional shares, with full power of substitution, for the purposes of implementing the provisions of this sub-Article 9(b)(v).”

 

8.In Article 12(a), “either at par or at a premium, or subject to the provisions of the Companies Law, at a discount and/or with payment of commission” is replaced with “at such price as the Board of Directors deems fit (including, in the case of shares having a nominal value, at par, at a premium or, subject to the provisions of the Companies Law, at a discount) and/or with payment of commission”, and “either at par or at a premium, or, subject as aforesaid, at a discount and/or with payment of commission” is replaced with “at such price as aforesaid and/or with payment of commission”.

 

9.In Article 14(c), “(whether on account of such nominal value of such share or by way of premium)” is replaced with “(whether on account of the issue price of such share or otherwise)”.

 

10.In Article 53(b), “in respect of the nominal value of such shares” is replaced with “in respect of the issue price of such shares”.

 

11.In Article 55, “either at par or at such premium as the resolution may provide” is replaced with “at such price as the resolution may provide”.

 

12.In Article 69, “in proportion to the nominal value of their respective holdings of the shares in respect of which such distribution is being made” is replaced with “pro rata to the number of shares held by them in respect of which such distribution is being made”.

 

D-3

 

 

PART C - INCREASE IN AUTHORIZED SHARE CAPITAL [Proposal 2]

 

Subject to and conditional upon Part B becoming effective, and with effect from the later of the adoption of the resolution approving this Part C and the effectiveness of Part B, the authorized share capital of the Company is increased from 18,000,000 Ordinary Shares of no par value to 175,000,000 Ordinary Shares of no par value, by the creation of 157,000,000 additional Ordinary Shares of no par value ranking pari passu in all respects with the existing Ordinary Shares, and Article 6(a), as amended by Part B, is replaced with the following:

 

“(a) The share capital of the Company shall consist of 175,000,000 Ordinary Shares of no par value (referred to in this Article 6 as the “Shares” and elsewhere throughout these Articles as “shares”).”

 

PART D - NEW ARTICLE 42A: EXTERNAL DIRECTORS [Proposal 6]

 

The following new Article 42A is inserted immediately after Article 42:

 

“42A. EXTERNAL DIRECTORS - (a) The powers of the Board of Directors and of the continuing Directors under Article 42 to appoint Directors, including to fill a vacancy and where the number of Directors in office is less than the minimum number provided for in Article 39, do not include the power to appoint an External Director. External Directors shall be elected only by the General Meeting in accordance with Section 239 of the Companies Law. (b) If the office of an External Director becomes vacant and two other External Directors are not then serving, the Board of Directors (or the continuing Directors) shall convene a Special General Meeting, at the earliest practicable date, the agenda of which shall include the election of an External Director in accordance with the Companies Law.”

 

PART E - EFFECTIVENESS AND FILING

 

1.Each of Parts A, B, C and D is the subject of a separate resolution. Except as provided in Part C, the approval and effectiveness of each Part is not conditional upon the approval of any other Part.

 

2.Paragraph 1 of Part A, Part B and Part D take effect upon the adoption of the resolutions approving them. Part C takes effect upon the later of the adoption of the resolution approving it and the effectiveness of Part B. Paragraph 2 of Part A takes effect, if at all, as provided in that paragraph.

 

3.The Company shall deliver the text of each resolution amending the Articles to the Registrar of Companies within fourteen (14) days after its adoption, in accordance with Section 21(b) of the Companies Law, and shall file the change of name, if any, for registration under Section 40 of the Companies Law. The Board of Directors, and any officer of the Company designated by it, is authorized to take all actions necessary to give effect to the amendments in this Appendix D, including the filing of a restated version of the Articles reflecting the amendments then in effect.

 

4.Except as amended by this Appendix D, the Articles remain in full force and effect.

 

D-4

Exhibit 99.3

 

MBODY AI LTD.

PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS

 

To be held on December 22, 2026 in two sessions: the first at 10:00 a.m., Eastern Time for Items 4, 3, 3A, 6, 7, 1 and 2, and the second, to which the first session will be adjourned, at 2:00 p.m., Eastern Time on the same day for Items 5, 8 and 9, each to be held as a virtual meeting by live audio webcast at https://edge.media-server.com/mmc/p/im8ebjko (password: mbodyai2026)

 

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

 

The undersigned shareholder of MBody AI Ltd. (the “Company”) hereby appoints Sean Donahue and Carl Sherer (neither of whom is an office holder of the Company or has a personal interest in any Proposal), and each of them, with full power of substitution, as proxies for the undersigned, to attend the Annual General Meeting of Shareholders of the Company, to be held as a virtual meeting, to be held on December 22, 2026 in two sessions (together, the “Meeting”), and any further adjournment or postponement of it, including to vote in favor of the adjournment of the first session to the second session on the same day, and to vote all Ordinary Shares, nominal value NIS 48.00 per share (or, following the effectiveness of Item 1, of no par value), of the Company that the undersigned is entitled to vote, as directed on this card, and, to the extent permitted by applicable law, in their discretion on such other matters as may properly come before the Meeting.

 

This proxy, when properly executed and returned, will be voted in the manner directed. If no direction is given for a Proposal, this proxy will be voted FOR that Proposal, subject to the personal interest confirmation below. This proxy is valid for both sessions of the Meeting. A proxy may be changed or revoked only until the proxy deadline stated below, which applies to both sessions, except that a shareholder of record may attend the virtual Meeting and vote online. Proxies must be received by the Company’s transfer agent, Equiniti Trust Company, LLC, Attn: Proxy Department, 1110 Centre Pointe Curve, Suite 101, Mendota Heights, MN 55120-4100, no later than December 20, 2026 at 10:00 a.m. Eastern Time. Shareholders holding through a bank, broker or other nominee should follow the voting instructions provided by that nominee.

 

The Board of Directors recommends a vote FOR each of the Proposals below.

 

PROPOSAL   FOR   AGAINST   ABSTAIN
             
FIRST SESSION 10:00 a.m. ET: Items 4, 3, 3A, 6, 7, 1 and 2            
             
4. Auditor            
4. To appoint SIMON & EDWARD, LLP, the successor by merger to BCRG LLP, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 and until the next annual general meeting of shareholders, and to authorize the Board of Directors, upon the recommendation of the Audit Committee, to fix its compensation.   ☐   ☐   ☐
             
3. Election of directors            
             
3(a). To elect Regan McGee as a director of the Company, to serve until the next annual general meeting of shareholders, unless his office is vacated earlier in accordance with the Articles of Association or the Companies Law.   ☐   ☐   ☐
             
3(b). To elect John Fowler as a director of the Company, to serve until the next annual general meeting of shareholders, unless his office is vacated earlier in accordance with the Articles of Association or the Companies Law.   ☐   ☐   ☐
             
3(c). To elect David Lontini as a director of the Company, to serve until the next annual general meeting of shareholders, unless his office is vacated earlier in accordance with the Articles of Association or the Companies Law.   ☐   ☐   ☐
             
3A. Election of external directors            
             

3A(a). To elect Fiona George as an external director of the Company for a three-year term commencing on the date of the Meeting, in accordance with the Israeli Companies Law, 5759-1999.

Special majority. See the personal interest confirmation below.

  ☐   ☐   ☐
             

3A(b). Subject to and conditional upon the election of Fiona George under Item 3A(a), to elect Daniel Kokiw as an external director of the Company for a three-year term commencing on the date of the Meeting, in accordance with the Israeli Companies Law, 5759-1999.

 Special majority. See the personal interest confirmation below.

  ☐   ☐   ☐

 

 

 

 

PROPOSAL   FOR   AGAINST   ABSTAIN
             
6. Articles of Association: external directors not appointed by the Board (new Article 42A)            
             
6. To approve the adoption of a new Article 42A of the Articles of Association, in the form set out in Part D of Appendix D to the Proxy Statement, confirming that the powers of the Board and of the continuing directors under Article 42 to appoint directors do not include the power to appoint external directors, who may be elected only by the General Meeting in accordance with Section 239 of the Companies Law, and providing that if the office of an external director becomes vacant the Board will convene a General Meeting to elect an external director in accordance with the Companies Law.   ☐   ☐   ☐
             
7. Change of the Company’s name (optional authority to the Board)            
             
7. To authorize the Board of Directors, in its discretion and at any time within 24 months after the date of the Meeting, to change the name of the Company from “MBody AI Ltd.” to “MBody SI Ltd.”, or to such similar name as the Registrar of Companies may approve, and to approve the corresponding amendment of the Articles of Association of the Company, in the form set out in Part A of Appendix D to the Proxy Statement, effective upon the determination of the Board of Directors and the approval of the Registrar of Companies, all as described in the Proxy Statement.   ☐   ☐   ☐
             
1. Re-designation of the Ordinary Shares as no par value shares            
1. To approve the amendment of the Company’s Articles of Association so that all authorized and issued Ordinary Shares of the Company, currently of nominal value NIS 48.00 each, are re-designated as Ordinary Shares of no par value, such that the authorized share capital of the Company shall consist of 18,000,000 Ordinary Shares of no par value, together with conforming amendments to Articles 2, 6, 7, 9, 12, 14, 53, 55 and 69 of the Articles of Association, in each case in the form set out in Part B of Appendix D to the Proxy Statement, and to confirm that the Company shall not seek payment of any unpaid nominal value from any holder of Ordinary Shares issued before the effective time of the amendment at a price per share below NIS 48.00, all as described in the Proxy Statement.   ☐   ☐   ☐
             
2. Increase of the authorized share capital            
             
2. Subject to and conditional upon Proposal 1 becoming effective, to approve the increase of the authorized share capital of the Company from 18,000,000 Ordinary Shares of no par value to 175,000,000 Ordinary Shares of no par value, by the creation of 157,000,000 additional Ordinary Shares of no par value ranking pari passu in all respects with the existing Ordinary Shares, and the corresponding amendment of the Articles of Association in the form set out in Part C of Appendix D to the Proxy Statement, as described in the Proxy Statement.   ☐   ☐   ☐

 

 

 

 

SECOND SESSION (RECONVENED) 2:00 p.m. ET: Items 5, 8 and 9            
             
PROPOSAL   FOR   AGAINST   ABSTAIN
             
5. Equity incentive plan            
             
5. To approve the MBody AI Ltd. 2026 Equity Incentive Plan, including its Israeli, United States and Canadian appendices, in the form attached as Appendix B to the Proxy Statement, with a reserve of 1,841,517 Ordinary Shares, and to acknowledge that the Check-Cap Ltd. 2015 Equity Incentive Plan expired by its terms on June 23, 2025, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to it, including those given between the two sessions of the Meeting.   ☐   ☐   ☐
             
8. Compensation policy            
             

8. To approve the amended and restated Compensation Policy for Executive Officers and Directors of the Company, including the amended compensation caps and ratios, in the form attached as Appendix A to the Proxy Statement, for a period of three years from the date of the Meeting, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to it, including those given between the two sessions of the Meeting.

Special majority. See the personal interest confirmation below.

  ☐   ☐   ☐
             
9. Office holder compensation            
             

9(a). To approve the terms of office and engagement of John Fowler as Chief Executive Officer of the Company, as described in the Proxy Statement, including the guarantee by the Company of the obligations of MBody AI Corp. to Mr. Fowler under his employment agreement, the indemnification and exculpation undertaking in the form attached as Appendix C to the Proxy Statement and the amended and restated indemnification agreement between MBody AI Corp. and Mr. Fowler, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to them, including those given between the two sessions of the Meeting.

Special majority. See the personal interest confirmation below.

  ☐   ☐   ☐
             

9(b). To approve the compensation of the non-employee directors of the Company, other than the external directors and any director who is a controlling shareholder of the Company, as described in the Proxy Statement, with the equity component subject to and conditional upon the approval of Proposal 5, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to it, including those given between the two sessions of the Meeting.

Special majority. See the personal interest confirmation below.

  ☐   ☐   ☐
             

9(c). Subject to and conditional upon the approval of Proposal 9(b), to approve, in accordance with Regulation 5(f) of the Companies Regulations (Reliefs for Companies with Securities Listed on an Exchange Outside of Israel), 5760-2000, and Regulations 8A and 8B of the Companies Regulations (Rules Regarding Compensation and Expenses of External Directors), 5760-2000, the compensation of the external directors of the Company, consisting of annual cash compensation of US$40,000 and an annual equity award with a grant date value of US$60,000, together with reimbursement of expenses, with the equity award identical to and on the same terms as the equity awards to the other directors of the Company and subject to and conditional upon the approval of Proposal 5, all as described in the Proxy Statement.

Special majority. See the personal interest confirmation below.

  ☐   ☐   ☐

 

 

 

 

PROPOSAL   FOR   AGAINST   ABSTAIN
             

9(d). To approve the grant of indemnification and exculpation undertakings to the directors of the Company, in the form attached as Appendix C to the Proxy Statement, to each director of the Company serving from time to time, including each director and external director elected at the Meeting, other than the Chief Executive Officer, whose undertaking is approved under Proposal 9(a), and any director who is a controlling shareholder of the Company, and to approve, to the extent required, the approvals of the Compensation Committee and the Board of Directors relating to them, including those given between the two sessions of the Meeting.

Special majority. See the personal interest confirmation below.

  ☐   ☐   ☐

 

In addition, the audited consolidated financial statements of the Company for the year ended December 31, 2025, as included in the Company’s Annual Report on Form 20-F for that year, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 27, 2026, under the Company’s former name, Check-Cap Ltd. (the “2025 Annual Report”), will be presented and discussed at the first session of the Meeting. The 2025 Annual Report is available on the SEC’s website at www.sec.gov and on the Company’s website at ir.mbody.ai. It is not part of the proxy solicitation material. No vote is required on this item.

 

PERSONAL INTEREST AND CONTROLLING SHAREHOLDER CONFIRMATION

 

Items 3A(a), 3A(b), 8, 9(a), 9(b), 9(c) and 9(d) require a special majority under the Companies Law. In counting that majority, the votes of a “controlling shareholder” of the Company and of any shareholder having a “personal interest” in the approval of the relevant Proposal (in the case of Items 3A(a), 3A(b) and 9(c), only a personal interest arising from a relationship with the controlling shareholder), each as defined in the Companies Law and explained in the Proxy Statement, are excluded from the second count. The second count is the separate count of votes of shareholders who are not controlling shareholders and do not have a personal interest; it does not refer to the second session of the Meeting.

 

By signing and returning this proxy card, or by voting online, you confirm that you are NOT a controlling shareholder of the Company and do NOT have a personal interest in the approval of any of those Items, unless you have delivered to the Company a notice in writing stating otherwise, no later than December 20, 2026 at 10:00 a.m. Eastern Time, to the attention of the Company’s Chief Financial Officer, Tim Hayden, at 7111 Syntex Drive, 3rd Floor, Mississauga, Ontario, Canada or by e-mail to ir@mbody.ai, or you check the box below and specify the Item(s) concerned. Your confirmation that you do not have a personal interest is given in accordance with Regulation 3A of the Israeli Companies Regulations (Reliefs for Companies with Securities Listed on an Exchange Outside of Israel), 5760-2000. If you hold your shares in “street name” (through a bank, broker or other nominee) and believe that you are a controlling shareholder or have a personal interest in any of those Items, you may also contact the representative managing your account, who can contact the Company’s Chief Financial Officer on your behalf.

 

☐ Check this box ONLY if you are a controlling shareholder of the Company or have a personal interest in the approval of one or more of the Proposals listed above and specify the Proposal(s): ______________________________. If you check this box without specifying, your vote will be excluded from the second count on all of the Proposals listed above.

 

Holding 5% or more. If you hold 5% or more of the outstanding Ordinary Shares or of the voting rights of the Company, please so indicate: ☐ Yes.

 

 

 

 

SIGNATURE

 

Please sign exactly as your name appears on this proxy card. Joint holders should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give your full title. If the shareholder is a corporation or partnership, please sign in the full corporate or partnership name by a duly authorized officer or partner and state the title.

 

   
Signature of shareholder   Signature of joint holder, if any
     
     
Name (print)   Date: __________________________, 2026

 

PLEASE MARK, SIGN, DATE AND RETURN THIS PROXY CARD PROMPTLY IN THE ENCLOSED ENVELOPE, OR VOTE ONLINE AS DESCRIBED IN THE PROXY STATEMENT. The Notice of Annual General Meeting and Proxy Statement are available at ir.mbody.ai/events-presentations/ and were furnished to the Securities and Exchange Commission on Form 6-K on or about November 17, 2026. 

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading